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Summary 
Epilepsy is one of the most prevalent non-communicable conditions and also one of the most 
common neurological disorders affecting approximately 50 million people in the world, about 
80% of who live in low and middle income countries (LMIC). It is characterized by recurrent 
(two or more) unprovoked seizures, with active epilepsy (AE) being defined as at least one 
seizure in the last 5 years although in LMIC it is often defined when one of the seizures is within 
12 months of identification. 
Epilepsy is associated with significant psychosocial co-morbidities that impact on the health- 
related quality of life of patients and also influence prognosis. In LMIC, the perceptions of 
causes and consequences of epilepsy may differ from those in the high income countries (HIC) 
and often lead to stigmatization. The stigma may in turn hide a proportion of the burden of 
epilepsy since patients are unwilling to seek medical advice, translating into large treatment 
gaps. Many studies of LMIC have shown that the majority of PWE do not receive appropriate 
treatment despite the availability of cost effective treatment. 
The estimates of the burden of epilepsy in LMIC are based upon little data and between and 
within country estimates vary considerably. Causes of this heterogeneity have not been 
established but it is thought to be due to differences in methodological approaches, case 
definitions and ascertainment and lack of validation of screening instruments, as well as genuine 
differences in the magnitude of the burden of epilepsy. 
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In view of the serious health, quality of life and outcome implications of epilepsy, its attendant 
co-morbidity and inadequacy of data on the burden and outcome, there is need for 
epidemiological studies of epilepsy in LMIC. These countries have large rural populations with 
few specialists in neurology, scantily allocated heath care resources and a substantial burden of 
disease. 
These problems have been recognized by the global level with the initiation of The Global 
Campaign Against Epilepsy (GCAE), a partnership between the International League Against 
Epilepsy ([LAE), the World Health Organization (WHO) and the International Bureau for 
Epilepsy (IBE). This campaign aims to bring epilepsy `out of the shadows' by supporting LMIC 
to reduce the burden caused by epilepsy through improved acceptability, access to services, 
prevention and quality of care. The overall goal of GCAE is to improve the identification and 
management of people with convulsive epilepsies within existing primary health care systems. 
The studies reported in this thesis support these efforts by estimating the burden of epilepsy more 
accurately (particularly patients with Active Epilepsy, who should be on treatment) at the global 
level. The studies also described the distribution of active convulsive epilepsy (ACE) as well as 
factors associated with an important component of prognosis (i. e. mortality) in selected regions 
of LMIC in sub-Saharan Africa (SSA). 
Several research methodologies were used in these studies: (i) Systematic reviews and meta- 
analysis of published studies were used to determine the burden and characterize the 
heterogeneity in the distribution of epilepsy. (ii) A three-stage cross-sectional screening 
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methodology used to identify cases of ACE in LMIC was validated against the gold standard of 
clinical diagnosis by trained neurologists. (iii) Cross-sectional screening studies in four Health 
and Demographic Surveillance System (HDSS) sites were used to determine prevalence and 
heterogeneity of ACE in SSA and, (iv) prospective population-based cohort studies were carried 
out to determine the incidence, mortality and risk factors associated with mortality in PWE in 
one of the study sites. 
The systematic review reported in chapter 2 indicated that the prevalence of epilepsy (both life- 
time and active epilepsy) was more than two times higher in LMIC compared to HIC. Within the 
LMIC, the prevalence in rural areas was twice as high that of urban areas. There was strong 
evidence of between-study heterogeneity which was associated with age of study participants, 
study size and rural location. Likewise, the review reported in chapter 3 showed that incidence 
of epilepsy was about two times higher in LMIC compared to HIC albeit with significant 
heterogeneity. Population-based studies were associated with higher incidence estimates than 
hospital-based studies while retrospective study design was associated with lower estimates than 
prospective studies. This suggested the need for prospective population-based studies to 
accurately determine the incidence of epilepsy in LMIC. 
Chapter 4 provides details of the validation of the three-stage cross-sectional screening 
methodology used to identify cases of ACE in population-based studies. This study was 
conducted on a randomly selected sample of participants of the three-stage prevalence census of 
epilepsy. Clinician diagnosis of ACE was the gold standard. The findings showed that the three- 
stage methodology had a poor sensitivity of 48.6%, most of which was attributed to the first 
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stage of the survey. This method however had a specificity of 100% and was 60% cheaper than 
the clinician-conducted two-stage survey and as such wide-spread use of this method would 
require careful balancing between the poor sensitivity and the cost savings as well as validation 
in target populations. 
Chapter 5 describes the studies to determine the prevalence and heterogeneity of ACE across 
four HDSS sites in SSA. The three-stage cross-sectional screening method nested within on- 
going censuses in the HDSS sites was used to identify people with ACE. The findings showed 
substantial heterogeneity of prevalence between HDSS sites and between different age groups 
within and between sites. Site-specific estimates ranged between 7.0/1000 (95% CI: 6.2-7.4) in 
Agincourt HDSS in South Africa to 14.8/1000 (95% Cl: 13.8-15.4) in Ifakara HDSS in 
Tanzania. Prevalence varied by age in all sites and was highest in the adolescents (13-18 years) 
in Ifakara HDSS and in the youngest age-group (<=5 years) in Iganga-Mayuge HDSS in Uganda 
while it was lowest in the youngest age-group (<=5 years) in Agincourt HDSS. There were 
decreasing and increasing trends of prevalence with age for Iganga-Mayuge and Agincourt 
HDSSs respectively. Kilifi (Kenya) and Ifakara HDSSs had increasing then decreasing trends of 
prevalence with age. These findings suggest real heterogeneity that could be related to 
differences in the distribution and types of risk factors for development of epilepsy across SSA 
or age-related differences in vulnerability to endemic risk factors within study sites. It may also 
suggest that risk factors like malaria have varied considerably over time. These results reflect the 
burden of the people with active epilepsy that should be on treatment in these sites and suggests 
the need for studies to identify modifiable risk factors that could be targeted in public health 
interventions. 
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The incidence study described in chapter 6 demonstrated high incidence of ACE (at 
77/100,000/year) in the Kilifi HDSS, with the implication that incidence of life-time epilepsy 
could be much higher than reported previously. There was strong evidence of association 
between incidence and age with the lowest incidence occurring in the 29-49 year age group. This 
finding suggests that the increased risk in the other age groups could be due aetiologies that 
occur early as well as late in life and preventive interventions should target exposures that occur 
in these age groups. 
In the mortality study reported in chapter 6, people with ACE were more than 6 times more 
likely to die than people without ACE and mortality was elevated in all ages compared to the 
reference population. The most important risk factor for mortality was non-adherence to 
treatment which is amenable to public health intervention. 
The studies reported in this thesis have examined the burden, distribution and outcome of 
epilepsy from a global, regional and a local perspective. They have documented high 
prevalence, incidence and mortality in people with ACE, suggesting that epilepsy has far 
reaching effects on the health, welfare and quality of life of patients in the sites in which the 
studies were conducted and in LMIC more generally. At the global level, these studies show that 
the burden of epilepsy is much larger than previously thought and have provided estimates of the 
burden of active epilepsy representing people who should be on treatment. 
The findings support prioritization of epilepsy as an important global public health problem and 
lobby for increased resources, particularly in LMIC, to improve diagnostic, treatment and 
preventive services. 
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For local health systems, these findings translate into increased health expenditure in the short 
term, for treatment services for the patients identified in these studies. In the medium term, the 
findings suggest a need to increase and sustain capacity to provide more specialized health 
services to people with epilepsy at the primary care level. In the long term, preventive 
interventions must be given priority, which means addressing the preventable causes of epilepsy. 
To conclude, a raft of preventive measures and avenues for further epidemiological inquiry are 
proposed. These include educating the communities on the causes of epilepsy as well as risk 
factors of mortality in PWE, improving antenatal and perinatal services, prompt and effective 
treatment of traumatic head injuries and infections of central nervous system (CNS) as well as 
vaccinations for vaccine preventable causes of CNS infections. Suggested future work includes 
case-control studies to identify causes of epilepsy and studies of cause-specific mortality to 
identify causes of death in PWE. 
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Chapter 1: General Introduction 
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Global Burden of Epilepsy 
Epilepsy is one of the most prevalent non-communicable conditions and also one of the most 
common neurological disorders (WHO, 2001). It was thought to affect approximately 50 million 
people in the world in 2002, about 80% of who lived in low and middle income countries 
(LMIC). This worldwide proportion of epilepsy represents approximately 0.5% of the global 
burden of disease, which translates to more than 7 million disability-adjusted life-years (DALY) 
annually (Leonardi M and Ustan TB, 2002). 
Definitions and classification of seizures and epilepsy 
Epilepsy is characterized by recurrent (two or more) seizures unprovoked by any immediately 
identifiable cause and occurring at least 24 hours apart, with active epilepsy (AE) being defined 
as at least one seizure in the last 5 years (Commission on Epidemiology and Prognosis: 
International League Against Epilepsy, 1993). In LMIC, AE is often defined when one of 
seizures is within 12 months of identification (Meinardi et al., 2001), mainly due to poor recall of 
seizure events that occurred long ago (Snow et al., 1993a), poor documentation of medical 
records and also because in some countries, anti-epileptic drugs (AED) are recommended for 
people with at least one seizure per year (Ministry of Health, 2002). 
An epileptic seizure is defined as a transient occurrence of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain (Fisher et al., 2005). These 
signs or symptoms include sudden and transitory abnormal phenomena such as alterations of 
24 
consciousness, or involuntary motor, sensory, autonomic, or psychic events perceived by the 
patient or an observer (Berg AT et al., 2010; Commission on Epidemiology and Prognosis: 
International League Against Epilepsy, 1993; Thurman et al., 2011). 
Epileptic seizures are classified into generalised (both convulsive and non-convulsive), partial 
(focal) seizures (localised convulsive movements and those that become secondarily generalised) 
and unclassified. Partial seizures arise from single foci in the brain, while generalized seizures 
may arise from the central parts of the brain or spread so rapidly that their origin cannot be 
determined by standard techniques. Unclassified epileptic seizures include all seizures which 
cannot be classified because of inadequate or incomplete data, or seizures that defy classification 
in the partial or generalized categories. 
The epilepsies can be divided into symptomatic (those with a known or suspected cerebral 
dysfunction), or idiopathic (epilepsies of unknown aetiology) (ILAE: Commission on 
Epidemiology and Prognosis, 1993). Recently, the Commission on Classification and 
Terminology of the International League Against Epilepsy (ILAE) proposed a revised 
terminology and concepts for classifying seizures (Table 1.1) and epilepsies (Table 1.2). This 
revision recommended that the classification be grouped within categories of "electroclinical 
syndromes, " "constellations, " "epilepsies associated with structural or metabolic conditions, " 
and "epilepsies of unknown cause"(Berg AT et al., 2010; Thurman et al., 2011). 
Population-based studies from LMIC usually report only convulsive epilepsies since convulsions 
are easily identified. These epilepsies are associated with higher mortality, stigma and greater 
resource implications for prevention and control than non-convulsive epilepsies. 
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Table 1.1: Simplified clinical classification of seizure types 
Generalized Focal Undetermined 
1) Predominantly motor 
Convulsive Generalized Focal onset with Convulsive 
convulsive' secondary undetermined` 
eneralizationb 
Other motor Generalized other Focal motor' Other motor 
motors undetermined 
2 Predominant non-motor 
Impaired responsiveness' Generalized Dyscognitive focal Impaired 
absenceh seizures (formerly responsiveness, 
complex partial)' undetermined). 
Other non-motor Not appropriate Sensory, psychic, Not appropriate 
and other, 
including 
autonomick 
3) Unknown Generalized Focal seizure, Seizure, 
seizure, unspecified unspecified unspecified 
aSeizure onset is manifested by generalized tonic and/or clonic (convulsive) motor activity and 
unconsciousness. Focal features may occur. 
bSeizure onset has focal manifestations that evolve to generalized convulsive activity. 
cFocal or generalized nature of seizure onset is undetermined, but seizures manifest generalized 
convulsive activity. 
d Include myoclonic seizures, eyelid myoclonus, epileptic spasms, atonic seizures, other, and 
unspecified generalized motor seizures with or without impairment of consciousness. 
eSeizure has focal manifestations (including myoclonic, inhibitory, Jacksonian march, focal 
asymmetric tonic, hemiclonic, hyperkinetic, and other focal motor seizures) that do not evolve to 
F. eneralized convulsive activity. 
Unspecified motor seizures; includes neonatal and other seizures. 
'Staring spells, unresponsiveness, or other alteration of consciousness. 
hlncludes typical and atypical absence seizures. 
'Focal seizure associated with impairment of consciousness (formerly termed "complex 
partial") without secondary generalization (Commission on Classification and Terminology of 
the International League Against Epilepsy, 1989). 
iSeizure manifested by transient decreased responsiveness or "staring, " undetermined if absence 
or dyscognitive ("complex partial") in type. 
kIncludes auras without alteration of consciousness or secondary generalization (including 
somatosensory and experiential seizures), autonomic, and other nonmotor seizures. 
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Table 1.2: Classification of epilepsies by causes 
Genetic/Presumed genetic Structural/Metabolic Unknown or 
Undetermined 
Specific genetic epilepsy Infections Epilepsy of unknown' 
syndromes Traumatic brain injury etiology 
Genetic and chromosomal Stroke Epilepsy of 
developmental Neoplasia undeterminede etiology 
encephalopathiesa Mesial temporal sclerosisb 
Other Degenerative neurologic diseases 
Metabolic or toxic insults to brain` 
Perinatal insults 
Intraventricular hemorrhage 
Hypoxic-ischemic encephalopathy 
Otherd 
Malformations of cortical or other 
brain development 
Neurocutaneous syndromes 
Inborn errors of metabolism 
Other 
aWithout known aetiology despite adequate evaluation (e. g., history, examination, EEG, and 
other testing determined to be relevant such as neuroimaging or genetic testing). 
bWhere evidence is lacking that the structural pathology precedes the onset of epilepsy, it is not 
assumed that such pathology causes epilepsy. 
'With epilepsy as a late effect. For distinction with acute symptomatic seizures. 
dlncludes conditions where underlying etiology is undocumented or available information is 
limited to terms such as "intellectual disability"/"mental retardation" or "cerebral palsy" 
when these preceded the onset of seizures. 
eWithout adequate evaluation to determine etiology as defined by investigators. 
Causes of epilepsy 
Epilepsy is caused by many conditions that result in brain injury such as birth asphyxia, head 
trauma or cerebral infections. There are also genetically determined epilepsies. However, for 
most cases of epilepsy an identifiable cause cannot be found. The known aetiological factors for 
development of epilepsy in LMIC include parasitic infections affecting the brain such as 
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neurocysticercosis (Newell et al., 1997a; Nicoletti et al., 2002; Nsengiyumva et al., 2003), 
onchocerciasis (Druet-Cabanac et at, 1999; Newell et at, 1997b) and toxocara (Nicoletti et al., 
2002; Nicoletti et al., 2007). Other factors, elicited through clinical history, include family 
history of both febrile and non-febrile seizures (including epilepsy) (Edwards T et al., 2008; 
Matuja et al., 2001; Nsengiyumva et at, 2003; Ogunniyi et al., 1987), perl-natal complications 
(Edwards T et al., 2008; Matuja et al., 2001; Nsengiyumva et al., 2003) traumatic head injuries 
(Edwards T et al., 2008; Ogunniyi et at, 1987) and history of admission to hospital with cerebral 
malaria (Carter JA, 2004; Ngoungou et al., 2006). Specific genes have been associated with 
development of rare sub-types of epilepsy (Tan et al., 2006), with an increasing evidence base 
for the role of genetics in the generalized epilepsies (Choueiri et al., 2001; Mulley et al., 2005; 
Ottman et al., 2005; Sander T, 2000). However, there are only a few studies detailing the role of 
genetic risk factors in LMIC (Kesavan et al., 2011; Kumari et al., 2011), particularly given that a 
large proportion of all epilepsies do not have an identified cause with suspected genetic 
aetio logy. 
Diagnosis of epilepsy 
The diagnosis of epilepsy is clinical, usually based on history of epileptic seizures, often reported 
by the sufferer or an eye witness and should be preferably confirmed by a health professional 
with expertise in epilepsy using available clinical history and seizure description (Commission 
on Epidemiology and Prognosis: International League Against Epilepsy, 1993). The neurological 
examination may point to aetiology e. g. stigmata of neurocutaneous syndromes or the 
consequence of epilepsy e. g. burns. Electroencephalography may demonstrate epileptic 
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discharges in less than a third of cases of epilepsy, but is more useful in defining the type of 
seizures e. g. focal seizures or epileptic syndromes e. g. rolandic epilepsy. 
Epidemiology of Epilepsy 
Globally, epidemiological studies measuring the burden of epilepsy have been conducted in the 
last 40 years (Kostopoulos I et al., 2002). However, there are only a few epidemiological studies 
examining prevalence and incidence of epilepsy in Africa (Sander JW and Shorvon SD, 1996; 
Sander JW, 2003). The prevalence of epilepsy is higher in LMIC compared to the high income 
countries (HIC) but the high incidence rates derived from a few studies suggest that prevalence 
should be much higher than in the HIC (Sander JW and Shorvon SD, 1996). This discrepancy 
could be caused by increased mortality, spontaneous remission or methodological differences. 
The few studies that examine the mortality of epilepsy in Africa (Coleman R et al., 2002; Diop 
AG et al., 2005; Jilek-Aall L and Rwiza HT, 1992) suggest that mortality is higher than in HIC, 
but by how much is unclear, and the risk factors for death have not been investigated. 
Epidemiological studies are therefore important to determine the burden of epilepsy and to 
inform public health initiatives in LMIC. 
Many people with epilepsy (PWE) in LMIC have a poor quality of life. In many communities, 
PWE are ostracized, prevented from employment and/or marriage (Baskind R and Birbeck G L, 
2005; Birbeck GL and Kalichi E M, 2003; El Sharkawy G et al., 2006; Nubukpo P et al., 2004). 
Furthermore, many patients do not receive appropriate treatment, despite the fact that treatment 
with cost-effective anti-epileptic drugs (AEDs) such as phenobarbital or phenytoin, may control 
seizures in over 70% of cases (Mbuba CK et al., 2008; Meinardi H et al., 2001; Scott RA et al., 
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2001; Wang WZ et al., 2006). The reasons for this treatment gap (i. e. number of people with 
epilepsy who would benefit from treatment but are not getting AEDs) (Kale R, 2002) vary from 
one area to another. In some areas stigmatization of PWE interferes with management, whilst in 
other areas lack of AED or health facilities prevent access to AED. The World Health 
Organization (WHO) has identified these two as priorities in the management of epilepsy i. e. 
elimination of stigma and reduction of the treatment gap (ILAE/IBE/WHO, 2003; WHO, 2004). 
But in order for these problems to be tackled, the burden of epilepsy needs to be estimated. 
Comparing estimates form epidemiological studies of epilepsy in LMIC is problematic. These 
problems include differences in methodological approaches, case definition and ascertainment 
and lack of validation of screening instruments. Furthermore, there are differences in study sizes 
(ranging from a few hundred to several thousand participants) and age-groups studied (children 
only studies versus only adults or all age-groups). These factors are aggravated by resource 
constraints and logistical difficulties. Subsequently, data from LMIC shows considerable 
heterogeneity (Leonardi M and Ustan TB, 2002). 
While developed countries utilize medical and service records to provide epidemiological data, 
these records are often not available in LMIC. Single round surveys and key informants have 
been used in LMIC, but these methods under-report cases (Kaamugisha J and Feksi AT, 1988). 
Two-phase surveys in which the population is screened with a questionnaire and the diagnosis 
confirmed by clinical history and assessment have been recommended (Placencia M et al., 1992). 
These surveys depend on the sensitivity and specificity of the screening questionnaires and they 
often require piloting and validation in the target populations. These points are frequently 
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neglected and some published questionnaires are inadequate, which leads to underreporting of 
cases (Sander JW and Shorvon SD, 1987). Cross sectional survey methods can be improved by 
capture-recapture methods using other sources of cases such as key-informants (e. g. village 
elders) and, where available, medical records from hospitals and clinics (Debrock C, 2000 Apr) 
as part of triangulation of data sources. These methodologies however pose considerable 
logistical and cost implications when used in large populations. 
A cross-sectional study method that has attempted to address these limitations is the three-stage 
approach. This has been used previously to estimate the prevalence of ACE in the Kilifi HDSS, 
Kenya (Edwards T et al., 2008). This approach is aimed at screening large populations in HDSS 
rapidly while simplifying logistics and reducing costs but it has not been validated in the target 
populations. 
Prevalence and incidence 
Reported range of prevalence in Africa is 5-74/1000 persons (Preux PM and Druet-Cabanc M, 
2005) while in HIC the estimate is 5-10/1000 (Sander JW and Shorvon SD, 1996; Sander JW, 
2003). Meta-analyses of the burden of epilepsy conducted as part of this thesis have estimated 
the prevalence and incidence of epilepsy in LMIC at 13/1000 and 81/100,000 persons per year 
respectively, albeit with considerable heterogeneity (Ngugi et al., 2010; Ngugi et al., 2011). 
A number of studies of epidemiology of epilepsy have been reported from the Kilifi HDSS in 
Kenya but all used different methodologies or were on different age groups (that were not 
representative of the general population) thus they yielded varied estimates. A community 
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survey in 1992, which used key informants in the household to report on any member with 
epilepsy, estimated the prevalence of active epilepsy to be 4/1000 (Snow RW et al., 1994) in the 
population above 5 years old. A study based upon histories of epilepsy in relatives of children 
who acted as controls for study on malaria conducted in 2001/2 reported the prevalence of all 
types of epilepsy to be 1 l/1000 (Versteeg AC et al., 2003). In both these studies the diagnoses 
were not confirmed by clinicians or further assessment, and may either under report the 
prevalence of epilepsy or include cases that do not have epilepsy or may double count cases. In 
2001/2, a survey of neurological impairment and disability in children aged 6-9 years also 
identified cases of epilepsy and estimated a point prevalence of 11/1000 and a life-time 
prevalence of 41/1000 (Mung'ala-Odera et al., 2008). A more recent three-stage cross-sectional 
survey conducted on individuals above 6 years of age and which used clinicians to confirm the 
diagnosis of active convulsive epilepsy (ACE) estimated a prevalence of 4.5/1000 after adjusting 
for non-response (Edwards T et al., 2008). 
In the HIC the annual incidence of epilepsy is 40-70 per 100,000 per year, whilst in the LMIC 
annual incidence may be double at >80 per 100,000 per year (Sander JW and Shorvon SD, 
1996). There are few studies that have attempted to estimate the incidence of epilepsy in Africa. 
A study of a small population (18,000 people) in Tanzania over a 10-year period estimated the 
incidence to be 73/100,000 per year (Rwiza HT et al., 1992 Nov-Dec). A community based study 
of 61,687 people in Ethiopia estimated the incidence to be 64/100,000 per year (Tekle-Haimanot 
R et al., 1997 May), while a study of 4,743 people in Uganda estimated an incidence rate of 
215/100,000 (Kaiser C et al., May 1998). The Tanzanian study in particular was based upon the 
recall of seizures over a prolonged period of time while in the Ethiopian study, different methods 
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were used to identify cases at different time points. The Ugandan study was in an area with high 
prevalence of Onchocerciasis (suspected to cause epilepsy) implying that this estimate was not 
representative of the typical Ugandan population. 
Mortality 
In HIC, mortality is elevated in PWE, compared to the general population, with standardized 
mortality ratios (SMR) ranging between 1.6-4.1 (Holden EW, 2005 Feb; Kochen S, 2005 Dec; 
Lindsten H, 2000 Nov; Olafsson E, 1998 Jan) but there is little data from LMIC. The estimates 
of mortality are predominantly presented as mortality ratios standardized on the age distribution 
of the study reference populations i. e. the SMR. While this makes it easier to compare mortality 
between different groups within the same populations, these estimates are difficult to compare 
across populations that have different age and/or sex profiles. In Africa, only a few population 
based mortality studies have been conducted, with follow-up ranging between 2-30 years. These 
studies are based upon a combined total of 186 deaths and show that mortality is higher in people 
with epilepsy (Coleman R et al., 2002; Jilek-Aall L and Rwiza HT, 1992; Kaiser C et al., 2007; 
Kamgno J, 2003 Jul; Snow RW et al., 1994). Three of these studies have provided more accurate 
measures of mortality, with one reporting a rate of 23/1000 person years based upon a selected 
hospital cohort (Jilek-Aall L and Rwiza HT, 1992), the other a rate of 77/1000/year was based 
upon only three deaths (Coleman R et al., 2002) and one study reported SMR of 7.2 in an area 
with high prevalence of Onchocerciasis (Kaiser C et al., 2007). The cause of death in one of 
these studies was attributed to status epilepticus or accidents (such as drowning or bums) but the 
risk factors for death were not investigated (Jilek-Aall L and Rwiza HT, 1992). 
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In the HIC population-based studies, excess mortality is highest in the first few years after 
diagnosis of the epilepsy and is mainly due to the underlying causes of epilepsy (Cockerel] OC et 
al., 1994). Many studies focus on single epilepsy syndromes or on sub-populations with specific 
syndromes (Beghi E et at., 2005; Hesdorffer DC and D' Amelio M, 2005; Lorgoscino G et at., 
2005; Sperling MR et al., 2005). Death in PWE has been associated with a number of factors, 
which include: underlying brain disease such as tumor or infection, seizures in dangerous 
circumstances leading to drowning, bums or head injury, possible respiratory or cardio- 
respiratory arrest during seizure and suicide and/or unexplained causes (sudden unexpected death 
in epilepsy (SUDEP)). The importance of SUDEP in Africa is unknown, but in the HIC, it 
accounts for up to 17% of the epilepsy deaths (Ficker DM, 2000), but is widely variable 
depending on the populations studies. The incidence of SUDEP ranges between 0.35-2.7/1000 
per year in population based studies (Annegers JF and Coan SP, 1999) and can be as high as 
6.3/1000 per year in selected epilepsy populations (Tomson et at., 2008) and accounts for more 
than 50% of mortality in patients with refractory epilepsy/candidates for epilepsy surgery 
(Sperling et al., 2005). In the HIC, SUDEP is more common in young adults and males, and 
those with refractory seizures, remote symptomatic epilepsy and non-adherence to treatment 
(Annegers JF and Coan SP, 1999; Langan Y et al., 2005; Tomson T et al., 2005), all of which are 
typical features of convulsive epilepsy in sub-Saharan Africa (SSA) and thus may represent 
important risk factors of mortality in people with epilepsy (PWE) in Africa. 
Symptomatic epilepsy carries the greatest risk of death (Beghi E et al., 2005; Cockerell OC et al., 
1994; Forsgren L et al., 2005; Lhatoo SD et al., 2001), with the convulsive epilepsies associated 
with the highest mortality (Lhatoo SD et al., 2001). In the HIC, deaths related directly or 
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indirectly to epilepsy are infrequent, but these causes may be more frequent in SSA (Caprio A et 
al., 2005; Diop AG et al., 2005; Kamgno J, 2003 Jul). 
Current research 
Background to the thesis 
The studies described in this thesis were part of a larger study of epidemiology and treatment of 
epilepsy in SSA namely Studies of Epidemiology of Epilepsy in Demographic Surveillance sites 
(SEEDS) under the INDEPTH network (http: //www. indepth-network. oriz/). INDEPTH is a 
network of research sites in LMIC in Africa, Asia, Oceania and Central America that carry out 
continuous demographic and health surveillance of populations. Activities within these sites are 
characterized by regular re-enumeration and vital registration of geographically defined 
populations with maintenance of regularly updated population registers. These provide accurate 
denominator data and efficient follow-up infrastructure for population-based cross-sectional and 
longitudinal studies. 
The SEEDS studies were nested within on-going demographic re-evaluations in five Health and 
Demographic Surveillance System (HDSS) sites in SSA. A HDSS setting offers obvious 
advantages for studies to determine the burden of epilepsy and monitor health, treatment and 
outcomes in epilepsy patients. These advantages include: coverage of large (mostly rural) 
populations that provide adequate sampling frames; regular re-enumeration during which large 
populations can be screened efficiently; census field staff requiring minimal study-specific 
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training thereby minimizing cost; availability of necessary logistics and follow-up information 
on individuals e. g. deaths in an epilepsy cohort can be updated during the regular census surveys. 
Justification for the research 
Epilepsy appears to be common in LMIC, but there are no reliable estimates of prevalence, 
incidence and mortality on which to base and assess public health interventions. By using similar 
methodology, definitions and operational procedures across several sites in Africa, the SEEDS 
studies aimed to determine if the heterogeneity observed in previous prevalence studies in LMIC 
was methodological or "real" e. g. due to differences in prevalence of risk factors. The other 
objectives of SEEDS included: i) to determine the association of putative risk factors, 
particularly parasitic infestations of the brain (Malaria, Neurocystcercosis, Onchocerciasis, 
Toxocara and Toxoplasma) and HIV infection, with the development of epilepsy using case- 
control studies, ii) to quantify mortality in PWE, and, iii) to identify modifiable risk factors for 
death in people with epilepsy in this region. 
Further, the studies would enable the establishment of baseline parameters for epilepsy in this 
region and cohorts of people with epilepsy on which further longitudinal studies of prognosis and 
interventions can be based. 
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Study Hypotheses 
In this thesis I plan to examine the following null hypotheses: 
1) The three-stage prevalence screening is not a valid methodology for detecting cases of 
ACE in population-based studies. 
2) There is no heterogeneity in the prevalence of ACE in SSA. 
3) Mortality in people with ACE is not higher than that in people without epilepsy in the 
Kilifi HDSS. 
4) Mortality in people with ACE is not associated with seizure frequency, seizure type, 
adherence to anti-epileptic drugs (AEDs) and age at onset of seizures. 
Study objectives 
1) To determine the global burden of epilepsy especially AE which should be on treatment 
and identify study-level factors associated with heterogeneity of estimates. 
2) To estimate the global incidence of epilepsy and study-level factors associated with 
heterogeneity of incidence estimates. 
3) To determine the sensitivity and specificity of the three-stage methodology for detecting 
cases of ACE in population-based epilepsy surveys. 
4) To determine the prevalence and heterogeneity of ACE in four HDSS sites in SSA. 
5) To determine the incidence of ACE in the Kilifi HDSS. 
6) To estimate the mortality ratios and identify risk factors for mortality in a cohort of 
people with ACE in the Kilifi HDSS. 
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Study sites 
Most of the studies were conducted in the Kilifi HDSS. The HDSS sites in Agincourt in South 
Africa, Iganga-Mayuge in Uganda and Ifakara in Tanzania (Fig. 1.1) were used to determine 
prevalence and examine the heterogeneity of the prevalence of ACE in SSA. These sites were 
selected on the basis of the presence of hospital/clinic within the HDSS to provide support for 
the clinical aspects and follow-up of ACE patients in the longitudinal studies, availability of 
laboratory facilities to process the collected samples, operational costs to the study and the 
endemicity of parasitic diseases that could cause epilepsy. 
Figure 1.1: Map of Africa showing the location of the four Health and Demographic 
Surveillance System study sites 
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Kilifi HDSS, Kenya 
The Kilifi HDSS is in Kilifi District of the Coast province of Kenya, located about 60 kilometres 
to the north of Mombasa city (Figure 1.1). Kilifi District, with a total area of 4,779 km2 and a 
population of 678,702 people includes some of the poorest areas in Kenya (Central Bureau of 
Statistics (CBS) - Kenya, 2007). It consists of rural and peri-urban communities. There are two 
urban centres: Mtwapa in the south almost joined to the northern edge of Mombasa has a 
population of 70,000 and Kilifi town, the district administrative centre with a population of 
30,000. Most of the district is rural with subsistence farming. The main crops are maize and tree 
crops such as coconuts and cashew nuts. Soil fertility is low and variability of rainfall means that 
in some years crops fail. Average daytime temperatures vary between 28 and 34°C and average 
annual rainfall is 118cm, though there is considerable year to year variation. There are two rainy 
seasons, the long rains from April to July and the short rains in November and December. 
This study was conducted within the Kilifi HDSS (http: //www. kemri-wellcome. ory/khdss). This 
is a system of demographic surveillance and vital registration in the densely inhabited coastal 
strip of 40 km in length and extending about 15 km in the interior (Fig. 1.2). The estimated study 
area is 891 km2, which is about 18% of the total area of Kilifi District with 233,881 residents in 
25,526 homesteads in 2008. These homesteads are situated within 15 administrative locations 
with 40 sub-locations which are further sub-divided into 186 enumeration zones. 
The Kilifi HDSS area has been mapped using global positioning system (GPS) receivers and 
digital maps are used to locate homesteads and study subjects. Census field personnel conduct 
re-enumeration and vital status registration to update the population registers by visiting every 
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homestead two-three times per year. Most (80%) of the population uses the Kilifi District 
Hospital (KDH) as the main hospital for admissions. 
Figure 1.2: Map of Africa showing the position of the Kilifi Health and Demographic 
Surveillance System study area in Kenya. 
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Kenya Medical Research Institute (KEMRI) (http: //www. kemri-welicome. org/khdss/) has been 
running the Kilifi-HDSS in the well demarcated study area in Kilifi District since year 2000. The 
people are mainly Mijikenda, a Bantu grouping of nine tribes with Girima (45%), Chonyi (33%) 
and Kauma (11%) being the most common. About 55% of the population is considered 
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absolutely poor; per capita monthly income is about USD 10. The majority (80%) depend on 
peasant farming, which is limited by the low productivity of the land (only 19% of the total land 
is arable). Literacy levels are low: only 45% of people can read and write. 
Crude birth and death rates for this area are 35/1,000 and 6/1,000 per year respectively, and 
migration rates are approximately 100/1,000 per year, most of which is within the study area 
(Scott JA et al., 2011). Malaria is seasonal, with two peaks in transmission during May to 
August and December to January (Snow et at., 1993b). The area has however experienced 
dramatic decline in slide-positive admissions over the last decade (O'Meara et al., 2008). 
Agincourt HDSS, South Africa 
The Agincourt HDSS (http: //web wits ac. za/Academic/Health/PubIicHealth/A incourt/) was 
founded in 1992 as a research arm of the School of Public Health of the University of the 
Witwatersrand, South Africa. This was in response to the need for vital registration and health 
and social transitions information in the Agincourt rural sub-district of the Bushbuckridge 
District of Mpumalanga province in North Eastern South Africa (Fig. 1.3). This was part of a 
nationwide programme to decentralise health systems research and development that aimed to 
inform the efforts of the new South African Ministry of Health. 
The total population then numbered some 58,000 persons, increasing to about 87,000 in 2007 in 
14,382 households across 26 villages and covering about 420 sq km. Agincourt HDSS is located 
alongside the western border of Mozambique, forming part of rural north-eastern South Africa 
(Fig. 1.3). There are significant numbers of former Mozambican refugees - some 30% of the 
sub-district population. The Agincourt HDSS includes annual census and special events updates 
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(systematic recording of all births, deaths and migrations). The overlap between the 
administrative boundaries of the sub-district and those of the defined population of the HDSS 
facilitate the transfer and application of research findings to local health and development efforts. 
ýýýýv. indcpth nctýýork. ur ) Reproduced from the INDEPTH %%ebsite: (hap: 
Ifakara HDSS, Tanzania 
The Ifakara HDSS (http: //www. ihi. or. tz/) study area is located in southern Tanzania and covers 
parts of two districts, Kilombero and Ulanga both in the Morogoro region (Fig. 1.4). The Ifakara 
HDSS site was established in September 1996 and the baseline census was conducted between 
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Figure 1.3: Map of Africa showing the position of Agincourt Health and Demographic 
Surveillance System study area in South Africa. 
September and December of the same year. The HDSS covers a total of 25 villages with a 
population of about 105,000 people in 14,000 households. Since January 1997 each household is 
visited once every four months (three times in a year) to record births, pregnancies, deaths and 
migration. In order to document causes of death, verbal autopsies have been conducted since 
September 2000. 
The area is predominately rural with scattered households. The main ethnic groups are 
Wapogoro, Wandamba, Wabena and Wambunga. Subsistence farming of maize and rice 
occupies the majority of the villagers. The literacy level in adults is quite high, 88% for men and 
69% for women. The mean household size is five people who usually live in a compound with 
one or two houses. The main rainy season is from November to May. In some years, floods are 
experienced in several parts of the HDSS area, particularly in April. During floods, accessibility 
to some households is difficult. 
Figure 1.4: Map of Africa showing the position of Ifakara Health and Demographic 
Surveillance System study area in Tanzania. 
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Iganga/Mayuge HDSS, Uganda 
Iganga/Mayuge HDSS in Uganda (Fig. 1.5) was established in August 2004. It is located in the 
eastern part of the country 115km from the capital city, Kampala. According to results from the 
Baseline Census conducted between March-July 2005, the HDSS had a population of 62,000 
people, about 80% living in rural and 20% perl-urban areas. Currently, the population stands at 
68,000 people. Data for update rounds is collected 3 times in a year. The Iganga/Mayuge HDSS 
uses paper based protocol of data collection but has been changing gradually to use of handheld 
computers (PDAs). 
The core demographic events covered are migrations, births, death and verbal autopsies. Other 
modules collected include pregnancies, education and socio-economic status. 
Figure 1.5: Map Africa showing the location of the Iganga-Mayuge Health and 
Demographic Surveillance System study area in Uganda. 
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Overview of the methods 
I employed various methodologies to collect and analyze data to meet the objectives of these 
studies. In the second and the third chapters I used formal systematic review procedures to 
search for and evaluate previously published literature and meta-analysis techniques to analyze 
the data. To validate the three-stage methodology for detecting cases of ACE in population-based 
studies, the gold standard method for the identification of cases of epilepsy (i. e. clinical history 
taken by clinicians with experience in diagnosis and management of epilepsy) was administered 
on a randomly selected sample of 5,796 Kilifi HDSS residents. The gold standard diagnoses 
were then compared with those obtained from the three-stage prevalence survey and the 
sensitivity and specificity were estimated in 2x2 tables. 
The prevalence of ACE in all study sites was estimated from the three-stage cross-sectional 
survey that had been used previously in the Kilifi HDSS. The first stage of the three-stage survey 
was a general population screen using a simple tool to detect individuals with a history of 
convulsions that could be administered by the census field personnel easily. These were then 
interviewed with a questionnaire which is much more specific for epilepsy in the second stage. 
The diagnosis and case ascertainment of ACE was made using detailed history taken during the 
third stage by clinicians trained in the diagnosis and management of epilepsy. Prevalence was 
then estimated as the number of cases confirmed in the third stage as a proportion of the 
population screened in the first stage. I used logistic regression method to determine the 
heterogeneity of ACE across the study sites. 
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The incidence of ACE in the Kilifi HDSS was based on two cross-sectional studies conducted 
five years apart. The first survey in 2003 determined the ACE status of residents and identified a 
cohort of individuals without epilepsy. In the second survey in 2008,1 re-examined this cohort to 
determine the number that had developed ACE during the intervening period. Assuming a 
Poisson distribution for the number of incident cases, the incidence of ACE together with the 
95% confidence interval (95%CI) was calculated by dividing the number of incident cases by the 
person years of observation among the cohort members re-identified in the second survey. 
Estimates of mortality ratios and identification of risk factors for death in people with ACE were 
based on cohorts of people with and without ACE identified in a baseline three-stage population 
wide prevalence screening within the Kilifi HDSS. These were actively followed-up regularly 
for three years within the HDSS infrastructure for registration of mortality and within the 
epilepsy longitudinal study to capture demographic data and putative risk factors for mortality. I 
calculated the case fatality proportion for the ACE cohort and standardized mortality ratio 
(SMR) by direct standardization against the population without ACE at baseline. Poisson 
regression with time-dependent co-variates was used to identify factors associated with mortality 
in people with ACE. 
More detailed descriptions of the methods are presented in each chapter. 
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Layout of the thesis 
This work describes the rationale, methods and findings of my studies of global prevalence and 
incidence of epilepsy and heterogeneity of ACE in the four HDSS Sites in sub-Saharan Africa, 
and incidence and mortality of ACE in the Kilifi HDSS. 
The first chapter is the general introduction of the basic epidemiology of epilepsy, contrasting 
LMIC with the HIC, and presenting the rationale and objectives of the thesis. It also describes 
the study sites and presents a summary of the methods. 
The second and the third chapters of the thesis present two systematic reviews and meta-analyses 
of prevalence and incidence of epilepsy which also compare the burden and heterogeneity of 
epilepsy in HIC and LMIC. These reviews identify the study-level factors associated with the 
heterogeneity of the observed estimates, which forms the basis for further inquiry into the types 
(clinical or methodological) of the heterogeneity in the prevalence chapter. 
The fourth chapter of the thesis is a validation study of the three-stage cross-sectional screening 
methodology that was used to identify cases of ACE to determine prevalence in all four sites. 
In the fifth chapter, I describe the methods and results of studies of prevalence and heterogeneity 
of ACE in the four HDSS sites in sub-Saharan Africa. The sixth chapter describes the estimation 
of the incidence of ACE, and the seventh describes mortality and risk factors associated with 
mortality in people living with ACE in the Kilifi HDSS in Kenya. 
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The eighth chapter includes the general discussion and conclusions which put into context and 
provide insights into the public health implications of my findings. This chapter also offers 
recommendations for public health interventions and directions for future research. 
Overall, the research reported in this thesis contributes to our broad understanding of the basic 
epidemiology of epilepsy in resource limited settings. Specifically, it provides a reproducible and 
data driven estimate of the global burden of epilepsy as well as an estimate of the burden with 
active epilepsy that should be on treatment. Further, this research provides insights into the 
causes and type of heterogeneity both globally (in the meta-analysis chapters) and in a resource 
poor setting (in the prevalence chapter). This aspect of the distribution of ACE has not been 
evaluated in any previous research. The research also estimates the magnitude of mortality and 
factors associated with it in people with ACE in the Kilifi HDSS, which are key to informing 
public health interventions to reduce mortality in PWE. It is hoped that this research will ignite 
debate and form the basis for studies to collect much needed data on epidemiology of epilepsy in 
other LMIC and for informing and assessing public health interventions. 
Personal statement on my roles in the SEEDS study 
Development of SEEDS studies in INDEPTH HDSS sites 
The studies reported in this thesis were conducted as a component of SEEDS in 5 HDSS sites in 
sub-Saharan Africa (SSA). SEEDS was put together through a joint effort of my supervisor Prof. 
Charles Newton, Dr. Victor Doku (Institute of Psichiatry, King's College, University of London) 
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and I. I made the initial contact with the site leaders of the sites that are now involved in the 
SEEDS project during the 6`h Annual INDEPTH General Meeting and Scientific Conference in 
Ouagadougou, Burkina Faso in September 2006. During this meeting, I also presented data from 
a previous study of prevalence of epilepsy in the Kilifi HDSS and made a call for expression of 
interest in the SEEDS study that was then in the conceptual stage. 
Jointly with Prof. Newton and Dr. Doku, we drafted the concept paper for the SEEDS thereafter 
(Appendix 1.1) which was circulated within the INDEPTH Network as a call for expression of 
interest in epilepsy studies. Out of 12 sites that initially expressed interest (3 in Asia and 9 in 
Africa), 5 sites were selected. Thereafter, I supported the SEEDS study PI (Prof. Charles 
Newton) during the drafting of the funding proposal by putting together data and some aspects of 
the analysis that were needed for the proposal development. 
I developed the training manuals (Appendix 1.2) for the SEEDS study (based upon the 
experiences of similar studies in the Kilifi HDSS) and information sheets and consent forms 
(with the help of the Kilifi Social and Behavioural Research Group) (Appendix 1.3). I conducted 
the training for the stages I and II field staff and for the study project managers in all sites. 
Further, I supported and advised the project managers on some logistical aspects during initiation 
of the studies and continually on all aspects of the study during implementation and monitored 
data quality using monitoring tools that I developed. 
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Prevalence surveys in MEPTH HDSS sites validation of the screening methodology in 
Kilifi HDSS 
I wrote the proposal for the validation of the 3-stage survey methodology in the Kilifi HDSS and 
was actively involved in managing data collection. Under the supervision and advice from my 
supervisors Prof. Newton, Dr. Kleinschmidt and Dr Bottomley, I analyzed and wrote-up the 
validation and prevalence data from these aspects of the study with. 
Incidence study in the Kilifi DSS 
I conducted the re-evaluation screening of the initial non-epilepsy cohort in 2008, linked study 
participants in the two surveys and analyzed and wrote up the incidence chapter of this thesis 
under the supervision and advice of my supervisors. 
Mortality studies in the Kilifi DSS 
I identified the study participants with ACE in the epilepsy screening of 2008 and conducted the 
follow-up of the mortality cohort (directing and supervising field work and data handling) for 
three years. I also analyzed wrote-up the mortality chapter of this thesis with guidance from my 
supervisors. 
The contributions of the authors of the two chapters that have been published so far are detailed 
at the end of the individual chapters. 
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Abstract 
Purpose: To estimate the burden of life-time epilepsy (LTE) and active epilepsy (AE) and 
examine the influence of study characteristics on prevalence estimates. 
Methods: We searched online databases and identified articles using pre-specified criteria. 
Random effects meta-analyses were used to estimate the median prevalence in developed 
countries and in urban and rural settings in developing countries. The impact of study 
characteristics on prevalence estimates was determined using meta-regression models. 
Results: The median LTE prevalence for developed countries was 5.8/1,000 (5th - 95th percentile 
range: 2.7-12.4) compared to 15.4/1,000 (4.8-49.6) for rural and 10.3 (2.8-37.7) for urban studies 
in developing countries. The median prevalence of AE was 4.9/1,000 (2.3-10.3) for developed 
countries and 12.7/1,000 (3.5-45.5) and 5.9 (3.4-10.2) in rural and urban studies in developing 
countries. The estimates of burden for LTE and AE in developed countries were 6.8 million (511, - 
95th percentile range: 3.2-14.7) and 5.7 million (2.7-12.2), respectively. In developing countries 
these were: 45 (14-145) million LTE and 17 (10-133) million AE in rural areas and 17 (5-61) 
million LTE and 10 (5-17) million AE in urban areas. Studies involving all ages or only adults 
showed higher estimates than paediatric studies. Higher prevalence estimates were also 
associated with rural location and small study size. 
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Conclusions: This study estimates the global burden of epilepsy and the proportions with AE, 
which may benefit from treatment. There are systematic differences in reported prevalence 
estimates, which are only partially explained by study characteristics. 
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Introduction 
Epilepsy is one of the most common neurological conditions in the world, but the current 
estimates of 50 million people worldwide (WHO, 2004) lack precision and do not provide an 
estimate of the proportion with active epilepsy (AE), i. e. who may benefit from treatment. 
The epidemiological studies describing the burden of epilepsy in the last 40 years are 
problematic (Kotsopoulos I et al., 2005; Kotsopoulos et al., 2002). Data on epilepsy are still 
scarce in many parts of the world, while the available data is inconsistent because of differences 
in sampling frames, case definitions, measurements (e. g. point versus period or lifetime 
prevalence), screening tools, diagnostic accuracy and different methodological approaches 
(Leonardi M and Ustan TB, 2002). 
In the developed world where routine medical statistics are available and easily accessible, 
investigators have used research and hospital databases, rather than population-based studies to 
estimate the prevalence of epilepsy. This practice, however, discriminates against those who 
underutilize medical services (Morgan CL et al., 2000 ; Wright J et al., 2000). Community-based 
surveys are more commonly used in developing countries, but often do not make use of validated 
tools to screen the population. Even where validated tools are used these studies may have higher 
sensitivity for convulsive epilepsies and thus more subtle forms of epilepsy are underestimated 
(da Mota Gomes M et al., 2002; Racoosin JA, 2003). 
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The prevalence of epilepsy is reported to vary substantially between developed and developing 
countries: estimated as 4- 7/1000 persons in the developed countries (Sander JW and Shorvon 
SD, 1996) and 5- 74/1000 in developing countries (Preux PM and Druet-Cabanc M, 2005). The 
wider variations in the estimates of prevalence from resource poor compared to developed 
countries complicate the use of these data in estimating the number who may benefit from 
treatment and in informing public health policy. 
Heterogeneity in prevalence estimates, though anecdotally referred to, has not been investigated 
systematically. The heterogeneity could be due to differences in the prevalence of causes, case 
definitions or case ascertainment. Knowledge of these factors would be useful in the design and 
implementation of multi-site studies of epilepsy. Further, differences in causes could have 
implications in resource allocation in public health interventions. 
We conducted a systematic review of published literature to determine heterogeneity in 
prevalence between studies and to provide estimates of the global burden of epilepsy, in 
particular to provide numbers of those with AE who may benefit from treatment. Furthermore, 
we modelled the influence of study level covariates on the prevalence estimates. 
Methods 
Literature searches 
Online databases; MEDLINE, EMBASE, PsycINFO, African Index Medicus, Index Medicus for 
South East Asia, Index Medicus for Eastern Mediterranean Region, BVS Virtual Health Library 
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(Lilacs, Adolec, Medcarib, PAHO and WHOLIS), SIGLE, Proquest, Wang Fang Database of 
English and Chinese online journals published in mainland China, SCIELO, CINAHL and 
Global Health were systematically searched by the first author. Reference lists of identified 
articles were also searched for relevant titles and these were in turn searched online. 
Search strategies 
Where applicable, combined text words and Medical Subject Headings (MeSH) terminology 
were used in addition to the two main search terms [Epilepsy & Prevalence] to identify relevant 
articles (Appendix 2.1). Boolean operators were used to combine search terms as necessary and 
the MeSH subheadings tree was used to increase the specificity of the search terms in MEDLINE 
and EMBASE databases. The review question was broken down into search terms/elemental 
facets to develop a search strategy (Appendix 2.1). This involved the use of the 
recommendations of the National Health Service Centre for Reviews and Disseminations (Khan 
KS et at., 2001). 
Study selection 
We included retrospective, cross-sectional or prospective population based studies measuring 
prevalence of epilepsy from anywhere in the world. Hospital based and medical records/research 
database studies were also examined. The estimate of the prevalence was obtained from papers 
that met the criteria outlined below, which included the International League Against Epilepsy 
(ILAE) definition of LTE and AE (Commission on Epidemiology and Prognosis: International 
League Against Epilepsy, 1993). An additional definition of AE that encompasses seizures 
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within the previous 12 months was also examined, since this is the criteria used for treatment in 
many developing countries. 
Inclusion and exclusion criteria 
A study was included if it: reported prevalence of LTE or AE; collected data using standardized 
previously validated questionnaires in door-to-door surveys, valid hospital and research 
databases and general practice records; provided the denominator to allow recalculation of the 
presented or required estimates; and, included a definition of epilepsy as two or more non- 
provoked seizures occurring at least 24 hours apart. 
A study was excluded if it: examined only acute symptomatic seizures, specific seizure patterns 
or epileptic syndromes e. g. absence seizures; was published as a review, an editorial, an abstract 
only, a letter or a comment; was a study on sub-populations e. g. prevalence of epilepsy on 
patients with a history of head trauma; or, was a part of duplicate populations i. e. those in which 
the same population overlapped different reports. 
Data extraction 
We extracted data using a proforma designed for this review. AKN extracted all the data while 
CRN re-extracted data from a sample of 10% of the studies. From each included study, we 
obtained information on author, country, study type, study population, data collection and 
ascertainment method(s), age of study subjects and whether the estimate was point or period 
prevalence. We used only studies that reported crude prevalence. We calculated the 95% 
67 
confidence interval (95%CI) around the estimates where these were not provided. All meta- 
analyses were carried out in STATA® 10 (College Station, TX, USA). 
Analysis 
In the summary tables, crude prevalence estimates expressed as the number of cases per 1,000 of 
the population were presented with their 95%CI. For all meta-analyses, models were fitted to 
logit-transformed observed prevalences. Estimates of the median, 5th and 95th percentile of the 
distribution of true prevalences (i. e., the distribution of study prevalences that excludes variation 
due to sampling error) were obtained by back-transforming estimates on the logit scale to the 
prevalence scale. 
The data were stratified on the World Bank classification of level of economic development of 
the study country (The World Bank, 2006) but since there were few studies, the countries were 
classified as developed or developing. Studies from developing countries were stratified further 
into urban and rural. Studies were also classified by age into those on all age groups (both 
children and adults), those on adults only (>15 years of age) and those on children only (<_15 
years of age). Studies reporting crude LTE and AE prevalence were analyzed separately. 
Description of heterogeneity 
We used forest plots (Lewis S and Clarke M, 2001) to visualize the heterogeneity among the 
studies. The standard test for heterogeneity, the Cochrane x2 test, was used to examine the null 
hypothesis that the observed heterogeneity was due to sampling error (Higgins JP and Thompson 
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SG, 2002). Since heterogeneity was expected a priori due to clinical and methodological 
diversity in the studies, we also quantified the degree of heterogeneity across studies using the 
statistic I2 = ((Q - df)/Q) x 100%, where Q is the Cochrane chi-squared statistic and df is its 
degrees of freedom (Higgins JP and Thompson SG, 2002; Higgins JP et al., 2003). 1z describes 
the percentage of the variability in estimates that is due to true heterogeneity (true differences in 
prevalence) rather than sampling error. A value greater than 50% was considered as substantial 
heterogeneity. 
The median of the logit transformed prevalences was estimated from the random effects model 
using the command "meta" in STATA®. In addition the 5th and 95`h percentiles were estimated 
as m± 1.96r, where r is the standard deviation of the random effect, i. e. the standard deviation of 
the true study prevalences on the logit scale. These quantities were then back-transformed to the 
original prevalence scale. This approach uses information on prevalence and study size (or 
equivalently standard errors/confidence intervals) and is applicable when there is significant 
heterogeneity (Goodman SN, 1989). It involves an assumption that the outcomes (such as logit 
prevalences) being estimated in the different studies are not identical, but follow a normal 
distribution, allowing for among study variation (Goodman SN, 1989). 
Estimation of the number of epilepsy cases 
Data on the mid-year population sizes of developed countries were obtained from the U. S. 
Census Bureau, International Data Base (US Census Bureau, 2007). Rural and urban population 
sizes in developing countries were obtained from the Columbia University's Global Rural-Urban 
Mapping Project (GRUMP) database (Center for International Earth Science Information 
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Network (CIESIN), Accessed 27 July, 2009). The numbers of cases of LTE and AE were 
estimated by multiplying the estimated median prevalence obtained from the meta-analysis by 
the average size of the population during the period in which studies in this review were 
conducted. A range was obtained using the 5`h and 95`h percentiles. 
Investigation of the sources of heterogeneity 
The following five study level covariates were investigated for their association with prevalence 
estimates: level of economic development, age of study participants, method of data collection, 
type of estimate (point or period prevalence) and study size. The influence of these variables on 
study prevalence was investigated using random effects meta-regression models. The models 
were fitted using the "meterreg" command in STATA®. This approach assumes two additive 
components of variance, one representing the variance within studies (i. e., error variance), and 
the other the variance between studies. The regression coefficients represent log odds ratios since 
the models are fitted to logit-transformed data. The proportion of heterogeneity explained by 
each of the covariates was estimated by comparing the between studies component of variance in 
the null model (io2) with the estimate of t2 for the model including covariates ((T02_ T)/ i 2). 
Both univariate and multivariable meta-regression were performed. Variables that were 
significant in the univariate analysis were included in the multivariable model using a forward 
selection strategy. The order in which variables were introduced into the multivariate model was 
determined by the size of the p-value in the univariate analysis (starting with the smallest p- 
value). No further variables were introduced when p>0.05 for the introduced variable. 
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Results 
Studies identified 
Literature searches from all sources were as displayed in Figure 2.1. Reasons for exclusion of the 
136 studies that underwent full text review are displayed in Appendix 2.2. Of the 65 studies 
included (Appendices 2.3(a) & (b)), 28 reported LTE prevalence only, 18 reported both LTE and 
AE prevalence while 19 reported prevalence of AE only. Thirty-four were from developing and 
31 from developed countries. Among studies from developing countries, LTE was reported in 16 
studies from rural areas and nine studies from urban areas. AE was reported in nine studies from 
rural areas and four from urban areas. Thirty-seven studies were conducted in both adults and 
children, 17 were in children only and 11 were in adults only. 
Period prevalence was estimated in 20 of the studies, while point prevalence was estimated in the 
rest. The studies did not all use the same methods for data collection: 20 studies used primarily 
medical records, 35 used questionnaires in cross-sectional field surveys while 10 used medical 
records to ascertain cases identified through questionnaires. Sixty papers were written in English, 
four were Spanish and one was in French. 
Three studies from developing countries defined AE as epilepsy in which the last seizure 
occurred in the previous 12 months. 
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Figure 2.1: Literature search and identification of studies for the meta-analysis. 
Application of search strategy 
on-line search 
(N = 2009) 
Inclusion criteria on titles/abstracts 
Not met Met criteria 
criteria (1808) (201) 
Full text review 
Not met Met criteria 
criteria (136) 
11 
(65) 
Developed 
countries 
(31) 
Developing 
countries 
(34) 
LTE only (28) 
LTE + AE (18) 
AE only (19) 
Description of heterogeneity for studies of LTE 
Most of the variability in prevalence estimates was attributable to study heterogeneity (12 = 98%, 
p<0.001) (Figure 2.2), both from developed (J2 > 99%; P<0.001) and developing countries 
(12=98%; P<0.001). The estimates also showed significant heterogeneity (I2 > 90%) after 
stratifying on age of study subjects and rural/urban locations for developing countries. 
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The estimated median prevalence for developed countries was 5.8/1,000 (51, - 95`h percentile 
range: 2.7 - 12.4). In developing countries, the median prevalence and range of LTE was 
15.4/1,000 (4.8 - 49.6) in rural areas and 10.3/1,000 (2.8 - 37.7) in urban areas (Table 2.1). On 
stratification by the age of study subjects, the median prevalence and 5th to 95th range was: 
9.7/1,000 (4.6 - 20.5) for all age groups, 11.3/1,000 (4.2 - 30.5) for studies with adults only and 
6.7/1,000 (1.6 - 27.2) for studies of children only. 
Description of heterogeneity for studies of AE 
The estimated median prevalence of AE for developed countries was 4.9/1,000 (5th - 95th 
percentile range: 2.3 - 10.3). In the developing countries, the median prevalence and range of 
AE was 12.7/1,000 (3.5 - 45.4) in rural areas and 5.9/1,000 (3.4 - 10.2) in urban areas (Table 1). 
When stratified on age of study participants, the median prevalence and range was 7.0/1,000 (2.9 
- 16.8) for all ages, 7.0/1,000 (2.4 - 20.6) for adults and 4.7/1,000 (3.3 - 6.9) for paediatric 
studies. There was substantial heterogeneity in the estimates, (I2= 90%, p<0.001). 
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Estimates of the number of epilepsy cases 
The estimated median number of people with LTE in developed countries was 6.8 million (5t' - 
95th range: 3.2 - 14.7 million) and for AE it was 5.7 million (2.7 - 12.2 million). In the 
developing countries, the median and range of LTE cases were 45 million (14 - 145 million) in 
rural areas and 17 million (5 - 61 million) in urban areas. AE constituted 38% of LTE cases in 
rural and 59% in urban areas (Table 2.1). 
Table 2.1: Median prevalence and numbers of cases of life-time and active epilepsy. 
Epilepsy R i 
Median 
th 5 Mean 
No. of cases in 
millions median 
Percent 
Type on eg prevalence/1,000 ( to 
95'h il 
Population* ( 5th to 95th 
LTE with 
e range) percent AE range) 
Developed 5.8 (2.7 - 12.4) 1,184,235,962 6.8 (3.2 -14.7) 84 
**Rural = 15.4 (4.8 - 2,929,891,835 45(14-145) 38 LTE 
Developing 49.6) 1,619,261,754 17(10-133) 59 
Urban = 10.3 (2.8 - 37.7) 
Developed 4.9 (2.3 -10.3) 1,184,235,962 5.7 (2.7 -12.2) 
AE : Rural 12.7 (3.5 - 45.4) 2,929,891,835 17(5-61) Developing 
Urban = 5.9 (3.4 - 10.2) 1,619,261,754 10(5-17) 
*averaged over the period the selected studies were conducted. 
** 1 study mixed rural and urban populations (not included in the analysis) 
$I study mixed rural/urban populations and 1 unknown (both not included in the analysis) 
Sources of heterogeneity in studies of LTE prevalence 
In the univariate analysis, study size explained 45.3% of the observed heterogeneity and studies 
with fewer than 1,000 subjects were more likely to have higher prevalence estimates than larger 
studies (p < 0.001). The development level of the study country explained 26.4 % of the between 
study variance. In developing countries, studies from both urban and rural areas had roughly two 
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times or more the prevalence of those from developed countries (Table 2.2). Age of subjects, 
method of data collection and type of estimate were not associated with prevalence. In the 
multivariable regression for all LTE studies, rural areas of developing countries, studies in all 
age groups and small studies (n <= 20,000) were significantly associated with the prevalence 
estimates (Appendix 2.4); together, these variables accounted for 52.8% of the observed 
heterogeneity. 
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Sources of heterogeneity in studies of AE prevalence 
In the univariate analysis of all AE studies, country development level and study size were 
significantly associated with prevalence estimates (p < 0.05), explaining 31.7% and 26.4% of the 
observed heterogeneity respectively. In the developing countries, studies from rural areas had 
significantly higher prevalence estimates (OR = 2.5 (95% Cl; 1.7 - 3.8)) relative to studies from 
developed countries. Small study size (n<1,000) was also associated with higher prevalence 
estimates (OR = 3.4 (95%CI; 1.7 - 6.6)). In the multivariable analysis, rural areas and small 
study size (n<1,000) were significantly associated with prevalence estimates and together 
accounted for 42% of the observed heterogeneity (Appendix 2.5). 
Discussion 
This study describes the distribution of prevalence in studies of people with LTE and AE across 
the world. Numbers of cases of LTE are provided for developed countries as well as for rural and 
urban locations of developing countries. Combined, these numbers provide a global estimate of 
cases of LTE which could be much higher than the figure of 50 million estimated by the WHO 
(WHO, 2004). The number of people with AE who should be considered for treatment in each 
region is also estimated. The studies included in these analyses however showed considerable 
heterogeneity, which we quantified using robust meta-analysis (Egger M et al., 1997; Higgins JP 
and Thompson SG, 2002; Higgins JP et al., 2003). There was substantial variation in the 
prevalence of both LTE and AE even within studies of similar age group or level of economic 
development. Other estimates of the prevalence of LTE from developed countries (Sander JW 
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and Shorvon SD, 1996) and from developing countries (Preux PM and Druet-Cabanc M, 2005) 
are within the ranges reported in this study. 
In this meta-analysis the prevalence of LTE is higher in studies of adults than studies of all ages 
(both adults and children), while it is lowest in children. The median prevalence of AE was 
similar for studies on all ages and adults only, but lower in studies on children. These data also 
showed that small studies (n < 1000), and studies conducted in less developed regions were 
associated with a higher prevalence of epilepsy. In developing countries, these data show that 
the prevalence of LTE is highest in rural areas, with the urban estimates being mid-way between 
those of rural areas and developed countries. Additionally, the prevalence of AE in urban areas 
of developing countries is closer to that of developed countries, with that of rural areas being 
considerably higher. 
To the best of our knowledge, this is the first study that comprehensively reviews and analyses 
available literature to provide robust estimates of the global burden of epilepsy, assesses and 
quantifies the variability of the estimates and investigates the influence of study level covariates 
in the observed heterogeneity. The few reviews conducted previously have been regional e. g. 
Latin America (Burneo JG et al., 2005), exploring incidence and prevalence only (Burneo JG et 
al., 2005), or incidence only (Kotsopoulos I et al., 2005; Kotsopoulos et al., 2002), or mortality 
only (Diop et al., 2005; Forsgen L et al., 2005). Furthermore, this is the first study that provides 
an estimate of the burden of AE that could benefit from treatment. 
79 
The difference in heterogeneity of LTE prevalence estimates between developed and resource- 
poor countries can be explained in part by the fact that medical records, used primarily to 
ascertain cases in developed countries, are to some extent standardized, and provide consistent, 
detailed information on patients leading to less variation in recorded data. Where available, 
medical records are also used to ascertain cases identified through questionnaires. Additionally, 
the smaller amount of variation in studies from developed countries could be caused by the use 
of single district, regional and/or national databases that use similar diagnostic codes such as the 
National General Practice Study of Epilepsy database in the UK. Others include use of the 
diagnostic record system in Rochester, US (da Mota Gomes M et al., 2002; Hauser WA et al., 
1993 ; Racoosin JA, 2003; Tidman L et al., 2003) or the use of the Health Maintenance 
Organizations' records (Annegers JF et al., 1999 ; Holden EW et al., 2005). 
Previously, data from developing countries was thought to vary widely due to differences in 
methodology (such as the use of non-standard screening tools), differences in definitions, 
diagnosis and classification (Leonardi M and Ustan TB, 2002; Preux PM and Druet-Cabanc M, 
2005). The selection criteria for our meta-analyses and the meta-regression models however 
suggest that these factors account for an insignificant amount of variation. Rather, age of study 
participants and sample size are more important causes of the observed heterogeneity. These 
factors may be further compounded by poor health care, lack of specialized medical personnel 
and diagnostic equipment. This is particularly evident given that the prevalence estimates for 
urban areas, with higher concentration of health facilities and specialists, are mid-way between 
those of rural areas and the developed countries. The higher estimates of LTE prevalence in 
developing countries are likely to be due to higher incidence of epilepsy (Sander JW and 
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Shorvon SD, 1996) which could in turn be attributable to infectious aetiology, particularly in 
rural areas (Matuja et al., 2001; Ogunniyi et al., 1987; Preux PM and Druet-Cabanc M, 2005). 
The trend towards a higher prevalence of AE is also apparent in rural areas of developing 
countries. A much lower prevalence of AE in urban areas that closely approximates estimates 
from developed countries could be due to better access to health services, diagnosis and 
management. Rural areas of developing countries have a large burden of untreated epilepsy 
possibly due to stigma, beliefs and attitudes about causes and consequences of epilepsy and 
limited access to health services. Further, recall of seizure events over a 5-year period may be 
poorer in rural areas due to low literacy levels and may lead to underestimation of prevalence 
(Saha SP et al., 2008). 
The proportions of people with AE are higher in developed countries and urban areas of 
developing countries than in rural areas could also be due to higher mortality in the latter, though 
few data on epilepsy mortality in developing countries are available and these are not segregated 
for rural and urban areas (Carpio et al., 2005; Diop et al., 2005). This could imply that people 
with better controlled seizures live longer on average even though they may continue to 
experience seizures. We have estimated the prevalence of treatment gap to be 56% (95% Cl; 31 
- 100%) in developing countries, with higher estimates for rural areas (Mbuba et al., 2008). The 
better access to healthcare in urban areas of developing countries and in the HIC suggests that 
not only management of seizures but also management of the less severe life threatening 
aetiologies improve life-expectancy in PWE. 
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The higher estimates of heterogeneity observed in rural areas could be due to spatial clustering of 
risk factors, particularly parasites (Brooker S et al., 2006), associated with development of 
epilepsy. This observation could be partly due to clustering of genetic risk factors in rural areas, 
where relatives tend to live in close vicinity. 
Small study size (fewer than 20,000 subjects screened) was associated with a higher prevalence 
of epilepsy possibly because some studies are conducted in communities where the prevalence of 
epilepsy is suspected to be high. For instance, one was in a small isolated population of 
Panamanian Indians where apparently a family history of epilepsy was a significant risk factor 
(risk ratio = 14) (Gracia F et al., 1990). 
The prevalence of epilepsy is determined by the rate at which new cases arise and the rate at 
which existing cases are lost due to death and recovery. The prevalence of LTE increases with 
age because there is, by definition, no recovery. Thus the older an individual is the more likely 
they are to have had epilepsy at some point during their lifetime. An association is observed 
between AE and age because of a low rate of loss of AE cases (due to recovery and death) from 
the population. 
The variables location, age of study participants and study size taken together account for 53% of 
the variance in prevalence of LTE. Thus much of the variation in study prevalence is attributable 
to factors not considered in this meta-analysis. For example, variability in the prevalence of 
genetic or parasitological risk factors or the extent of the treatment gap may be responsible for 
some of this unexplained variation. 
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Limitations of the study 
The main assumption of estimates of the number of epilepsy cases is that the studies used in the 
analysis are representative of the populations of both developed and developing countries. 
However, this is not the case, particularly as there are no data from many parts of the world. The 
estimates presented in this study therefore need to be interpreted judiciously. 
The estimates presented in these analyses are likely to be influenced by different demographic 
structures, particularly between developed and developing countries. However, it was not 
possible to derive age-adjusted estimates, mainly because studies presented different age 
categories, if at all. 
Despite the fact that there was no time-limit criterion for inclusion, almost all the selected studies 
were published after 1990. This was because of the definition criteria of epilepsy used, which 
was introduced by the ILAE at this time (Commission on Epidemiology and Prognosis: 
International League Against Epilepsy, 1993). The definition of AE often used in less developed 
regions is at least two unprovoked seizures one of which should be in the previous 12 months, 
but this was used in only 3 studies. It would have been interesting to compare the mean 
prevalence estimate based on this definition from a larger number of studies. 
In the meta-regression analysis, the choice of covariates was influenced by the availability of 
information and therefore heterogeneity could only be explained by factors for which 
information was available. Ideally future studies should include more appropriate factors, e. g. 
level of treatment gap, which may influence prevalence. 
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Conclusions 
This study uses a meta-analysis to provide estimates of the burden of epilepsy. We demonstrate 
substantial heterogeneity in estimates of the prevalence of epilepsy and identify factors 
responsible for this heterogeneity. This study provides estimates of the burden of AE which can 
be used as a guide to the number of people who could benefit from treatment. 
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Abstract 
Objective: To estimate the pooled incidence of epilepsy from published studies and investigate 
sources of heterogeneity in the estimates. 
Methods: We searched online databases for incidence studies and used meta-analytic methods to 
analyze the data. 
Results: Thirty-three articles met the entry criteria. The median incidence of epilepsy was 
50.4/100,000/year (interquartile range (IqR): 33.6-75.6), while it was 45.0 (IqR: 30.3-66.7) for 
high income countries and 81.7 (IqR: 28.0-239.5) for low and middle income countries. 
Population-based studies had higher incidence estimates than hospital-based studies (p=0.02) 
while retrospective study design was associated with lower estimates than prospective studies 
(p=0.04). 
Conclusion: We provide data that could potentially be used to assess the burden and analyze the 
trends in incidence of epilepsy. Our results support the need for large population-based incidence 
studies of epilepsy. 
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Introduction 
Epilepsy is one of the most prevalent non-communicable neurological conditions and an 
important cause of disability and mortality (WHO, 2004). It is estimated to affect almost 70 
million people worldwide. The prevalence of epilepsy in Low and Middle Income Countries 
(LMIC) is more than twice that of High Income Countries (HIC) (Chapter 2). Since mortality is 
high early in the course of epilepsy and spontaneous remission may occur (Carpio et al., 2005; 
Diop et al., 2005; Kwan and Sander, 2004; Sander, 1993), prevalence data may significantly 
underestimate the burden of epilepsy. Thus, incidence of epilepsy, which is not diminished by 
disease-specific mortality, could be useful in enriching prevalence data in the assessment of the 
burden of epilepsy. 
While many prevalence studies have been reported (Benamer HT and Grosset DG, 2009; Burneo 
JG et al., 2005; Preux PM and Druet-Cabanc M, 2005) including those presented in chapter 2 of 
this thesis, there are only a few studies of incidence. Existing studies suggest a higher incidence 
of epilepsy in LMIC than in HIC, although it is not clear if this difference is real or due to 
methodological differences (Sander JW, 2003). These estimates are diverse, limiting their utility 
in informing public health policy and resource allocation for prevention. Reasons for this 
variability are not clear. 
One published review of the incidence of epilepsy did not utilize meta-analytic methods 
(Kotsopoulos et al., 2002). It did not provide confidence intervals for the aggregate estimates, 
quantify heterogeneity in incidence rates or identify the reasons for the observed variation. 
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We conducted a systematic review and meta-analysis of published literature, estimating the 
median incidence of epilepsy among all the studies as well as within HIC and LMIC separately. 
We also investigated and quantified the sources of heterogeneity between the studies. 
Methods 
Data sources and search strategy 
We searched all published papers of population studies on the incidence of epilepsy in electronic 
databases MEDLINE and EMBASE (up to November, 2010), Index Medicus for South East 
Asia, Index Medicus for Eastern Mediterranean Region, Directorate of Open Access Journals, 
SCIELO and LILACS. We also searched OpenSIGLE, Proquest and the Wang Fang Database of 
English and Chinese online journals published in mainland China. In addition, we searched for 
potentially useful references cited in the key papers and conducted several trial searches to 
harmonize the final strategy and to increase the sensitivity and specificity of the search. Articles 
were identified with search terms "epilep*" and "incidence" in all databases and with limits 
[Humans, Clinical Conference, Journal Article, Multicenter Study, English, French, German, 
Spanish, Portugese] in MEDLINE and EMBASE (Appendix 3.1). Two authors (AKN & SMK) 
reviewed the titles and abstracts of articles obtained from on-line searches and reprints of articles 
eligible for full-text review were obtained. We broke down the review question into search 
terms/elemental facets to develop a search strategy. This involved using the recommendations of 
the National Health Service Centre for Reviews and Disseminations (Khan KS et al., 2001). 
92 
Inclusion and exclusion criteria 
We included all retrospective and prospective population-based studies measuring incidence of 
epilepsy, and included hospital-based and research database studies if they included a population 
denominator. We considered studies for inclusion if they included a definition of epilepsy as two 
or more unprovoked seizures occurring at least 24 hours apart and not acute symptomatic 
seizures (Commission on Epidemiology and Prognosis: International League Against Epilepsy, 
1993). We included studies measuring only cumulative incidence if they provided clear 
information on duration of follow-up and the numbers at risk at the beginning of the observation 
period. 
We excluded studies if they explored only acute symptomatic seizures or only specific seizure 
patterns or specific epileptic syndromes. We excluded reviews, editorials, single cases and case 
series, studies published only as abstracts, letters or commentaries, studies of special groups e. g. 
incidence of epilepsy in people with a history of head trauma, or if they were part of duplicate 
populations. 
Data extraction 
We designed, piloted and revised a standardized data abstraction form to capture all the relevant 
study-level information required for analysis. AKN and SMK extracted data independently and 
resolved disagreements by consensus. For included studies, we recorded information on author, 
year of publication, country, study design, study population (or total person-years of follow-up), 
duration of follow-up, data collection and ascertainment method (medical records or 
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questionnaires [with physical examination] in population-based studies), age of subjects, number 
of people with incident epilepsy and whether the outcome was a crude or an adjusted estimate. 
Analysis 
We tabulated crude incidence estimates expressed per 100,000 persons per year in summary 
tables along with their 95% confidence intervals (CI), and we classified studies as coming from 
HIC or LMIC (The World Bank: 2006). To estimate pooled median incidence rates and assess 
for heterogeneity, we fitted random effects models to log-transformed observed incidence in 
STATA vl1 (Stata corp, TX, USA). We obtained estimates of the median incidence, and 25th 
and 75th percentile of the distribution of true incidence by back-transforming the log estimates to 
the original incidence scale. 
We used the Cochrane x2 test to examine the null hypothesis that the observed heterogeneity was 
random (Higgins JP and Thompson SG, 2002) and calculated the degree of heterogeneity using 
the statistic 12 = ((Q - dt)/Q) x 100%, where Q is the Cochrane chi-squared statistic and df is the 
degrees of freedom (Higgins JP and Thompson SG, 2002; Higgins JP et al., 2003). 
To determine the influence of the study-level factors on the observed variability, we used 
random-effects meta-regression. We estimated the proportion of heterogeneity attributable to 
each covariate by comparing the between studies component of variance in the null model (T02) 
with the estimate of i2 for the model with the covariate of interest ((t02- r)/ T0). 
In these analyses, we investigated only the influence of standardized study-level covariates on 
the variability of the observed incidence estimates for all studies and for those conducted in HIC. 
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The small number of studies (n=9) from LMIC would not allow meaningful examination of the 
influence of these factors for these countries. We performed our analyses on observed crude 
incidence estimates only, primarily because there were very few studies that reported adjusted 
estimates only (n=4). 
A total of seven study-level covariates were investigated for their influence on incidence 
estimates for HIC and all countries (HIC and LMIC combined) (Appendix 3.2). We performed 
both univariate and multivariable meta-regression. Variables that showed evidence of an 
association at the significance level p_<0.25 in the univariate analysis were further investigated 
using multivariable models. Due to the small number of studies (n=33) relative to the number of 
covariates (n=7) (and following standard recommendations for model size relative to sample size 
(Altman D, 1991; Robins JM and Greenland S, 1986)), we included only level of development in 
each multivariable model in addition to the covariate of interest. 
Results 
Search results 
The initial search identified 2,304 articles, of which 43 were retained for full text review after 
examination of titles and abstracts. The search criteria and the total numbers of articles identified 
in these steps are shown in Figure 3.1. After full text review, we excluded ten studies: addressed 
seizures rather than epilepsy (n=1); only age-specific estimates provided (n=1); no definition of 
epilepsy and/or no denominator data (n=4); duplication (n=1); inappropriate definition of 
epilepsy (n=1); review (n=l); and no numerator provided (n=1). 
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Figure 3.1: Search results 
Online Search (All databases) 
2,304 Articles 
Inclusion/Exclusion criteria on 
titles and abstracts 
43 Articles selected 
Full text review 10 articles excluded (See text) 
33 Articles retained 
Of 33 studies retained, 19 had a prospective and 14 had a retrospective cohort design. In all, 24 
studies were from HIC while only 9 were from LMIC. Twelve studies were in children only 
while 21 were either in adults or all age groups. More than half of the studies (19/33) used solely 
medical records to identify incident cases in retrospective cohorts and 25/33 had population sizes 
above 20,000 people. Almost half (15/33) of the studies had follow-up of less than 3 years. All 
except one Spanish study (Dura et al., 2007) were published in English. 
Half (12/24) of the studies from HIC were pediatric studies and the other half included all age 
groups, whereas in LMIC all studies were in all age groups. Further, 18/24 of the studies from 
HIC used medical records to ascertain cases while 7/9 from LMIC identified cases using 
questionnaires with some form of clinical examination in population-based studies. More than 
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half (5/9) of the studies in LMIC followed cohorts of fewer than 20,000 subjects, and the 
majority of these (8/9) for less than 5 years. In contrast, 21/24 of the studies in HIC used cohorts 
of more than 20,000 individuals with 10/21 followed for more than 5 years. (See Appendix 3.3 
for details). 
Estimates of incidence and heterogeneity among studies 
The estimated median incidence of epilepsy for all studies combined was 50.4/100,000 
persons/year (interquartile range: 33.6-75.6). The LMIC median incidence rate of 81.7 (28.0- 
239.5) was higher and the interquartile range was greater than for HIC (45.0 (30.3 -66.7)/100,000 
persons/year). Most of the variability in the estimates was attributable to unexplained between- 
study heterogeneity for both HIC (J2 = 98.5%) and LMIC (I2 =98.2%). 
Sources of heterogeneity of incidence estimates 
In the univariate analysis of studies from HIC, age of study participants had a small association 
with incidence estimates (with pediatric studies associated with slightly higher incidence 
estimates than studies with both adults and children), accounting for 2.3% of the observed 
heterogeneity (Table 3.1). Studies with retrospective design were associated with lower 
incidence estimates, although this was marginal. 
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Table 3.1: Meta-regression of incidence of epilepsy from HIC, univariate analyses. 
Covariate Categories No. Rate Ratio P Heterogeneity Percent 
(1" listed is studies (95% CI) value (r2) Heterogeneity 
reference) 
Null model - 24 - - 0.078 
Age All Children 12 1.0 
0.18 0.076 2.3 
12 1.2 (0.9 - 1.5) 
Data Records 18 1.0 
collection Records & 6 1.0 (0.7 - 1.4) 0.86 0.082 Nil 
questionnaires 
Population >100,000 3 1.0 
size 20,000-100,000 10 1.0 (0.8 - 1.4) 0.94 0.086 Nil 
<20,000 11 1.0 0.7 - 1.6 
Duration >10 3 1.0 
(years) 5-10 7 0.9 (0.5 - 1.6) 0.36 0.076 2.7 
3-5 3 1.2 (0.8 - 1.9) 
<3 11 1.3(0 .8 -2.0) 
Decade 1980 5 1.0 
1990 9 1.0 (0.7 - 1.4) 0.77 0.083 Nil 
2000 10 1.1 0.8 -1.6) 
Study Design Prospective 13 1.0 
Retrospective 11 0.9 (0.7 - 1.1) 0.20 0.076 3.3 
Univariate analysis of the combined data showed that the level of income in the country was 
associated with variability of incidence estimates, accounting for 29.6% of the heterogeneity. 
Studies from LMIC had higher incidence estimates (RR = 1.8) than HIC (Table 3.2). Three other 
variables also influenced the incidence estimates (Table 3.2): study size (accounting for 14.9% of 
the observed heterogeneity), method of case identification (48.0%) and study design (10.7%). 
Studies using screening questionnaires to identify incident cases in population-based studies 
were associated with higher incidence estimates as were studies with sample sizes < 20,000. 
Retrospective study designs had lower incidence than prospective designs (Table 3.2). 
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Table 3.2: Meta-regression of incidence of epilepsy from all countries, univariate analyses 
(n = 33). 
Covariate Categories No. Rate Ratio P Heterogeneity Percent 
(Vt listed is studies (95% CI) value (T2) Heterogeneity 
reference) 
Null model - 33 - - 0.190 - 
Development HIC 24 1.0 
LMIC 9 1.8 1.3 - 2.5 <0.001 0.134 29.6 
Age All 21 1.0 0.61 0.196 Nil 
Children 12 0.9 (0.7 - 1.3) 
Data Records 19 1.0 
collection Questionnaires 7 2.3 (1.7 - 3.2) <0.001 0.099 48.0 
Records & 7 0.9 (0.7 - 1.3) 
questionnaires 
Population >100,000 11 1.0 
size 20,000-100,000 14 1.1 (0.8 - 1.6) 0.02 0.162 14.9 
<20,000 8 1.8 (1.2 - 2.7) 
Duration >10 3 1.0 
(years) 5-10 8 1.4 (0.7 - 2.7) 0.43 0.200 Nil 
3-5 7 1.7 (0.9 - 3.4) 
<3 15 1.3 (0.7-2.5) 
Decade 1980 6 1.0 
1990 14 1.4 (0.9 - 2.2) 0.3 0.189 0.5 
2000 13 1.3 0.8 - 2.1 
Study Design Prospective 19 0 
Retrospective 14 0.7 (0.6 - 0.9) 0.04 0.170 10.7 
In the multivariable analysis of the combined data (Table 3.3), studies using only screening 
questionnaires to identify cases were associated with higher estimates (RR=2.8) and the method 
of data collection explained 24.7% of the observed heterogeneity (after adjusting for level of 
development). Study design was also associated with variability of the incidence rates, with 
retrospective cohort studies reporting lower estimates than prospective studies (RR=0.8) and this 
accounted for 9% of the heterogeneity. 
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Table 3.3: Meta-regression of incidence of epilepsy from all countries, multivariable 
analyses: reported rate ratios are adjusted for level of development (n = 33). 
Covariate Categories No. Rate Ratio P Heterogeneity Percent 
(Vt listed is studies (95% CI) value (s2) Heterogeneity 
reference) 
Development HIC 24 1.0 
LMIC 9 1.8 (1.3 - 2.5) <0.001 0.134 - 
Data Records 19 1.0 
collection Questionnaires 7 2.8 (1.5 - 5.3) 0.003 0.101 24.7 
Records & 7 1.0 (0.7 - 1.3) 
questionnaires 
Population >100,000 11 1.0 
size 20,000-100,000 14 1.0 (0.7 - 1.4) 0.28 0.134 Nil 
<20,000 8 1.3(0.9- 
Study Design Prospective 19 1.0 
Retrospective 14 0.8 (0.7 - 1.0) 0.05 0.122 8.9 
Discussion 
Our estimates suggest that the incidence of epilepsy in LMIC is approximately twice that of HIC. 
A similar finding was made in a previous review, although heterogeneity was not examined". 
The cause of the higher incidence in resource poor compared to industrialized countries is likely 
to be multi-factorial. The higher incidence of head trauma and of infections and infestations of 
the central nervous system such as malaria, neurocysticercosis and invasive bacterial infections 
may be important causes (Carter JA, 2004; Matuja et al., 2001; Newell et al., 1997; Nicoletti et 
al., 2002; Nicoletti et at., 2007; Nsengiyumva et at., 2003; Ogunniyi et at., 1987; Preux PM and 
Druet-Cabanc M, 2005). Several studies have demonstrated important linkages between ion 
channel polymorphisms and development of seizures (Berkovic SF and Scheffer JE, 2001; 
Chioza B et al., 2002; ILAE, 2002; Sander T, 2000; Wallace RH et al., 2002), although it is not 
clear whether there are any differences in these polymorphisms between LMIC and HIC. Further 
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studies in Africa (Goudsmit J and van der Waals FW, 1983; Jilek-Aall L et al., 1979; Jilek WG 
and Jilek-Aall LM, 1970; Neuman RJ et al., 1995; Versteeg AC et al., 2003) have demonstrated 
familial clustering of epilepsy, suggesting that genetic factors could also play an important role 
in the high incidence of epilepsy. Some studies from LMIC may include people with acute 
symptomatic seizures in their measurements, thus raising incidence estimates. 
There is conflicting evidence regarding the role of socioeconomic deprivation in the 
development of epilepsy in the HIC where some studies have reported a positive association with 
level of deprivation while others found no association (Heaney et al., 2002; Hesdorffer et al., 
2005; Reading et al., 2006). One study in LMIC (Birbeck et al., 2007) found that people with 
epilepsy were of lower socio-economic status than people with non-stigmatized medical 
conditions although the direction of causality in this association was unclear. The difference in 
incidence could also be accounted for by methodological differences (Sander JW, 2003), 
although this is less likely (Chapter 2). 
The measures of heterogeneity (f) for both pooled estimates were above 50%, suggesting that 
the observed differences were due to between study variability rather than sampling variation 
(Higgins JP and Thompson SG, 2002; Higgins JP et al., 2003). The tendency towards larger 
heterogeneity of incidence estimates reflects what was observed in a review of prevalence 
(Chapter 2). This was documented despite using a standardized selection criteria for our analysis 
that was based on definitions of epilepsy used and study methodologies. In addition to the study- 
level covariates that we have investigated, we hypothesize that the observed heterogeneity could, 
101 
in part, be attributed to unmeasured factors such as between region differences in epilepsy risk 
factors, as well as levels and quality of health service provision. 
In the univariate analysis of the effect of study-level factors, age of study subjects and 
retrospective design explained a modest amount of variability in the incidence rates in HIC. 
The paediatric studies were associated with higher incidence estimates than those involving all 
age groups. This observation perhaps mirrors the risk factor profiles for these age groups, in 
which higher incidence in children has been attributed mainly to antenatal, perinatal and 
postnatal insults and CNS infections, causing cerebral palsy and intellectual disability 
(Commission on Epidemiology and Prognosis: International League Against Epilepsy, 1993), 
which could be prevented. In the combined analysis of data from both HIC and LMIC, the 
method used to identify incident cases, age of participants and duration of follow-up appeared to 
explain significant proportions of the observed heterogeneity. Use of screening questionnaires to 
identify cases in population-based studies was associated with higher estimates than studies 
using medical records in hospital-based studies. In resource-poor settings with scanty allocation 
of health care resources and few specialists coupled with poor access to services 
(WHO/IBE/ILAE, 2005), lack of knowledge and stigma associated with epilepsy (Baskind and 
Birbeck, 2005; Birbeck and Kalichi, 2003; El Sharkawy et al., 2006; Nubukpo et al., 2004), 
medical records are unavailable or unreliable and may underestimate the incidence. It is also 
possible that only people with very severe epilepsy in both HIC and LMIC present to hospital, 
leading to underestimation of incidence rates in hospital-based studies. Therefore, population- 
based studies, particularly in LMIC, should be encouraged to ensure valid estimates of incidence 
of epilepsy. 
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With regard to the observed association between small sample size (n: 520,000) and high 
incidence rates, a plausible explanation is that small studies are more likely to be conducted in 
areas with a higher risk of epilepsy such as a study in Uganda in an area with high prevalence of 
onchocerciasis, which is a putative risk factor for epilepsy (Kaiser C et al., 1998 May) and others 
conducted in areas with high prevalence of cysticercosis (Villaran et al., 2009). 
Results from multivariable analyses of all studies indicate that level of development, method of 
incident case identification and study design accounted for moderate proportions of the observed 
heterogeneity. Retrospective studies were associated with lower incidence estimates, most likely 
due to incomplete incident case identification in hospital-based records used in these study 
designs. Factors such as differences in prevalence and distribution of risk factors and patient 
characteristics could be responsible for most of the unexplained heterogeneity. 
Limitations of the study 
A major limitation of this study was the relatively small number of studies, particularly from 
LMIC. This led to wide confidence intervals for the pooled estimates and low power to detect 
associations between study-level covariates and the incidence estimates, even in the combined 
data from both HIC and LMIC. 
Another limitation was that it was not possible to use narrower age categories since studies 
provided either overall estimates or age-specific estimates with different age categories. We 
therefore grouped studies broadly into those that included children only or studies of entire 
populations. In the regression models, the choice of covariates was limited to the information 
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provided by the included studies. These covariates were able to explain only a limited amount of 
the observed study heterogeneity. The residual study heterogeneity is attributable to unmeasured 
factors such as the prevalence of epilepsy risk factors in the study populations. 
Conclusion 
We estimated the median incidence of epilepsy as almost twice as high in LMIC as in HIC. 
There was significant heterogeneity between study estimates but we could identify only a few 
factors that accounted for a small proportion of this heterogeneity in the studies. The small 
number of studies with wide variation limits their utility in informing public health policy and 
allocation of resources for prevention. These results provide baseline information that can be 
used to monitor future trends in the incidence of epilepsy, particularly in LMIC as they undergo 
epidemiological transition. 
The meta-regression analysis found that region of study (HIC vs. LMIC), field-based 
questionnaire studies and retrospective study design were associated with heterogeneity of the 
observed estimates. These findings suggest the need to standardize data collection in future 
incidence studies to help target interventions to prevent epilepsy. 
Our analysis also suggests the need for large population-based incidence studies of epilepsy, 
particularly in LMIC, to generate more accurate estimates as well as provide a reasonably robust 
assessment of heterogeneity. 
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Abstract 
Background: There are few studies on the epidemiology of epilepsy in large populations in Low 
and Middle Income Countries (LMIC). Most studies conducted in these regions use of two-stage 
population-based screening surveys, but these surveys are time-consuming and costly to 
implement in large populations required to generate accurate estimates. We examined the 
sensitivity and specificity of a three-stage cross-sectional screening methodology in detecting 
active-convulsive epilepsy (ACE), which can be used in large populations in demographic 
surveillance systems. 
Methods: We conducted a population-based validation of the three-stage cross-sectional 
screening methodology on a randomly selected sample of participants of a three-stage prevalence 
survey of epilepsy. Diagnosis of ACE by an experienced clinician was used as a `gold standard'. 
We further compared the expenditure of this method with the standard two-stage methodology. 
Results: We screened 4442 subjects in the validation survey and identified 35 cases of ACE. Of 
these, 18 were identified as false negatives, most of which (15/18) were missed in the first stage 
and a few (3/18) in the second stage of the three-stage screening. Overall, this methodology had 
a sensitivity of 48.6% and a specificity of 100% and was 60% cheaper than a clinician-conducted 
two-stage survey. 
Conclusion: This was the first study to evaluate the performance a multi-stage screening 
methodology used to detect epilepsy in demographic surveillance sites. Overall, this method had 
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poor sensitivity, which we attributed mainly to non-response in the first stage. Use of this 
method needs to take into consideration the poor sensitivity of the first stage and the savings in 
expenditure and time as well as validation in target populations. 
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Introduction 
Epidemiological studies of rare conditions are difficult and costly to conduct, particularly in Low 
and Middle Income Countries (LMIC) where majority of the population do not use the health 
care facilities and medical records and diagnostic facilities are poor (Alam et al., 2010; Bhatia 
and Cleland, 2001; D'Ambruoso et at., 2010; Mbagaya et al., 2005; Mesfin et al., 2009; Olusanya 
et al., 2010; Rahman et al., 1998; Shaikh and Hatcher, 2005; Shaikh and Hatcher, 2007). This 
problem is common for many neurological (including epilepsy) and psychiatric conditions as 
there are no simple diagnostic tests (e. g. blood measurements), and the diagnosis depends upon 
history and assessment by experienced specialists. There are relatively few specialists in LMIC 
and they are expensive to employ for epidemiological surveys (Mung'ala-Odera and Newton, 
2007; WHO/IBE/ILAE, 2005). 
Studies of neurological and psychiatric conditions are often conducted on high-risk populations 
e. g. those with high prevalence of putative risk factors (Kaiser C et al., 1998 May; Medina MT et 
al., 2003; Villaran et al., 2009), leading to high estimates of prevalence that are not 
representative of wider populations, or in which there still may not be adequate numbers of cases 
to identify clinically meaningful risk factors in case controls studies (Ruckinger and Boneberger, 
2008). Thus, for such conditions, there is need to survey more representative populations or 
conduct censuses to provide robust estimates of prevalence and incidence using methods that 
maximise detection of cases with least cost and effort (Ruckinger and Boneberger, 2008). 
Furthermore, large studies improve the precision of the estimates. 
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Epilepsy is a common non-communicable neurological condition and a significant cause of 
disability and mortality (WHO, 2004). It is estimated to affect nearly 70 million people 
worldwide, 90% of who live in LMIC (Chapter 2). While a large number of studies to determine 
the prevalence of epilepsy in LMIC have been conducted, these data have yielded a wide range 
of estimates (Chapter 2), and it is not clear if this is caused by different methods and tools used 
in the studies, many of which have not been validated in the target populations (Leonardi M and 
Ustan TB, 2002; Sander JW, 2003; Sander JW and Shorvon SD, 1996). 
In High Income Countries (HIC), researchers utilize medical and service records to provide data 
on epidemiology of epilepsy. In LMIC, single round surveys and key informants have been used, 
but these methods under-report cases (Kaamugisha J and Feksi AT, 1988). Two-stage surveys in 
which the population is initially screened with a questionnaire and the diagnoses confirmed by 
detailed clinical history and neurological assessment have been recommended for detecting 
convulsive seizures and epilepsies (Placencia M et al., 1992a) and were used in several studies 
(Borges et al., 2004; Haerer et al., 1987; Melcon et al., 2007; Meneghini et al., 1992; Nicoletti A, 
1999 Dec 10; Noronha et al., 2007; Osuntokun et al., 1987; Placencia M et al., 1992b; 
Schoenberg, 1987). However, these methods are costly to implement in large populations since 
the first stage often takes considerable time and the second stage requires the use of qualified 
medical personnel who often have to assess a large number of false positives. 
To address these issues in epidemiological studies of epilepsy, we have used a three-stage 
methodology to survey large populations within Health and Demographic Surveillance Systems 
(HDSS) (Edwards T et al., 2008), which are part of the INDEPTH network (http: //www. indepth- 
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network. orgl). Within the HDSS set-up, censuses are conducted 1-3 times a year, in which non- 
medical field personnel conduct re-enumeration and vital status registration by interviewing a 
senior member of the household (usually the house-hold head). The field personnel usually have 
3-6 months in which to cover the entire HDSS population. Thus, the epilepsy screen (first stage) 
needed to be embedded within an on-going census in order to be administered to the entire 
population using least cost and effort. The first stage of the survey is a general population screen 
using a simple tool which is intended to have high sensitivity to detect people with a history of 
convulsions. Those that are positive are then surveyed with a more specific tool to determine 
possibility of epilepsy. Cases that are likely to have epilepsy in the second stage are then invited 
for a clinical assessment for confirmation of epilepsy in the third stage. This method is an 
extension of the two-round surveys in which screening questions were introduced as the first 
stage of the study and can easily be implemented within on-going census in the HDSS. This 
stage has symptom-based questions which are designed to maximize sensitivity and be easily 
administered by non-medical personnel. The second stage is designed to be more specific, thus 
reducing the number of false positive cases that have to be assessed in the more expensive and 
logistically difficult third stage. The three-stage method allows rapid and efficient screening of 
large populations while simplifying the logistics and reducing costs. However, the sensitivity and 
specificity of this methodology have not been established. 
In this paper, we describe a study to assess the sensitivity and specificity of the three-stage 
method in detecting active convulsive epilepsy (ACE) and compare the expenditure of 
conducting the two-stage and the three-stage population-based epilepsy surveys. 
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Methods 
The study setting and study population 
The study was conducted in Kilifi district of the Coast province of Kenya. It consists of both 
rural and peri-urban communities. The study area is within a HDSS that covers 15 administrative 
locations with 40 sub-locations sub-divided into 186 enumeration zones. This subdivision 
allows study subjects to be easily located using digital maps of homesteads. The demographic 
surveillance and vital registration is performed 2-3 times a year and covers an area of densely 
inhabited coastal strip, 40 km in length, and extends about 15 km in the interior, with an area of 
891 sq. kms, which is about 18% of the total area of Kilif District (4840 sq. kms). There were 
233,881 residents and 25,526 homesteads in 2008 (Scott JA et at., 2011). The residents are 
mainly Mijikenda, a Bantu grouping of nine tribes with Girima (45%), Chonyi (33%) and Kauma 
(11%) being most common. About 55% of the population is considered absolutely poor, per 
capita income is about USD 10 per month. The majority (80%) are subsistence farmers, which is 
limited by the low productivity of the land (only 19% of the total land is arable). Literacy levels 
are low, since only 45% of people can read and write. 
Kenya Medical Research Institute (KEMRI) has been running the HDSS in Kilif District since 
year 2000. The entire study area has been mapped using global positioning system (GPS) 
receivers and digital maps derived from these data are used to locate homesteads and follow-up 
study subjects. The study population consisted of a random sample of 5,796 persons selected 
from the 16th round of re-enumeration within the HDSS in 2008. 
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Description of the three-stage cross-sectional survey method (prevalence survey) 
Stage 1 (SI): the general population screen 
The first stage of the survey is a general population screen using a simple tool, consisting of two 
questions to detect convulsions. These questions were piloted to maximise their sensitivity to 
detect individuals with the main symptoms (i. e. convulsions) of convulsive epilepsy. The aim of 
this stage is to screen large populations rapidly and efficiently, by the HDSS census field staff in 
their routine re-enumeration and vital registration. The field staffs conduct a door-to-door survey 
interviewing the head or senior member of each household or an individual who can provide 
information about each member of their household. It is important that the tool used during this 
stage is as sensitive as possible to detect all the possible individuals with the disorder even if this 
entails lower specificity for the first stage. The tool used in this stage of the epilepsy survey is 
shown in Appendix 4.1. 
Stage 2 (SII): the condition-specific screen 
In this stage, respondents identified with a positive history of convulsions in SI are followed-up 
by different interviewers who have more extensive training in epilepsy and more time to identify 
possible cases. The aim of this stage is to screen those with positive responses in SI, with a more 
specific tool for the detection of possible ACE so as to minimize the number of false positives by 
using a tool with higher specificity in order to reduce the cost of diagnosis in the subsequent 
stage. At the same time it is important that no true cases are lost at this stage (Appendix 4.2). 
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Stage 3 (SIII): Confirmation of diagnosis 
The respondents identified as potential cases of ACE in SII of the survey are invited for 
assessments and tests by clinicians to confirm the diagnosis. In the epilepsy survey, the diagnosis 
of ACE consists of taking clinical history by an experienced clinician. ACE was defined as at 
least two unprovoked convulsions (tonic and/or clonic seizures), of which one occurred in the 
preceding 12 months (Edwards T et al., 2008; Meinardi et al., 2001). 
The three-stage method identified an individual as a case of ACE if they were positive in all the 
three stages of the prevalence survey. 
Assessment of the three-stage methodology using a survey conducted by clinicians (Clinical 
Survey) 
Sampling and follow-up in the Clinical survey 
A random sample for the validation of the three-stage survey methodology was selected from the 
2008 Kilifi HDSS database. It was calculated that a sample size of 5,796 would be required to 
estimate the sensitivity of the three-stage method (assumed to be 85%) with a precision of 13% 
(i. e., half the width of the 95% Confidence Interval (95%CI)) (Burderer NMF, 1996) in a 
population with a prevalence of 5/1,000 (Edwards T et al., 2008). This sample was interviewed 
in the three stages of the prevalence survey conducted in 2008. To validate the prevalence survey 
methodology, everyone in the random sample had the SII questions administered by non-medical 
fieldworkers, as well as being interviewed by clinicians who received special training in epilepsy 
and followed the proforma administered in the Sill of the prevalence survey (Clinical Survey or 
the "gold standard"). The Clinical survey took place after the three-stage prevalence survey 
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during the period May 2009 to April 2011. Incident cases - those that were negative on the 
prevalence survey and positive in the Clinical Survey but who developed ACE after the three- 
stage prevalence survey - were treated as true negatives since they were negative at the time of 
the prevalence survey. Sill was conducted twice on those that were positive in SII of the 
prevalence survey (i. e. within the prevalence survey and the validation/clinical survey - because 
Sill was the clinical surveyl'gold" standard) and subjects were classified positive for ACE if 
they were positive in either of the two Sill assessments. 
Analysis 
Estimation of Sensitivity 
Sensitivities were estimated as: TP/(TP+FN), where TP = True Positive (i. e., positive on 
prevalence survey and Clinical Survey) and FN = False Negative (i. e., negative on prevalence 
survey but positive on Clinical Survey). The sensitivities of SI (single stage) and (SI & SII) (two- 
stage) and the (SI & SII & SIII) (three-stage) methods were evaluated against the Clinical 
Survey. For example, the sensitivity of the three-stage method was the proportion of individuals 
who were positive (SI+, SII+, SIII+) in the prevalence survey among those identified as cases of 
ACE in the Clinical Survey. 
Estimation of Specificity 
Specificity was estimated as: TN/(TN+FP), where TN = True Negative (i. e., those negative in 
both the prevalence and Clinical Surveys) and FP = False positive (positive in the prevalence 
survey but negative in the Clinical Survey). The specificities of single, two and three-stage 
methods were estimated. For the three stage method the specificity is 100% since there are no 
false positives because Sill of the prevalence survey is the Clinical Survey. For the single and 
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two stage methods the specificity may be less than 100%. In addition we estimated the 
proportion of false positives (1-specificity) and false negatives (1-sensitivity). 
Expenditure comparison study 
We compared the financial expenditure of conducting a two-stage survey (in which SII is 
conducted on those that are SI positive by experienced clinicians in the field) and the current 
three-stage epilepsy survey. Our analyses were based on the SI and SII positive rates and the 
marginal expenditure incurred in the Kilifi HDSS three-stage survey of 2008 (Tables 2(a) and 
(b)). In both situations, we assumed that the first stage (SI) would not incur any expenditure 
since it is nested within on-going re-enumeration in the HDSS study area. For the two-stage 
survey, we assumed that SII was the definitive stage since it is conducted by clinicians using the 
clinical history tool used in SIII of the three-stage survey. 
All analyses were performed in STATA version II (StataCorp, College Station, TX, USA). 
Ethical considerations 
Written informed consent was obtained from all study participants. Approval for the study was 
obtained from the Kenya Medical Research Institute/ National Ethical Review Committee. 
Results 
Flow of participants in the Clinical Survey 
The Clinical Survey targeted a sample of 5,488 participants who completed both SI and SII of 
the prevalence survey. Of these, 1,046 (19.1%) were lost to follow-up during the Clinical 
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Survey: 629 (60.1%) had moved, 225 (21.5%) could not be traced, 119 (11.4%) refused consent 
and 70 (6.7%) had died, while 3 (0.3%) were found to have been duplicate records (Figure 4.1). 
Figure 4.1: Flow of subjects in the Clinical Survey 
Random sample 
5,796 
=15, 
Not found in Si 
Completed SI 
93 Not 
found in SII 
Completed SII I 
Moved: 629 
5,488 Not found: 225 
No. Refused: 119 
1046 Died: 70 
Duplicate: 3 
Completed Clinical 
Survey: 4,442 
(76.6%) 
Of 4,442 subjects screened in the Clinical Survey, 18 ACE cases were identified when the 
Clinical Survey was applied to all the individuals who were negative in the prevalence survey i. e. 
the 4,321 (SI-) and 98 (SI+, SII-) (Figure 4.2). 
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Figure 4.2: Response status of subjects within the prevalence and Clinical Surveys 
N=4,442 
STAGE I 
STAGE 11 
4,321 - 
3 98 
CLINICAL CLINICAL CLINICAL 
SURVEY SURVEY SURVEY 
+++ 
17 63 95 15 
On examination of the reasons for the 18 false negative subjects, 15 were negative in SI (i. e. 
reported no history of convulsions), but the Clinical Survey documented that the subjects had 
convulsions that had occurred before the prevalence survey and therefore should have been 
identified as potential cases. The remaining 3 were positive in SI but were all classified as febrile 
convulsions in SII. 
Sensitivity and Specificity 
Sensitivity decreased, with an increase in the number of stages in the survey while specificity 
increased with the number of stages. The three-stage method (SI & SII &SIII) had a sensitivity 
of 48.6 % (i. e. 17/35) but with a specificity of 100.0 % (Table 4.1). At 57.1%, sensitivity was 
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highest for the one-stage (SI) screening method which also had the lowest specificity (97.7 °/a). 
Sensitivity and specificity of the various stages of the three-stage cross-sectional methodology 
are displayed in Table 4.1. 
Table 4.1: Estimation of the sensitivity and specificity of the single- and multi-stage survey 
methodologies using the Clinical Survey as gold standard 
Method Sensitivity ° 95 /o Cl Specificity 95% Cl TP FN FP TN 
One-stage 
57.1 39 4-73 7 97.7 97.2-98.1 20 15 101 4306 
(SI) . . 
Two-stage 51.4 32.4-67 6 99.9 99.7-100.0 18 
17 
6 4401 
SI & SII . 
Three-stage 
(SI & SII & 48.6 31.4-66.0 100.0 99.9-100.0 t 17 18 t0 4407 
SIII 
TP=true positive; FI'=talse positive; FN=false negative; 1 N--true negative 
tTP and FP are derived from 2"d Sill/Clinical Survey on those that were Sll+ (i. e. Sill was done twice on the SII+ 
participants). 
Expenditure comparison study 
From the proportion of respondents who were positive in SI (2.2%), we estimated that we would 
require to follow-up 6183 people in SII of the study. In the three-stage method (in which SII is 
conducted by lay field personnel), this would take 29.4 months to complete at a cost of USD 
109,120 (Table 4.2a). In the two-stage method (in which SII is conducted by clinicians), 
screening the 6183 people positive in SI would take 42.1 months and cost USD 171,922, which 
is 1.6 times more expensive than the three-stage method (Table 4.2b). 
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Table 4.2(a): Estimates of the expenditure of the three-stage survey conducted by lay field 
personnel 
State 11 field work 
SI +ve rate (%) 2.2 
SI Population 233,881 
Durationt 
- 
Expenditure 
Salary 
Follow-up FW days FW months Sala (Ksh) (USD) 
No of SI cases 5152.4 515.2 24.5 613,380.80 7667.3 
20% Follow-up* 1030.5 103 4.9 122,676.20 1533.5 
Sub-total 1 6182.9 618.3 29.4 736,056.90 9200.7 
State II transport costs 
Duration 
- 
Costs 
Follow-u FW das FW months Cost (Ksh) Cost USD 
No cases followed up 6182.9 618.3 29.4 7,419,453.70 92,743.20 
Sub-total 2 618.3 29.4 7,419,453.70 92,743.20 
Stage 11 cost 8,155,510.70 101,934.90 
State III 
SII +ve rate (%) 21.8 
No of SII cases 1125.1 
Durationt Costs 
Clinic Clinic Salary 
No screened das months Sala Ksh (USD) 
No of SII +ve cases 1125.1 160.7 7.7 574,019.20 7175.2 
No screened in SII 
1 
1125.1 160.7 7.7 574,019.40 7175.2 
Total Expenditure 
1 
8,729,529.90 109,119.10 
*Assume that at least 2V% or Lne bi positive Crises w ii uc tuiiuwcu uN uuv .. v., u . wJ< <Wlý. a.. 
t Both SH and SIR run concurrently therefore the total duration is 29.4 months. 
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Table 4.2(b): Estimates of the expenditure of the two-stage survey conducted by clinicians 
Staae II field work 
SI +ve rate (%) 2.2 
SI Population 233,881 
Duration Expenditure 
Follow- FW Salary 
FW das months Salary Ksh (USD) 
No of SI cases 5152.4 736.1 35.1 2,628,774.70 32,859.70 
20% Follow-up* 1030.5 147.2 7 525,754.90 6571.9 
Sub-total 1 6182.9 883.3 42.1 3,154,529.70 39,431.60 
Stage 11 transport 
costs 
Duration 
- 
Costs 
Follow- FW 
u FW das months Cost (Ksh) Cost (USD) 
No cases followed up 6182.9 883.3 42.1 10,599,219.60 132,490.20 
Sub-total 2 883.3 42.1 10,599,219.60 132,490.20 
Total Expenditure 13,753,749.30 171,921.90 
*Assume that at least 20% of the SI positive cases will be followed up in the field at least twice. 
Notes for Tables 4.2 (a & b): 
1) One field worker interviews 10 participants per day on average 
2) One working month = 21 working days 
3) A fieldworker's salary is Ksh 25,000 per month 
4) The study clinician interviews/assesses 7 participants per day 
5) A clinician's salary is Ksh 75,000 per month 
6) 1 USD = 80 Ksh 
7) FW = Field work 
8) Transport costs: 
a) Distance/day: estimated at 200km 
b) Cost per = Ksh 60/km (vehicle) 
126 
Discussion 
The three stage method had a low sensitivity of 48.6%. The savings in expenditure and time 
compared to the two-stage method have to be weighed up against its poor sensitivity. 
Sensitivities were slightly higher for the one-stage (57.1%) and two-stage (51.4%) methods. 
Specificities were marginally lower in single-stage (97.7%) compared to the three-stage method 
(100%). For this method to be recommended more generally, it will be essential to improve 
sensitivity of the questions in stage I. 
In this study, we examined the entire three-stage system for detecting ACE (in the prevalence 
survey, a subject was classified as a case if they were positive in all the three stages). Other 
studies have only validated hospital-based survey methods (Carpio et al., 2006; Melcon et al., 
2007; Meneghini et al., 1992) or the validity of a screening tool (within a three-stage method) in 
detecting epileptic seizures, but not epilepsy (Placencia M et al., 1992a). Generalization of 
validation parameters obtained from hospital-based studies is limited by selection bias (due to 
overrepresentation of cases with more severe forms of epilepsy), people who recognise that they 
have epilepsy and seek treatment, sample size and the fact that it is carried out in a setting that 
may not represent the situation in the field. This yields less accurate (often inflated) estimates of 
sensitivity than validation of population-based methods as described by Placencia (Placencia M 
et al., 1992a). The validation of population-based methods is applied directly to a wider 
population hence the findings are more generalizable, although this is usually costly. 
Furthermore, when compared to population-based studies, the validity of hospital-based studies 
may not be diminished by stigma-related concealment of seizures. 
127 
The precision of the validation depends upon the size of the sample. The sample size for our 
study was statistically determined and was larger than all other validation studies (Carpio et al., 
2006; Meneghini et al., 1992; Ottman et al., 2010). 
SI of the prevalence survey had the highest false positivity; this is because the SI questions 
targeted all convulsions (including febrile convulsions). SI as a general population screen is 
however necessary in order to detect all convulsions to avoid underestimating prevalence of 
convulsive epilepsies in SII and Sill of the prevalence survey. Even a small FP (1-Specificity) 
applied to a large population would have considerable logistical and cost implications. For 
instance, applying the Si false positivity of 2.3% to our study population of 233,881 individuals 
would have resulted in 5,379 false positive individuals that would otherwise have to be screened 
in Sill of the prevalence survey. The advantage of adding SII is that it substantially reduces the 
number of false positives screened in SIII. In our study these declined from 2.3% to 0.1%. 
We found that multi-stage methods (SI & SII and SI & SII & Sill) had poor sensitivity. This was 
observed in another validation study where if only epilepsy specific questions were used, 
sensitivity was substantially lower and the specificity higher when compared with questions on 
epilepsy and other seizures (Ottman et al., 2010). Specificity was also observed to be greater if 
epilepsy specific items were used alone but not when combined with questions on other seizures 
(Kelvin et al., 2007). These observations suggest that questions about seizures under any 
circumstances are important in avoiding false negatives. 
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In our study, stigma-related non-response could have been the main cause of the low sensitivity 
of the three-stage method. This could partly be attributed to the fact that SI (which contributed 
the largest proportion of false negatives i. e. 15/18) was conducted by field staff who are usually 
resident within the community and who were also involved in the regular HDSS re-enumerations 
within the study area. The Clinical Survey (our validation study) was conducted by clinicians 
experienced in the diagnosis of epilepsy, of whom PWE or their guardians would perhaps be 
more trusting (as opposed to non-medical field personnel that conducted SI and SII of the 
prevalence survey). This implies that the sensitivity of SI may be dependent on the cultural 
setting and the skills of the field staff in administering culturally sensitive questions. High 
sensitivity (79.3%) was estimated in a similar field validation which utilized `rural' doctors in an 
equivalent of SII of our prevalence survey (Placencia M et al., 1992a). However that study 
validated a prevalence survey that defined one as a case if they were positive in any of the three 
stages and included cases from sources other than the survey in the numerator of both the survey 
and the validation (Placencia M et al., 1992a; Placencia M et al., 1992b). Sensitivity of the three- 
stage method could be improved further by better training the SII field staff since they were 
unable to distinguish between febrile and non-febrile convulsions in 3 subjects, misclassifying 
these as false negatives. 
A lack of awareness of convulsions in family members by the household heads could have 
influenced the low sensitivity of our survey method. These household heads were the primary 
respondents in the HDSS re-enumeration within which Si was conducted while the actual index 
respondents (or their caretakers if they were cognitively challenged) were interviewed in the 
subsequent prevalence survey stages and in the Clinical Survey. 
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Additionally, increase in awareness of epilepsy in this population following the three-stage 
prevalence survey could have reduced levels of stigma and increased knowledge of epilepsy and 
therefore yielded more true positive responses within the Clinical Survey. Indeed, a treatment 
gap study conducted on the same population after the prevalence survey reported very low levels 
of perceived stigma (Mbuba et al., in preparation). 
The monetary cost and duration of the two-stage clinician conducted epilepsy survey would be 
higher compared to the three-stage survey by non-medical field personnel. This was attributed to 
the high salary expenditure of medical trained personnel and lack of field-work experience 
relative to lay field workers. For this additional expenditure however, the improvement in 
sensitivity of the two stage method would still be limited to eliminating the false negatives 
accruing from SII of the prevalence survey and would be thus be equivalent to the sensitivity of 
SI. 
Limitations of the study 
A major limitation of this study was the between-stages attrition of subjects over the two years of 
the Clinical Survey which could have caused non-response bias. These losses were observed 
despite efforts to rigorously follow-up subjects during the field implementation of the study. 
Conclusion 
To the best of our knowledge, this is the first study to determine the sensitivity and specificity of 
a multi-stage survey methodology as a single composite test in field-based validation. We found 
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that the three-stage method had poor sensitivity to detect ACE in population-based studies, 
which we could mainly attribute to stigma-related non-response in SI and a lack of awareness 
and knowledge of epilepsy. This method however has very high specificity (and thus very low 
false positivity), which reduces study costs. Widespread adoption of this method would require 
judicious balancing between the poor sensitivity and cost savings and also additional validation 
in populations with differing levels of stigma. 
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Abstract 
Objective: The prevalence of epilepsy in low and middle income countries (LMIC) is estimated 
to be more than twice that of high income countries (HIC). However, there is considerable 
heterogeneity in the estimates which could be due to real differences between geographical 
locations in the prevalence of causal factors, or differences between studies in methodological 
approaches or case definitions, although this has not been determined. We conducted studies to 
determine the prevalence and heterogeneity of active convulsive epilepsy (ACE) across four 
Health and Demographic Surveillance System (HDSS) sites in sub-Saharan Africa (SSA). 
Methods: We used three-stage cross-sectional surveys nested within on-going census in the 
HDSS sites to identify people with ACE. Prevalence was estimated as the ratio of confirmed 
cases of ACE to the population screened in the first stage of the survey. We adjusted the 
estimates for attrition between stages of the survey and for the sensitivity of the three-stage 
screening methodology and used logistic regression to assess for heterogeneity between and 
within study sites. 
Results: There was substantial heterogeneity of prevalence between HDSS sites and between 
different age groups within and between sites. Site-specific estimates ranged between 7.0/1000 
(95% Cl: 6.2-7.4) in Agincourt HDSS to 14.8/1000 (95% Cl: 13.8-15.4) in Ifakara HDSS. 
Prevalence varied by age and sex in the Kilifi HDSS and by age in the three other sites. 
Prevalence was highest in the adolescents (13-18 years) in Ifakara HDSS and in the youngest 
age-group (<=5 years) in Iganga-Mayuge HDSS while it was lowest in the youngest age-group 
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(<=5 years) in Agincourt HDSS. There were decreasing and increasing trends of prevalence 
with age for Iganga-Mayuge and Agincourt HDSSs respectively. Kilifi and Ifakara HDSSs had 
increasing then decreasing trends of prevalence with age, with the points of inflection being in 
the 13-18 year age groups. 
Conclusion: We used a standardized methodology to identify cases and similar definition of 
ACE and thus our findings suggest real heterogeneity that could be related to the differences in 
the distribution and types of risk factors for development of epilepsy across SSA or differences 
in vulnerability to endemic risk factors within study sites. These results reflect the burden of the 
people with active epilepsy that should be on treatment in these sites and also suggest the need 
for studies to identify modifiable risk factors that could be targeted in public health interventions. 
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Introduction 
Epilepsy is one of the most prevalent non-communicable conditions and affects nearly 70 million 
people in the world (Chapter 2). It represents approximately 0.5% of the global burden of disease 
and translates to more than 7 million disability-adjusted life-years annually (Leonardi M and 
Ustan TB, 2002). The prevalence of epilepsy in Low and Middle Income Countries (LMIC) was 
estimated to be more than twice that in high income countries (HIC) in a review of 46 studies 
that reported life-time prevalence (Chapter 2). However there was considerable heterogeneity 
even within similar settings. 
Heterogeneity in the prevalence of epilepsy could be due to real differences between 
geographical locations in the prevalence of causal factors, or differences between studies in 
methodological approaches, in particular the case definitions, methods of ascertainment and the 
screening instruments used (Leonardi M and Ustan TB, 2002; Ngugi et al., 2010). It has however 
not been clarified whether this heterogeneity is real i. e. clinical (e. g. due to differences in patient 
characteristic or distribution and types of risk factors) or due to differences in methodology. 
In 1997, the World Health Organization (WHO), the International League Against Epilepsy 
(ILAE) and the International Bureau for Epilepsy (IBE) launched the Global Campaign Against 
Epilepsy (GCAE), aimed at supporting developing countries world-wide to reduce the burden 
caused by epilepsy through improved acceptability, access to services, prevention and quality of 
care. The second phase of the GCAE was launched in 2001, with the specific objectives being, 
among others, to estimate prevalence of untreated active epilepsy in the LMIC. The overall goal 
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of the campaign was to improve the identification and management of people with convulsive 
epilepsies, particularly in rural areas, within existing primary health care systems 
(WHO/IBE/ILAE, 2001). 
We conducted large population-based cross-sectional surveys in four Health and Demographic 
Surveillance System sites (HDSSs) in sub-Saharan Africa (SSA) under the INDEPTH network. 
The objective of this study was to determine the prevalence of active convulsive epilepsy (ACE), 
and the heterogeneity in its distribution in a resource-limited setting using standardized tools, 
definitions and case detection methods. We aimed to generate reliable estimates of prevalence of 
ACE on which public health interventions and further studies of the aetiology and treatment of 
the condition can be based. 
Methods 
Background and study settings 
This study was conducted as part of a larger Study of Epidemiology of Epilepsy in Demographic 
Surveillance Systems (SEEDS) in sub-Saharan Africa. The study sites were Kilifi in Kenya, 
Agincourt in South Africa, Iganga-Mayuge in Uganda and Ifakara in Tanzania, which are 
described at the INDEPTH website (http: //www. indel2th-network. orgn and in chapter 1 of this 
thesis. These sites were selected on the basis of the availability of health facilities able to provide 
support to the clinical aspects of the study and follow-up of patients in longitudinal studies, the 
availability of laboratory facilities to handle biological samples for case-control studies, 
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operational costs to the study and the endemicity of parasitic diseases putatively associated with 
the development of epilepsy. 
Procedures 
The questionnaires used for screening epileptic seizures and epilepsy in the study communities 
were based upon those used in other studies (Kaamugisha J and Feksi AT, 1988; Osuntokun et 
al., 1987; Placencia M et al., 1992b; Rwiza HT et al., 1992 Nov-Dec; Tekle-Haimanot R et al., 
1990) including previous work in the Kilifi HDSS (Edwards T et al., 2008; Mung'ala-Odera et 
al., 2008; Snow RW et al., 1994; Versteeg AC et al., 2003). The appropriate terminology for key 
words in the questions e. g. seizures and epilepsy were derived by consensus in focus group 
discussions with the local residents and pre-tested in communities outside the study areas. We 
refined these terminologies during the training of the study field staff who were local residents 
with at least secondary school level education. The questionnaires underwent forward translation 
into the local vernacular and independent back translation into English through a well-developed 
process to remove any ambiguities. 
The three-stage survey methodology 
Stage I: Screening for convulsions in the community 
We conducted the first stage (SI) of the prevalence surveys during the routine re-enumeration 
and vital registration within the HDSS sites. The census field staff administered 2 questions 
(Appendix 4.1) to household heads to identify members of their households with histories of 
convulsions during the door-to-door surveys. Subjects who were positive to any of the questions 
were considered eligible for a follow-up interview in the second stage. 
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Stage II: Screening for possible ACE in the community 
In the second stage (SH), we interviewed all eligible participants within a week of SI. SII was 
conducted by a different team, trained to identify possible cases of ACE. A more detailed 
epilepsy screening questionnaire (Appendix 4.2) based upon an international validated 
questionnaire (Placencia M et at., 1992a) was used. Respondents considered positive in this stage 
were eligible for evaluation in the third stage. 
Stage 111: Confirmation of ACE at the hospital/epilepsy clinic 
The diagnosis of ACE was assessed in the third stage (SIII) of the survey within a week of the 
SII interview, using detailed history taken by clinicians trained in the diagnosis of epilepsy and 
fluent in the local languages and was supplemented by clinical examination (Appendices 5.1 and 
5.2) . ACE was defined as two or more unprovoked convulsions (seizures with tonic and/or 
clonic movements) occurring at least 24 hours apart with at least one seizure in the preceding 12 
months (Meinardi et al., 2001). We further asked individuals if they were currently (or had 
previously been) on anti-epileptic drugs. Those on medication and had experienced at least two 
seizures but none in the preceding year were classified as cases (Commission on Epidemiology 
and Prognosis: International League Against Epilepsy, 1993). The three-stage method identified 
individuals as cases of ACE if they were positive in all the three stages of the prevalence survey. 
After the surveys, all case notes were reviewed independently by at least two neurologists to 
confirm the diagnoses and classification assigned by the study clinicians. Where the neurologists 
disagreed with the study clinician and both independently assigned the same alternative 
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classification, the subjects were re-classified. Disagreements between the neurologists were 
resolved by consensus otherwise the subjects were assigned in to the non-classified category. 
To enable a comparison between the three-stage methodology of the current survey and the two- 
stage methodology that has been used in other population-based studies in developing countries 
(Birbeck GL and Kalichi EM, 2004 Jan; Kaamugisha J and Feksi AT, 1988; Osuntokun et al., 
1987; Rwiza HT et al., 1992 Nov-Dec; Tekle-Haimanot R et al., 1990), we selected random 
population samples of 4,500 to 6,000 individuals from each site's census database. The SII 
questionnaire of the study was administered (as the first stage) on these random population 
samples and those that were positive at this stage were assessed in SIll of the survey as was done 
within the main three-stage survey. . 
The prevalence surveys in the four sites were conducted between December 2007 and March 
2009: December 2007-July 2008 in Kilifi; August 2008-February 2009 in Agincourt; February- 
October 2009 in Iganga-Mayuge; and, May-December 2009 in Ifakara. 
Analysis 
We double entered and verified all data in MySQL Version 5 open source database (Oracle 
Corporation, Redwood Shores, CA, USA) and all statistical analyses were carried out in STATA 
Version 11 (StataCorp, College Station, TX, USA). We estimated the unadjusted prevalence of 
ACE and 95% confidence interval (95%CI) for each site as the number of cases of ACE 
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confirmed in SIII of the study divided by the total population screened in SI, expressed per 1,000 
persons. Age- and sex- specific prevalence of ACE were also estimated. 
We used multiple imputation (Rubin DB, 1987; van Buuren S, 2007) to reduce bias due to 
attrition between stages of the survey. Multiple imputation is a simulation-based technique for 
handling missing data that uses probability models that are fitted to observed data to predict 
values for missing observations. In the imputation model, we imputed missing data at each stage 
of the survey using the outcome of the previous stage. Multiple imputation was carried out using 
the method of chained equations which was implemented using the "ice" command in STATA. 
The process of imputation was carried out separately for each country (the highest missing was 
36% - between SI and SH in Iganga-Mayuge). 
' Five imputed datasets were created for each 
site. The technique of multiple imputation involves estimating parameters separately in each of 
the imputed datasets and then combining the estimates using Rubin's rules (Rubin DB, 1987). 
Prevalence estimates were divided by 0.486 to account for the sensitivity (48.6%) of the three- 
stage screening methodology (Chapter 4). 
We produced site-specific prevalence estimates adjusted to the age distribution of the mid-2000 
United States population (US Census Bureau, 2010) and we used logistic regression to test for 
heterogeneity of ACE between study sites after adjusting for age and sex. 
I The theory of multiple imputation (MI) requires that the number of imputations (M) should be infinite but the procedure is also known to have 
good statistical properties with finite M The relative efficiency (RE) of the hG procedure with finite Mcompared with infinite M is roughly 90% 
with only 2 imputations for a missing data rate as high as 50%. Most literature (Rubin 1987; van Buuren, Boshuzien and Knook 1999) 
recommend M= 5 (corresponding to RE of95% for a missing data rate of 50%) should 
be sufficient to obtain valid inference. 
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The site-specific counts of cases of ACE in the two-stage method (i. e. those identified within the 
population samples independent of the three-stage method) were generated from the data. 
Multiple Imputation was used to adjust for loss to follow-up in the comparison of both the two- 
and three-stage methods. Proportions of cases in the two-stage method not identified (missed) in 
the three-stage method were also estimated. 
Ethics approval was obtained from each of the local Institutional Review Boards (IRB) and the 
Institute of Child Health, University College London. 
Results 
The median (IQR) age of the study participants was highest in Agincourt; 21.0 (10.0 - 35.0) 
years and was lowest in Iganga-Mayuge; 15.0 (8.0 - 29.0). The distribution of sex and age for 
all sites are displayed in Table 5.1(a) and that of cases of ACE in Table 5.1(b). Age of onset 
varied between study sites. 
SI of the survey was administered to a combined population of 472,788 (96.3 %) residents of the 
study areas, nearly half (232,176) of whom were from Kilifi. A total of 12,004 were positive in 
SI. In SII of the study, we screened 82.5% (9,898/12,004) of the eligible subjects in all sites with 
the site-specific follow-up ranging between 64.0% in Iganga-Mayuge and 100.0% in Agincourt. 
We further screened 83.0% (2,078/2,505) of the eligible subjects in SIII of the survey, the 
highest proportion (92.7%) screened at this stage was in Agincourt and the lowest (64.2%) in 
Iganga-Mayuge (Table 5.2). 
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The prevalence of convulsive seizures (proportion positive in SI) was highest in Iganga-Mayuge 
and lowest in Agincourt (Table 5.2). The prevalence of ACE was highest in Ifakara (Tanzania) 
and was lowest in Iganga-Mayuge (Table 5.2). At 6.8/1000, age-standardized prevalence of ACE 
was lowest in Iganga-Mayuge and highest (15.5/1000) in Ifakara (Table 5.3). In the combined 
analysis, there was strong evidence of interaction between study site and age (p<0.001), but not 
with sex. 
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Prevalence of ACE varied by age and sex in Kilifi, being higher in males and in adolescents and 
young adults (aged 13-28 years). In the other sites, prevalence varied by age (but not by sex); it 
was lowest in the 0-5 year age group in Agincourt and Ifakara and highest in the same age group 
in Iganga-Mayuge (Table 5.4). 
When we adjusted for attrition between SI/SII and SII/SIII of the survey, there was a 2-fold and 
1.5-fold increase in the prevalence of ACE for Iganga-Mayuge and Ifakara, and less at the other 
sites which were able to follow up more subjects. 
In Iganga-Mayuge, prevalence of ACE decreased with age while the reverse was the case for 
Agincourt where there was a gradual increase. In Kilifi and Ifakara, prevalence initially 
increased with age reaching a peak among adolescents and young adults (aged 13-28 years). It 
then declined in middle to late adulthood (29-49 years), increasing again in the fifth decade of 
life (Figure 5.1). 
Prevalence estimates from the two-stage methodology (i. e. the population samples) were higher 
than the crude estimates from the three-stage methodology for Kilifi, Agincourt and Iganga- 
Mayuge sites, while there was no difference in the Ifakara HDSS. In the three study sites, 
between 35% and 64% of the cases of ACE identified within the population sample (two-stage 
method) had been missed within SI of the three-stage methodology when the data were adjusted 
for attrition between stages (Table 5.5). 
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Discussion 
We estimated the prevalence of active convulsive epilepsy (ACE) in four large populations in 
sub-Saharan Africa to range between 7.0-14.8/1000 persons, when adjusted for loss to follow-up 
and sensitivity of the screening method. A study in Kilifi which used similar three-stage cross- 
sectional methodology conducted in 2003 and adjusted for loss to follow up and the sensitivity of 
SII estimated prevalence of ACE at 4.5/1000 (Edwards T et al., 2008). The crude prevalence 
estimates were similar in both studies but the study by Edwards and colleagues probably under- 
estimated the true prevalence because it did not adjust for the sensitivity of the entire three stage 
methodology. 
To our knowledge, these are the largest population-based mufti site prevalence surveys of 
epilepsy anywhere in the LMIC. We utilized standardized tools, methodology and definitions of 
active epilepsy based on the recommendations by the International League Against Epilepsy 
(Commission on Epidemiology and Prognosis: International League Against Epilepsy, 1993) in 
order to minimize the methodological component of heterogeneity observed in a recent meta- 
analysis of prevalence studies (Chapter 2). Furthermore, our studies benefited from well 
established health and demographic surveillance infrastructure which allowed rapid and efficient 
screening of large populations. 
The crude prevalence estimates from the three-stage method were lower in three out of the four 
sites than estimates obtained from the two-stage methodology. In three of the study sites, 
between 35% and 64% of the cases identified with the two-stage method had not been detected 
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as people with histories of convulsions in the first stage (SI) of the three-stage methodology, 
after adjusting for loss to follow-up. Indeed, SI of the three-stage method contributed >80% of 
the false negatives in the validation study of the three-stage methodology, with the rest being 
misclassified as febrile seizures in SII (Chapter 4). It is likely that the false negatives in SI of 
the three-stage methodology were due to stigma-related concealment of seizures, particularly 
since the census field staff that conducted SI were usually resident in and had more regular 
contact with the study communities as opposed to the Si! field staff. Lower prevalence estimates 
in the three-stage methodology could also have been due to lack of awareness of seizure histories 
in households by household heads who were the primary respondents in SI. This is as opposed to 
SII in which the respondents were primarily the actual index person eligible for SII or their 
regular caretakers/guardians (if they were minors or cognitively impaired). 
We measured prevalence estimates that showed significant heterogeneity with age and study site. 
At 14.8/1000 persons, the adjusted site-specific prevalence was highest in Ifakara, and was also 
slightly higher than the 10.2/1000 reported in the same area in 1992, albeit with significant inter- 
village heterogeneity (Rwiza HT et al., 1992). The high prevalence of convulsive epilepsies in 
this region could be attributed to the high prevalence of malaria and onchocerciasis reported in 
this area of southern Tanzania (Carter JA, 2004; Drakeley et al., 2003; Loewenberg, 2008; 
Mwaiko et al., 1990; Mweya et al., 2007; Ngoungou et al., 2006; Schellenberg et al., 2003). The 
second highest prevalence of ACE (after adjusting for loss to follow-up and sensitivity of the 
screening method) was in Iganga-Mayuge in Uganda, which also had the highest prevalence of 
convulsions (77/1000) and the lowest median age (2.1 years) of onset of seizures. The 
combination of these factors is suggestive of acute symptomatic convulsions (particularly 
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malaria associated) as an important risk factor for development of epilepsy. Iganga-Mayuge 
HDSS is located along the north-western shores of Lake Victoria, a highland area that has 
recently been shown to have an increasing malaria transmission intensity (Chaves et al., 2011; 
Wandiga SO et at., 2010) compared to Kilifi where a decline in malaria admissions and malaria- 
associated seizures have been observed in the last 10 years (Kariuki et al., 2011; O'Meara et at., 
2008). The early age at onset of seizures and epilepsy in the Iganga-Mayuge site could also 
suggest other important risk factors such as bacterial meningitis and adverse peri-natal events 
which would need to be investigated in case-control studies. In Kilifi, an important cause of 
bacterial meningitis (Haemophilus influenza) has been mitigated through a successful 
introduction of Haemophilus influenza type b (Hib) vaccination into routine childhood 
immunization in Kenya since 2002 (Cowgill et al., 2006), a factor which could partly explain the 
comparatively lower prevalence in Kilifi, particularly in younger age groups. 
The prevalence of ACE in Kilifi was lower than that reported for Ifakara although both sites had 
a similar age-pattern. Despite the early age at onset of seizures, this could reflect differences in 
the prevalence of parasitic infections between these sites; for instance, a decline in incidence of 
slide positive malaria admissions and malaria-associated seizures in Kilifi over the past decade 
(Kariuki et al., 2011; O'Meara et al., 2008) as well as a decline in the incidence of haemophilus 
meningitis following the introduction of Hib vaccine (Cowgill et al., 2006). These factors could 
translate to reduced incidence of epilepsy associated with acute symptomatic seizures, for which 
the malaria-attributable fraction was estimated at >90% (Kariuki et al., 2011). We estimated a 
low prevalence of convulsions in SI of this study (22/1000 persons) and history of febrile 
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convulsions was identified as one of important risk factors of epilepsy in a case-control study in 
Kilifi (Edwards T et al., 2008). 
Compared to the other sites, the prevalence of ACE was significantly lower in the Agincourt 
HDSS even when the data were adjusted for between-stage attrition of respondents and 
sensitivity of the screening methodology. South Africa has a high burden of HIV and AIDS 
which is related to cyclical labour migration, particularly from poor rural areas, with up to 60% 
of adult males (and - 20% of adult females) absent from households most of the time (Collinson 
MA et al., 2001; Kahn K et at., 2003). HIV seropositivity in Agincourt, based on the SEEDS 
case-control study, was 20.5% compared to 2.9% in Iganga-Mayuge and 5.1% in Kilifi (SEEDS 
case-control study - unpublished). This results in reduced 
life expectancy and high HIV-related 
mortality at population-level (Adjuik et al., 2006), particularly in rural areas such as Agincourt 
where infected migrants are thought to return home to die (Clark et al., 2007). It is therefore 
probable, that high mortality rate in HIV infected people with epilepsy could be the cause of 
comparatively low prevalence. The other possible reason for lower prevalence of ACE in 
Agincourt is that the area is hypo-endemic for malaria (Adjuik et al., 2006) and thus low 
prevalence of malaria-attributable acute symptomatic seizures compared to, for example, Ifakara 
(Drakeley et al., 2003) and Iganga-Mayuge (Chaves et al., 2011; Wandiga SO et al., 2010). In 
Agincourt, this explanation is supported by the very low (7/1000) prevalence of convulsions in 
SI of our study and the highest median age (13.7 years) at onset of seizures, although the 
Agincourt population and cases of ACE were relatively older. The low prevalence of ACE in 
Agincourt could also reflect living standards and access to healthcare that are relatively closer to 
the HIC setting than the other sites. 
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We observed the highest prevalence of ACE in children aged below 5 years in Iganga-Mayuge 
which is also reflected in the age at onset of seizures in Iganga-Mayuge and suggests aetiologies 
that occur early in childhood such as adverse peri-natal events e. g. hypoxic-ischaemic 
encephalopathy and intra-cranial infections. In contrast, the lowest prevalence in children less 
than 5 years occurred in Agincourt, where these factors appear to be absent and could perhaps be 
explained by the relatively better health care system. In Agincourt, the age/prevalence 
relationship suggests exposures that occur later in life and well into adulthood. These could 
include traumatic head injuries (mainly due to interpersonal violence particularly amongst 
males), HIV-related encephalopathies and stroke (Connor et al., 2004; Nell and Brown, 1991). 
The decrease in prevalence with age could reflect a decrease in incidence over time in Iganga- 
Mayuge as older age groups were less exposed to risk factors for epilepsy in the past, than their 
juvenile counterparts. This could be related to the documented increase in malaria transmission 
in this area (Chaves et al., 2011; Wandiga SO et al., 2010). Additionally, mortality and/or 
spontaneous remission could further explain this observation, since most of the epilepsy appears 
to start at young age. 
The age-specific prevalences were similar in Kilifi and Ifakara, being low in childhood, peaking 
at adolescence, with a dip in early middle-age and a second increase in the late middle-age and 
old age. This pattern suggests two explanations: i) low prevalence of risk factors associated with 
early childhood-onset epilepsy (such as febrile illnesses and adverse peri-natal events, which can 
also cause remote-symptomatic epilepsies in later ages) relative to factors that occur in late 
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childhood and adolescence e. g. previous head injuries and family history of both febrile and non- 
febrile seizures and, ii) remote symptomatic epilepsies caused by exposures in early childhood 
and which manifest as recurrent seizures later in life due to formation of neurological sequelae 
(if an individual survives the acute phase). Both these scenarios may occur in Kilifi (Carter JA, 
2004; Edwards T et al., 2008) although other exposures such as Toxoplasmosis and 
Onchocerciasis have not been investigated. The observed increase in prevalence of ACE in late 
middle and old age could imply epilepsy that is associated with progressive encephalopathies 
such as tumours, stroke and neuro-degenerative conditions (Commission on Epidemiology and 
Prognosis: International League Against Epilepsy, 1993), a relationship which needs to be 
investigated in the context of resource limited settings. 
Limitations of the study 
We used a three-stage cross-sectional survey methodology that had low sensitivity in identifying 
potential cases of ACE and in the Iganga-Mayuge site, the study also experienced high attrition 
rates between survey stages due to logistical difficulties in following up eligible participants. We 
however adjusted our estimates for these factors in these analyses. 
In this study, we have discussed the possible ecological causes of the observed between age and 
between study site heterogeneity. These associations should be interpreted with caution as they 
are not informed by the appropriate cases-control data. 
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Conclusion 
We have shown that the prevalence of ACE is heterogeneous across sub-Saharan Africa. We 
used similar methodologies to identify cases as well as similar definitions of epilepsy and 
operational procedures across different sites in this region. This was in an effort to systematically 
minimize the methodological component of the heterogeneity reported in a previous meta- 
analysis (Chapter 2). Our fmdings suggest real (clinical) heterogeneity of epilepsy that could be 
related to the distribution and types of risk factors for development of epilepsy or age differences 
in vulnerability to endemic risk factors within sites. These results are indicative of the burden of 
the people with epilepsy that should be on treatment in these sites and also form the basis for 
case-control studies to identify modifiable risk factors of epilepsy that could be targeted in public 
health interventions. 
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Abstract 
Objective: There are only a few studies of incidence of epilepsy in Low and Middle Income 
Countries (LMIC). These are often small, or in specific age groups, or conducted in areas with 
high prevalence of risk factors of epilepsy and therefore not representative of the general 
populations. We aimed to determine the incidence of active convulsive epilepsy (ACE) in a large 
rural population in Kenya. 
Methods: We conducted two cross-sectional surveys five years apart within a health and 
demographic surveillance system. In the first survey (2003) we identified residents without ACE 
who were then re-examined in the follow-up survey (2008) to determine the number of new 
cases. We estimated the overall incidence of ACE as well as incidence rates by age-group, sex 
and by administrative location. Estimates were adjusted for loss to follow-up during case 
identification and for the sensitivity of the screening method. 
Results: The incidence rate of ACE was 77.0/100,000 persons/year (95% confidence intervals 
(95%CI): 67.7 - 87.4). There was strong evidence of a U-shaped association between incidence 
and age with the lowest incidence occurring in the 29-49 year age group (37.4/100,000 
persons/year; 95% Cl: 25.7 - 54.7). 
Conclusion: We estimated a high incidence of convulsive epilepsy in this population. Our 
findings suggest that the risk of epilepsy was lowest in the middle-aged. The increased risk in the 
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other age groups is suggestive of aetiologies that occur early as well as late in life and preventive 
interventions should target exposures that occur in these age groups. 
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Introduction 
Epilepsy is one of the most common neurological conditions in the world and an important cause 
of disability and mortality, accounting for 1% of days lost to illness globally (Leonardi M and 
Ustan TB, 2002) and confers a 2-7 fold increased rate of mortality compared with the general 
population (Carpio et al., 2005; Forsgen L et al., 2005; Kaiser et al., 2007). It is estimated to 
affect 7 million people in high income countries (HIC) and 61 million people in low and middle 
income countries (LMIC) (Chapter 2). These estimates are however based on life-time 
prevalence data, which may underestimate the burden since epilepsy is associated with 
considerable mortality early after the onset of seizures and may spontaneously remit (Carpio et 
at., 2005; Diop et al., 2005; Kwan and Sander, 2004; Sander, 1993). Incidence is not affected by 
either of these factors and may provide a more accurate assessment of the burden of epilepsy. 
While a large number of studies have measured the prevalence of epilepsy in LMIC (as 
described in several reviews) (Benamer HT and Grosset DG, 2009; Burneo JG et al., 2005; 
Ngugi et al., 2010; Preux PM and Druet-Cabanc M, 2005), there are few estimates of the 
incidence of epilepsy (Kaiser C et al., 1998 May; Medina MT et al., 2005 Jan; Mung'ala Odera 
V et al., 2008; Rwiza HT et al., 1992 Nov-Dec; Saha SP et al., 2008; Tekle-Haimanot R et al., 
1997 May; Winkler AS et al., 2009). This is mainly due lack of health facility data to identify 
incident cases and the high cost of continuous surveillance of population-based cohorts required 
for accurate incidence estimates. 
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In HIC, incident cases can be identified through medical records (Annegers JF et al., 1999 Apr; 
Camfield CS, 1996 Jan; Freitag CM, 2001 Aug; Hauser WA et al., 1993 ; Heaney DC, 2002 Nov 
2; Kotsopoulos I et al., 2005; Olafsson E et al., 2005 Oct; Oun A et al., 2003 Oct), which are 
available to researchers. Better and accessible health care systems, specialized personnel and 
advanced medical technology and diagnostic accuracy further improve case detection in these 
countries. 
In LMIC with poor health-care resources and few specialists in neurology (WHO, 2004), the 
burden of epilepsy is usually determined using population-based studies. Due to cost, poor 
infrastructure and other resource constraints, the few studies of incidence that have been 
conducted in these countries are often small (Kaiser C et al., 1998 May; Medina MT et al., 2005 
Jan; Winkler AS et al., 2009) and of short follow-up duration (Kaiser C et al., 1998 May; Medina 
MT et al., 2005 Jan; Mung'ala Odera V et al., 2008). LMIC studies are also quite often restricted 
to specific age-groups (Mung'ala Odera V et al., 2008), or are conducted in areas with high 
prevalence of epilepsy or have used different methods to ascertain cases over the course of the 
follow-up period (Medina MT et al., 2005 Jan; Tekle-Haimanot R et at., 1997 May). These 
factors are likely to have contributed to the considerable variability in incidence estimates 
reported in LMIC (Chapter 3), ranging from 42/100,000 per year in India (Saha SP et al., 2008) 
to 215/100,000 per year in Uganda (Kaiser C et al., 1998 May). 
Our meta-analysis of published incidence studies suggested the need for large population-based 
studies in LMIC to accurately estimate the incidence of epilepsy (Chapter 2). 
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In this study we estimate the incidence of active convulsive epilepsy (ACE) in a large 
population-based cohort in a rural area of Kenya over a five year period. 
Methods 
Our study consisted of two cross-sectional surveys, separated by five years, nested in a 
demographic surveillance system. In the first survey we determined the ACE status of residents 
to identify a cohort of individuals without epilepsy; in the second survey we re-examined this 
cohort to determine the number that had developed ACE during the intervening period. The 
incidence of epilepsy was then calculated by dividing the number of incident cases by the person 
years of observation among cohort members (re-identified in the second survey). 
Study setting and study population 
We conducted the study within the Kilifi Health and Demographic Surveillance System (KHDSS 
- http: //www. kemri-wellcome. org/khdss/) which covers an area of 891 km2, in Kilifi District, one 
of the poorest districts in Kenya comprising of a population of 233,881 persons in 2008 living in 
25,526 homesteads (Scott JA et al., 2011). The KHDSS area has been mapped using global 
positioning system (GPS) receivers, and digital maps derived from these data are used to locate 
homesteads and follow up study participants. Community based field workers conduct re- 
enumeration and vital status registration to update the population registers by visiting every 
homestead two or three times per year. The population is served by the Kilifi District Hospital 
(KDH) which is located at the centre of the KHDSS area. 
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Residents of the study area are predominantly Mijikenda, a Bantu grouping of nine tribes with 
Girima (45%), Chonyi (33%) and Kauma (11%) being the most common. About 55% of the 
population is considered absolutely poor with per capita monthly income of about USD 10. The 
majority (80%) depend on subsistence farming, which is constrained by the low agricultural 
potential of the land (only 19% is arable). Only 45% of people are literate. Crude birth and death 
rates for this area are approximately 35/1,000 and 6/1,000 per year respectively, and migration 
rates are approximately 100/1,000 per year, most of which is within the study area (Scott JA et 
al., 2011). Malaria is seasonal, with two peaks in transmission during May to August and 
December to January (Snow et al., 1993b). Infectious diseases such as malaria, pneumonia or 
bacteraemia are common causes of paediatric admission to KDH (Berkley et al., 2003). The area 
has however experienced dramatic decline in slide-positive malaria admissions over the last 
decade (O'Meara et al., 2008). 
Cohort identification and follow-up 
We identified cohorts of people with and without ACE in a baseline cross-sectional survey 
described by Edwards et al., (Edwards T et al., 2008). The survey was undertaken by door-to- 
door visits of all residences within the KHDSS between August and November 2003. 
The three-stage method used to identify cases has been described elsewhere in detail (Chapters 4 
and 5). Briefly, the first stage (SI) involved asking the head of each household two screening 
questions to identify members of the household with a history of convulsions. Those that were 
positive were followed-up in Stage II (SII) and were interviewed by a team of field personnel 
trained to administer a more detailed and specific ACE screening tool (Appendix 4.2). 
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Respondents positive in SII were then evaluated in the stage III (Sill) where a diagnosis of ACE 
was made using detailed clinical history taken by a clinician trained in epilepsy and fluent in the 
local languages (Appendix 5.1). The International League Against Epilepsy (ILAE) definitions 
of active epilepsy were used (Commission on Epidemiology and Prognosis: International League 
Against Epilepsy, 1993; Meinardi et at., 2001), but a cut-off of at least one seizure in the 
preceding 12 months was used for active epilepsy (Ministry of Health, 2002). Children less than 
6 years of age were excluded in SI1 of the baseline survey due to difficulties of differentiating 
febrile seizures and epilepsy in younger children. 
Deaths and migration were identified during the routine re-numeration within the KHDSS during 
the follow up period. In the second cross-sectional survey, conducted between December 2007 
and June 2008, we attempted to interview every subject in the cohort who had not died and was 
still a resident in the KHDSS. No attempt was made to find subjects from the first survey who 
had migrated out of the study area due to logistical and cost implications. The second cross- 
sectional survey used the same methodology as the first cross-sectional survey to identify new 
cases of ACE. 
In both surveys, we defined ACE as at least two unprovoked convulsions (tonic and/or clonic 
seizures) of which one occurred in the 12 months preceding the survey (Meinardi et al., 2001). 
An incident case of ACE was a participant who was found not to have ACE in the first survey 
but was subsequently detected as a case in the follow-up survey. For an incident case, the first 
seizure may have occurred days or years before the second survey (Jallon et al., 2001). These 
cases were included in the analysis because there had been no other diagnosis of epilepsy prior to 
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presentation in the current study (Hauser et al., 1996; Olafsson E et al., 2005 Oct). We thus 
defined an incident case on the basis of the date of diagnosis of epilepsy rather than on the date 
of the second unprovoked seizure (Commission on Epidemiology and Prognosis: International 
League Against Epilepsy, 1993) since the recall of dates by the patients and their care-takers was 
likely to have been poor. 
Analysis 
We estimated incidence rates (IR) of ACE as the number of new diagnoses of ACE among the 
subjects that did not have ACE in the baseline cross-sectional survey, divided by the total person 
years of observation (pyo). Person-observation time lost due to out-migration or death was 
excluded from the denominator. We estimated an overall incidence rate together with 95% 
confidence interval (95% Cl) assuming a Poisson model for the number of incident cases. 
Incidence rates were also estimated by age-group, sex and by administrative location. 
We used the technique of multiple imputation (MI) with five imputations to reduce bias due to 
loss to follow-up between stages of the two surveys (Rubin DB, 1987; van Buuren S, 2007). The 
imputation model used the outcome from SI to impute SII where this was missing, and the 
outcome from SII to impute SIll. All incidence estimates were adjusted for the low sensitivity 
(48.6%) of the screening methodology (Chapter 4). Incidence rates were compared between age, 
sex and administrative area categories using incidence rate ratios (IRR) obtained from Poisson 
regression models. 
All analyses were carried out in STATA version 1l (StataCorp. College Station, TX, USA) 
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Written informed consent was obtained from all study participants. Where the patient was a child 
or an adult who could not respond, a caregiver was interviewed. Approval for the study was 
obtained from the Kenya Medical Research Institute/ National Ethical Review Committee. 
Results 
In the baseline survey, we identified 448 subjects with ACE and 150,960 subjects without ACE. 
At the follow up survey, 45,809 (30.3%) participants of the cohort had been lost [42,506 (92.8%) 
had out-migrated, 2,703 (5.9%) had died and 600 (1.3%) could not be traced]. The baseline 
characteristics of cohort members who were found and were not found in the 2008 survey are 
displayed in Table 6.1. We found 194 incident cases of ACE and estimated that there would be 
233 incident cases (after adjustment for loss to follow-up) and 479 incident cases (after 
adjustment for both loss to follow-up and sensitivity of the screening methodology described in 
chapter 4). The median (IQR) age of incident cases was 19.5 (14-31) years. The proportion of 
males was 49%. 
The total person-years of observation (pyo) for this cohort was 623,004 and the overall incidence 
rate was 77.0/100,000 pyo (95% Cl: 67.7 - 87.4) after adjusting for loss to follow-up and the 
sensitivity of the three-stage survey methodology. 
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Table 6.1: Main characteristics of the incidence study completers and those lost to follow- 
up. 
Recaptured Lost 
at follow up at follow up 
Attribute Category N % N % 
Sex Male 47,548 45.2 22,278 48.6 
Mean age (years) 26.2 24.6 
Roka-M-Mt 14,691 14.0 5,654 12.3 
Ngerenya 6,352 6.0 2,703 5.9 
Tezo 13,590 12.9 5,843 12.8 
Chonyi 21,133 20.1 6,841 14.9 
Area Sokoke 3,886 3.7 1,691 3.7 
Jarubini-Kauma 6,143 5.8 2,348 5.1 
Junju 17,979 17.1 7,626 16.7 
Takaungu 10,723 10.2 4,454 9.7 
Kilifi Township 10,654 10.13 8,649 18.9 
Giriama 45,310 43.1 20,506 44.8 
Chonyi 36,687 34.9 12,757 27.9 
Ethnicity Kauma 12,133 11.5 4,872 10.6 
Other Mijikendas 5,723 5.4 3,002 6.6 
Luos 593 0.6 856 1.9 
Others 4,702 4.5 3,803 8.3 
Stage I status at 
baseline Positive 1,425 1.4 475 1.0 
All cohort members 105,151 45,809 
T Koka-Matsangon i-M i da 
There was strong evidence of variation of incidence of ACE with age and the association 
appeared to follow a U-shape. The lowest incidence was in the 29-49 year age group 
(37.4/100,000 persons/year; 95% Cl: 25.7 - 54.7) and the highest was in the 6-12 year old age 
group (96.1/100,000 persons/year; 95% Cl: 78.4 - 117.9). The rate ratio for this association was 
0.46 (95% Cl: 0.31 - 0.71) (Table 6.2). Incidence did not vary by sex, administrative area of 
residence or ethnicity and there were no incident cases amongst the Luo ethnic group which also 
had the least person-years of follow-up (Table 6.2). 
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Table 6.2: Incidence rates and ratios for age, sex, ethnicity and area of residence for active 
convulsive epilepsy in Kilifi, Kenya. 
Incidence Rate 
o Cases* Rate* 95% CI ratio 95% CI P value 
Age group 
6-12 197040 189 96.1 78.4-117.9 1.0 
13-17 90246 82 91.2 66.9-124.3 0.91 0.62-1.33 
18-28 102426 84 82.3 60.7-111.9 0.82 0.56-1.20 0.008 
29-49 148020 56 37.4 25.7- 54.7 0.46 0.31-0.71 
50+ 85272 68 79.6 56.6-111.9 0.86 0.57-1.28 
Sex 
Female 341406 249 72.8 61.1-87.2 1.0 0.3 
Male 281598 230 81.9 67.9-98.6 1.2 0.9-1.5 
Ethnics 
Giriama 268206 210 78.2 64.4-95.1 1.0 
Chonyi 218370 158 72.6 58.0-90.7 0.94 0.69- 1.27 
Kauma 71814 68 94.7 67.3-132.9 1.35 0.92- 1.98 0.65 
Other Mijikenda 33864 29 85.0 50.4-143.6 0.98 0.54-1.78 
Luo 3390 0 0 - 0 
Other 27360 14 52.7 25.1-110.5 1.01 0.53- 1.93 
Area 
Roka- 
Matsangoni- 
Mida 86808 93 106.6 79.6-142.8 1.0 
Ngerenya 37962 29 75.9 44.9-128.2 0.65 0.35-1.20 
Tezo 80664 56 68.9 47.3-100.4 0.61 0.38-. 098 
Chonyi 126204 93 73.5 54.7-98.4 0.63 0.41-0.95 0.35 
Sokoke 23070 25 107.0 60.7-188.5 0.82 0.41-1.62 
Jaribuni 36612 33 89.9 55.1-146.7 0.77 0.43-1.38 
Junju 106938 80 75.1 54.7-102.7 0.67 0.44-1.03 
Takaungu 63762 43 67.7 44.2-103.9 0.56 0.33-0.96 
Kilifi Township 60984 29 47.3 28.0-79.8 0.59 0.34-1.00 
*Adjusted for loss to follow-up and sensitivity of the screening methodology 
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Discussion 
In this large-scale study, we estimated an overall incident rate of ACE at 77.0/100,000 persons 
per year with evidence for variation with age. We used two cross-sectional surveys 5 years apart 
within an existing HDSS of a rural population in Kenya to identify incident cases of ACE. Cases 
were identified in three-stage cross-sectional surveys at the beginning and at the end of the 
follow-up period. ILAE definitions (Commission on Epidemiology and Prognosis: International 
League Against Epilepsy, 1993) were used to define cases and non-cases (Edwards T et al., 
2008). 
Within the KHDSS framework, our study benefited from continuous follow-up for migration and 
death but was only able to determine the cumulative incidence of new cases from the cross 
sectional study that was conducted at the end of the study. It was not possible to determine the 
epilepsy status of residents who migrated away or died, although the demographic profile of 
these people was similar to that of the cohort members who were found at the second cross- 
sectional survey. In particular, the proportions of people with histories of convulsions at baseline 
(i. e., positive in the first stage of the baseline survey and therefore more likely to develop ACE) 
were similar among those lost and those who remained in the cohort. However, since mortality is 
typically highest in the first 1-3 years following the onset of seizures (Cockerell et at., 1994; 
Forsgen L et at., 2005), incidence may have been underestimated because we evaluated our 
cohort five years apart. 
We investigated ACE as opposed to all epilepsies (and life-time epilepsy) for two major reasons 
Firstly, convulsive epilepsies are much easier to recognize in community based settings and 
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hence do not require specialized personnel to identify, reducing cost and enabling us to survey a 
large HDSS population efficiently. Secondly, convulsive epilepsies are more likely to be 
associated with disability, mortality and stigma and are also more amenable to prevention and 
control. We excluded children under six years of age because of difficulties in differentiating 
between neonatal seizures, febrile seizures and epilepsy in this age group. 
At the rate of 77/100,000 pyo, the incidence of ACE was in the 42.1-81.1/100,000 persons/year 
range reported for both convulsive and non-convulsive epilepsies in other LMIC (Rwiza HT et 
al., 1992 Nov-Dec; Saha SP et al., 2008; Tekle-Haimanot R et al., 1997 May; Winkler AS et al., 
2009), the pooled estimates for LMIC reported in chapter 3 of this thesis and one study in 
Denmark that reported an incidence rate of 83.8/100,000 persons per year (Christensen et al., 
2007). This estimate was however higher than that reported for other HIC (Kotsopoulos I et al., 
2005; Ngugi et al., 2011; Olafsson E et al., 2005 Oct). Prevalence studies that have included non- 
convulsive epilepsies (Birbeck GL, 2004 Jan; Kaamugisha J and Feksi AT, 1988) have reported 
prevalence estimates that were 2-3 times higher than those that studied convulsive epilepsies 
only (Rwiza HT et al., 1992 Nov-Dec; Tekle-Haimanot R et al., 1997 May). Assuming similar 
rates for mortality and remission across studies, these findings would suggest that the incidence 
of all epilepsies (including focal epilepsies) in our population could be in the range of 154- 
231/100,000 persons/year, which are higher than those reported from other LMIC (Medina MT 
et al., 2005 Jan; Rwiza HT et al., 1992 Nov-Dec; Winkler AS et al., 2009). This rate would 
however be similar to that reported in an Onchocerciasis endemic area of Uganda (Kaiser C et 
al., 1998 May) and within the range estimated for LMIC in a recent review of incidence of life- 
time epilepsy (Chapter 3). We used an active epilepsy definition in which the last seizure was 
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within the previous 12 months as suggested by Meinardi (Meinardi et al., 2001) and because 
recall of seizures over a year ago is poor (Snow et al., 1993a). Other studies have used a 5-year 
cut-off (Commission on Epidemiology and Prognosis: International League Against Epilepsy, 
1993) and thus under our definition, the incidence of convulsive epilepsy in this population could 
be considerably higher. 
Overall, the incidence rate was not different between males and females in our study population, 
which was contrary to findings from other LMIC which reported higher incidence in females 
(Rwiza HT et a1., 1992 Nov-Dec; Winkler AS et al., 2009), or in males (Tekle-Haimanot R et al., 
1997). 
Age-specific incidence was highest in the children, adolescents and young adults aged 6-28 years 
and in the old age (50+ years), relative to the 29-49 year age-group. In the 6-28 year age group, 
onset of recurrent seizures could be related to perinatal insults and infections of the central 
nervous system particularly in the younger children (Mung'ala-Odera et al., 2008; Preux PM and 
Druet-Cabanc M, 2005). Many genetically determined epilepsies may also manifest during this 
period (Edwards T et al., 2008; Goudsmit J and van der Waals FW, 1983; Jilek-Aall L et al., 
1979; Jilek WG and Jilek-Aall LM, 1970; Matuja et al., 2001). In the adolescents and young 
adults, recurrent seizures may develop as a consequence of temporally remote aetiologies that 
result in static encephalopathies e. g. infectious brain insults earlier in life, cerebral palsy and 
mental retardation or engaging in activities that increase the risk of head injuries (Edwards T et 
al., 2008; Nell and Brown, 1991; Ogunniyi et al., 1987). 
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The age-incidence relationship in our study showed a characteristic U-shape, with lower risk in 
the young and middle aged adults as has been observed in the HIC (Jallon P et al., 1997 May; 
Olafsson E et al., 2005 Oct). In this age group (29-49 years), the incidence rate was 54% lower 
than the 6-12 years age group. This suggests that most of the epilepsy in this community affects 
the younger population. The incidence rate was also higher in the elderly (50+ years) compared 
to younger adults, which has also been observed in industrialized countries (Everitt and Sander, 
1998; Forsgren L et al., 1996 Mar; Kotsopoulos I et al., 2005; Olafsson E, 1996 Oct; Sander et 
al., 1990) and in one study in Tanzania (Rwiza HT et al., 1992 Nov-Dec) but not in another study 
in Ethiopia (Tekle-Haimanot R et al., 1997 May). Although it has not been documented in 
LMIC, elderly people may experience higher risk of developing epilepsy associated with 
progressive brain conditions which include tumours, cerebro-vascular accidents and neuro- 
degenerative conditions such as Alzheimer's disease (Commission on Epidemiology and 
Prognosis: International League Against Epilepsy, 1993). 
In view of the high incidence of ACE in this population, aetiological studies are necessary in 
order to elucidate causes, particularly among children, adolescents and the elderly who are at 
highest risk. Furthermore these age groups should be targeted for preventive public health 
interventions. 
Limitations of the study 
We utilized a three-stage survey methodology that had low sensitivity (48.6%) to detect cases of 
ACE (Chapter 4). Although we were able to adjust estimates for the low sensitivity it is possible 
that some cases of ACE missed during the baseline survey due to low sensitivity could have been 
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counted as incident cases in the follow-up survey thus causing an overestimation of incidence 
rate. 
On the other hand, it is also likely that early mortality due to epilepsy and remission may also 
have led to an underestimate of the number of incident cases, given the duration and the design 
of follow-up in this study. Future studies would benefit from a more frequent re-evaluation (e. g. 
every six months) of the cohort to ensure maximum detection of incident cases i. e. follow-up of 
prospectively identified cohorts of incidence cases, preferably population-based. We also 
excluded children <=5 years of age from this study, which may have resulted in a further 
underestimation of incidence in the study population. 
Conclusion 
We estimated the incidence of ACE in the largest population-based prospective cohort in Africa 
that was twice as high as that in HIC and within range of estimates reported for LMIC. The risk 
of epilepsy was highest in children, adolescents and young adults and the elderly and as such, 
preventive interventions should target exposures that occur early and later in life. 
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Abstract 
Objective: Most of the epilepsy mortality studies from Low and Middle Income Countries 
(LMIC) are based on small cohorts of people with epilepsy (PWE) while some have been 
conducted in areas where the incidence of epilepsy is very high and thus may not be 
representative of the general population. Furthermore, there are currently no studies on risk 
factors associated with mortality PWE in LMICs. We conducted a study to estimate the mortality 
rate and identify factors associated with mortality in a large cohort of people with active 
convulsive epilepsy (ACE) in a rural area of Kenya. 
Methods: 
People with ACE were identified in a cross-sectional population screening and followed up 
every three months for three years to collect information on putative risk factors of mortality. We 
estimated, mortality rates (MR), mortality ratios and standardized mortality ratio (SMR) based 
on age distribution of the Kilifi Health and Demographic Surveillance System (KHDSS) 
population at the baseline cross-sectional screening. We used Poisson regression analysis to 
examine the influence of potential risk factors on mortality. 
Results: 
We registered 61 deaths from among 754 people with ACE, yielding a mortality rate of 
33.3/1,000 person/year (95% confidence interval [CI]: 25.9-42.8). The overall SMR was 6.5 
(95% CI: 5.0-8.3) and mortality was significantly higher in people with ACE for all age groups. 
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Non-adherence to anti-epileptic drugs (AEDs) was associated with mortality in this population; 
the adjusted rate ratio was 4.0 (95% Cl: 2.1-7.7). 
Conclusion: 
We estimated that mortality in people with ACE in the Kilifi HDSS population was more than 
six fold that of the general population and was increased in all age groups. Mortality is 
associated with non-adherence to treatment which is amenable to intervention. 
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Introduction 
Epilepsy is one of the most prevalent non-communicable neurological conditions in the world 
and an important cause of disability and mortality (WHO, 2004). It is estimated to affect 
approximately 69 million people in the world, with up to 90% living in low and middle income 
countries (LMIC) (Chapter 2). A large number of mortality studies in people with epilepsy have 
been carried out in High Income Countries (HIC) (Benn et al., 2009; Cockerel] et al., 1994; 
Forsgen L et al., 2005; Hauser et al., 1980; Holden EW et al., 2005; Kochen S and Melcon MO, 
2005 Dec; Lhatoo and Sander, 2005; Lindsten H, 2000 Nov; Mohanraj R, 2006 Jun; Nilsson L, 
1997 Oct; Olafsson E, 1998 Jan; Tsai JJ, 2005) and in LMIC (Carpio et al., 2005; Coleman et al., 
2002; Ding et al., 2006; Diop et al., 2005; Kaiser et al., 2007; Kamgno J, 2003 Jul; Mu et al., 
2011; Snow RW et al., 1994). 
Most of the mortality data from LMICs are based on small cohorts of people with epilepsy which 
register small numbers of mortality events (Coleman et al., 2002; Kaiser et al., 2007; Snow RW 
et al., 1994), leading to imprecise estimates. Some studies have been conducted in areas where 
the incidence is very high (Kaiser et at., 2007) and thus may not be representative of this region. 
This limitation could be attributed to the high cost and requirement for continuous surveillance 
of large cohorts of patients needed to generate accurate estimates. Furthermore, mortality rates 
between these studies are difficult to compare since they estimated different epidemiological 
measures of mortality (mortality rates, proportional mortality, relative risk of death in a case- 
control study in Cameroon (Kamgno J, 2003 Jul) and standardized mortality ratios). 
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Cause-specific mortality in epilepsy has been investigated in a number of HIC (Forsgen L et at., 
2005; Lhatoo and Sander, 2005) but so far only in China (Ding et al., 2006; Mu et at., 2011) 
among the LMIC. In HIC, mortality in people with epilepsy has been associated with age at 
onset of seizures; highest in those developing seizures in childhood (<15 years) or in the elderly 
(> 65 years) (Hesdorffer et al., 2011; Tomson and Forsgren, 2005; Tomson et at., 2005), and 
duration of epilepsy (risk being highest in the first 1-2 years following the onset of seizures) 
(Forsgen L et al., 2005). Other important factors include: 1) seizure frequency (higher in those 
with more frequent seizures) (Tomson et al., 2005), 2) seizure types (higher in generalized tonic- 
clonic seizures (Hesdort%r et al., 2011; Langan et al., 2005; Tomson et al., 2005), myoclonic 
(Forsgen L et at., 2005), and epilepsy syndromes (remote symptomatic epilepsies) (Beghi et al., 
2005; Cockerel] et al., 1994)and, 3) non-adherence to AED (Langan et al., 2005). 
To estimate the rate of mortality and factors associated with mortality among individuals with 
epilepsy in a resource-limited setting, we conducted a population-based prospective study in a 
large cohort of people with active convulsive epilepsy (ACE) in a rural area of Kenya. 
Methods 
Study setting and study population 
The study setting and characteristics of the study population have been described previously 
(Chapters 4 and 5). Briefly, we conducted the study within the KHDSS (http: //www. kemri- 
wellcome. org/khdss/) which is within the Coast province of Kenya. The study area comprised of 
a population of 233,800 persons in 2008 living in 25,526 homesteads (Scott JA et al., 2011). The 
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area has been mapped using global positioning system (GPS) receivers, and digital maps are 
used to locate homesteads and follow up study participants. The KHDSS field personnel 
conduct re-enumeration and vital status registration to update the population registers by visiting 
every homestead three times per year. The population is served by the Kilifi District Hospital 
(KDH) which is located approximately at the centre of the KHDSS area. 
Residents of the study area are predominantly Mijikenda, a Bantu grouping of nine tribes with 
the most common being the Girima (45%), Chonyi (33%) and Kauma (11%). Approximately 
55% of the population is considered to be absolutely poor with per capita monthly income of 
about USD 10. A large proportion of the population (-80%) depend on subsistence farming, 
which is constrained by the low agricultural potential of the land (only 19% is arable) and the 
rest are engaged in salaried employment (both casual and formal) or petty trading. Only about 
45% of the population is literate. Crude birth and death rates for this area are 35/1,000 and 
6/1,000 per year respectively, and migration rates are approximately 100/1,000 per year, most of 
which is within the study area (Scott JA et at., 2011). 
Identification and follow-up of cohorts of participants with and without ACE 
Cohorts of people with and without ACE were identified in a baseline three-stage population 
wide prevalence screening within the KHDSS between December 2007 and June 2008 as 
described elsewhere (Chapter 4). Briefly, the first stage (SI) involved asking the head of each 
household two screening questions to identify members of the household with a history of 
convulsions. Those that were positive were followed-up in Stage 11 (SII) and were interviewed 
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by a team of field personnel trained to administer a more detailed epilepsy screening tool. Those 
positive in SIl were then evaluated in the third stage (Sill) where a diagnosis of ACE was made 
using detailed clinical history taken by a specialist epilepsy clinician. These diagnoses were 
further confirmed independently by a panel of neurologists. 
We used the International League Against Epilepsy (ILAE) definitions of epilepsy (Commission 
on Epidemiology and Prognosis: International League Against Epilepsy, 1993), but defined 
active epilepsy as at least one seizure in the preceding 12 months (Meinardi et al., 2001), since 
this is also the criteria for offering anti-epileptic treatment in Kenya (Ministry of Health, 2002). 
The ACE cohort identified at the baseline screening was followed up every three months in the 
study clinic for dose adjustments, assessment of adverse events, monitoring adherence and to 
replenish supplies of AEDs. Those members of the cohort that failed to attend the clinic 
appointments were followed up in the community within two weeks by trained epilepsy study 
field personnel. During each review follow-up, we administered a questionnaire to capture 
demographic data and information on the risk factors for mortality, which included seizure 
frequency and types, adherence to AED and age of onset of seizures. 
Classification of seizure types for all patients was done by a study clinician using the 
recommendations of the Commission of the Classification and Terminology of the ILAE (Berg 
AT et aL, 2010). Participants who were not on treatment (i. e. were not on any AED) during any 
of the follow-ups were classified as non-adherent to medication. This was determined by asking 
whether they were currently taking AEDs as well as asking to see the medication. 
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The cohort of people without ACE was followed-up for vital status and migration during the 
routine (four-monthly) re-enumeration within the KHDSS. Participants were followed-up till 
death, or censored at out-migration (and during the last clinic contact or withdrawal of 
consent/refusal for cases of ACE), and at the end of the study in March 2011. 
Analyses 
The crude mortality rates for the ACE and non-ACE cohorts were estimated as the number of 
deaths divided by their respective total person years of observation (pyo). To compare mortality 
between people with and without ACE, mortality among patients with ACE was tabulated in age 
strata and indirectly standardized against the population without ACE at the baseline survey to 
estimate the standardized mortality ratio (SMR). 
Among the cohort with ACE we examined the influence of 6 putative risk factors on mortality: 
(i) age (years) at onset of seizures (grouped as 0-5,6-12,13-17,18-28,29-49 and 50+ year age 
bands), (ii) sex (male, female), (iii) seizure types (none, focal, generalized tonic-clinic (GTCS), 
partial becoming secondarily generalized (PBSG) and others), (iv) number of seizure types 
(none, 1, >=2), (v) seizure frequency per month (<=2, >2) and, (vi) number of AEDs (none, 
>=1). 
To further explore the relationship between AED usage and mortality we used Poisson 
regression to adjust for the potential confounding effects of number of seizure types, seizure 
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frequency, and current age (0-5,6-12,13-17,18-28,29-49 and 50+ years). Each of these 
potential confounders was included in the Poisson model as a time-dependent cova te. 
All analyses were carried out in STATA v. II (StataCorp. College Station, TX, USA). 
Written informed consent was obtained from all study participants. Where the PWE was a child 
or an adult who could not respond, a caregiver was interviewed. Approval for the study was 
obtained from the Kenya Medical Research Institute/ National Ethical Review Committee. 
Results 
At commencement of the study 232,176 individuals were screened within the Kilifi HDSS 
(Chapter 5), identifying 762 individuals with ACE. Of the total population 12 participants could 
not be traced at the start of the study and 232,164 entered follow-up, comprising of 754 
individuals with and 231,410 without ACE. The median (IQR) follow-up was 18 (9-24) months. 
Within the ACE group we recorded a total of 7,331 patient contacts episodes with a mean of 9.7 
follow-up contacts per person. During the 39 months of the study, we registered 61 mortality 
events in people with ACE and 3,291 in people without ACE. Study outcomes of participants by 
ACE status are displayed in Table 7.1. 
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Table 7.1: Follow-up of study participants with and without active convulsive epilepsy in 
Kilifi, Kenya. 
Status Non-ACE % ACE % Total 
Moved 70,339 30.40 49 6.50 70,388 
Lost 92 0.04 15 1.99 107 
Refused 0 0.00 23 3.05 23 
Died 3,291 1.42 61 8.09 3,352 
Completed 157,688 68.14 606 80.37 158,294 
Total 231,410 100.00 754 100.00 232,164 
The total person-years of observation for the ACE cohort was 1,832.8 and that of the non-ACE 
group was 540,909.3, yielding crude mortality rate estimates of 33.3/1,000 pyo (95% CI: 25.9- 
42.8) and 6.1/1,000 pyo (95% Cl: 5.9-6.3) respectively. 
There was strong evidence that mortality was associated with ACE in this population. The 
overall SMR for ACE was 6.5 (95% Cl: 5.0-8.3). Comparative mortality was highest in the 6-12 
year age group in people with ACE: rate ratio was 22.5 (95%CI: 12.4-40.6), and was high in all 
age groups with ACE (Fig 7.1). 
In the univariable analysis, patients who were not adherent to medication had a 3.0 fold the risk 
of mortality that of patients who were on at least one AED (Table 7.2). In the multivariable 
analyses (Table 7.3), we adjusted the effect of non-adherence for seizure frequency and number 
of seizure types since these were likely to confound the relationship between non-adherence and 
mortality. The multivariable Poisson regression showed that patients not taking AED were at 
higher risk of death; adjusted rate ratio was 4.0 (95% Cl: 2.1-7.7) (Table 7.3). 
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Figure 7.1: Age-specific mortality rate ratios and standardized mortality ratio (SMR) for 
active convulsive epilepsy in Kilifi, Kenya. 
Table 7.2: Univariable analysis of factors associated with mortality in people with active 
convulsive epilepsy in Kilifi, Kenya. 
Mortality Unadjusted 
Factor Person-time Deaths rate 95% CI Rate Ratio 95% CI P-value 
Age at Onset 
0-5 1108.7 27 24.4 (16.7-35.5) 1.0 
6-12 278.7 10 35.9 (19.3-66.7) 1.4 (0.7-3.0) 
13-18 165.5 8 48.3 (24.2-96.7) 1.7 (0.7-4.0) 
19-28 111.3 1 9.0 (1.3-63.8) 0.6 (0.1-2.7) 0.2 
29-49 76 3 39.5 (12.7-122.4) 1.5 (0.3-6.7) 
50+ 92.5 12 129.7 (73.7-228.4) 5.8 (0.9-36.8) 
Sex 
Female 881.7 32 36.3 (25.7-51.3) 
Male 951 29 30.5 (21.2-43.9) 0.9 (0.5-1.5) 0.6 
Seizure Type 
None 1176.7 37 31.4 (22.8-43.4) 1.0 
Focal 173.8 3 17.3 (5.6-53.5) 0.6 (0.2-1.9) 
GTCS 256.7 11 42.8 (23.7-77.4) 1.4 (0.7-2.8) 0.5 
PBSG 151.3 7 46.3 (22.1-97.1) 1.6 (0.7-3.6) 
Others 74.3 3 40.4 (13.0-125.3) 1.5 (0.5-4.8) 
No. of Seizure types 
none 1176.7 37 31.4 (22.8-43.9) 1.0 
one 623.7 22 35.3 (23.2-53.6) 1.4 (0.8-2.4) 
>--2 32.3 2 62 (12.5-248.0) 2.4 (0.6-9.9) 0.3 
Seizure F uency 
c2/month 1717.5 55 32 (24.6-41.7) 1.0 
>2/month 115.3 6 52.1 23.4-115.9 1.7 (0.7-4.0) 0.2 
No. of AEDs 
>=1 870.2 14 16.1 (9.5-27.2) 1.0 
None 962.5 47 48.8 (36.7-65.0) 3.1 1.7-5.6 <0.001 
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Table 7.3: Multivariable analysis of factors associated with mortality in people with active 
convulsive epilepsy in Kilifi, Kenya. 
Mortality Adjusted 
Person-time Deaths rate 95% Cl Rate Ratio 95% CI P-value 
No. of Seizure types 
none 1176.7 37 31.4 (22.8-43.9) 1.0 
one 623.7 22 35.3 (23.2-53.6) 1.9 (1.0-3.4) 
>=2 32.3 2 62.0 (12.5-248.0) 4.7 1.0-22.1 0.06 
Seizure Freq uency 
<=2/month 1717.5 55 32.0 (24.6-41.7) 1.0 
>2/month 115.3 6 52.1 (23.4-115.9) 1.3 (0.5-3.2) 0.6 
No. of AEDs 
>=1 870.2 14 16.1 (9.5-27.2) 1.0 
None 962.5 47 48.8 (36.7-65.0) 4.0 (2.1-7.7) <0.001 
Discussion 
To our knowledge, this is the first study to report on factors associated with mortality in people 
living with epilepsy in LMIC. We used a cross-sectional survey to identify people with and those 
without ACE and a prospective cohort design to follow-up cases at regular intervals. We 
minimized attrition within the study by following up people in the community if they failed to 
attend scheduled clinic appointments. Our study benefitted from an established demographic 
surveillance system that maintains a regularly updated population register and provides relatively 
accurate denominator data, for the estimation of mortality rates. 
Our findings showed that people with ACE in this area had more than 6-fold risk of death 
compared to people without ACE. Although mortality was elevated 
for all ages relative to the 
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general population, this increase was more marked in the older children, adolescents and young 
adults aged 6-28 years. 
The high mortality rate in our study, relative to other studies that reported mortality rates ranging 
between 0.024-6.2/1000 person-years (Harvey et al., 1993; Hauser et al., 1996; Sillanpaa et al., 
1998; Zielinski JJ, 1974), could partly be due to the fact that we focused on active convulsive 
epilepsy, which is associated with higher risk of psychosocial co-morbidity and death than life- 
time and non-convulsive epilepsies (Forsgen L et al., 2005; Lhatoo and Sander, 2005). This 
fording could also be a reflection of the severity of epilepsy and its underlying causes. 
The age-SMR relationship in our study could be due to low mortality in the corresponding age 
groups in the general population. Indeed, the age-specific mortality rates in people without ACE 
were lowest in the 6-28 year age-groups which also had the highest SMR. On the other hand the 
lower SMR in the young children (0-5 years) and older adults and the elderly (29-49 and 50+ 
years) indicate relatively higher mortality in the general population. Mortality in these age- 
groups is related to perinatal, nutritional and infectious causes in the very young (Berkley et al., 
2003; Moisi et al., 2011) and HIV-related and cardiovascular causes in the older age groups 
(Bauni et al., 2011). 
The higher relative mortality (compared to people without ACE) in older children (6-12 years), 
adolescents (13-17 years) and young adults (18-28 years) was similar to the observation in a 
Ugandan study in which mortality was highest in patients aged 10-20 years (Kaiser et al., 2007) 
and in one study in China (Ding et al., 2006). This fording points to the possibility of epilepsy 
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related causes of death, either directly or indirectly, such as status epilepticus and drowning 
(Jilek-Aall and Rwiza, 1992). In our study of incidence of epilepsy in the same population, 
incidence was highest in the same age groups (Chapter 5), which conforms to the observation 
that mortality tends to be highest in the first few years following the onset of epilepsy (Cockerell 
et al., 1994; Forsgen L et al., 2005). In these age groups, it is likely that aetiologies of epilepsy 
are also important causes of death in people with epilepsy. For example, these age groups are 
more likely to engage in activities that increase the risk of traumatic head injuries which may 
cause epilepsy and also increase the risk of accidental death due to occurrence of seizures in 
dangerous circumstances. Alternatively, it is possible that large proportions of cases in this age 
group could be remote symptomatic epilepsies that develop as a consequence of temporally 
remote aetiologies that result in static encephalopathies e. g. cerebral hypoxia at birth, infectious 
brain insults, cerebral palsy and mental retardation. 
In the univariable analysis, patients who were non-adherent to anti-epileptic medication were at a 
higher risk of mortality. We adjusted for potential confounding of the relationship between this 
variable and mortality by seizure frequency and number of seizure types in the multivariable 
analyses since these were associated with non-adherence in this study (p<0.001) and have been 
shown to be important predictors of mortality in other studies. High seizure frequency is a risk 
factor for epilepsy associated causes of death such as accidents (accidental fall from heights and 
drowning) and sudden unexpected death in epilepsy (SUDEP) (Lhatoo and Sander, 2005). It is 
related to poor seizure control in non-adherent patients and in those with refractory epilepsy 
(Langan et al., 2005). In the adjusted analysis non-adherent patients had a fourfold the risk of 
. mortality compared to those on at least one drug. This 
finding is important in view of the high 
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epilepsy treatment gap (75%) estimated in a recent study in Kilifi (Mbuba CK et al., 2012) and 
concurs with findings of one study from HIC (Langan et al., 2005) but were contrary to another 
study in LMIC (Kaiser et al., 2007) which did not find higher mortality among non-adherers. 
Possible reasons for disagreement between our study and that of Kaiser and his co-workers are: 
(i) the latter study was relatively small (61 patients) and they recorded only 18 deaths in their 
cohort, (ii) they measured adherence subjectively by constructing an adherence index based on 
self-reported adherence and assessment of clinical notes, and it has been shown that self-reported 
adherence has low sensitivity when compared to blood-levels of AEDs in a recent study in Kilifi 
(Mbuba CK et al., 2012), (iii) self-reported adherence in the study by Kaiser was based on long 
recall as it was assessed at only two time points over a six year follow-up period, and (iv) Kaiser 
and colleagues measured adherence in a life-time epilepsy cohort, in which some patients could 
have entered remission. The possible mechanism through which adherence to AEDs exerts an 
effect on the risk of mortality is through seizure control. Non-adherence leads to poorly 
controlled seizures, which increases the severity of epilepsy (with respect to frequency and 
duration of seizures as well as duration of epilepsy) and thus higher risk of epilepsy-related 
mortality. 
Given the high risk of mortality in people with epilepsy in this area, particularly those not 
adherent to medication, there is an urgent need for preventive interventions. These could include 
instituting measures to reduce the incidence of epilepsy (e. g. prevention of trauma through use 
of head protection when riding motorcycles or bicycles, good prenatal care, including avoiding 
alcohol and treatment of high blood pressure and infections during pregnancy, reduction of 
childhood infections by improved public hygiene and immunization to reduce the risk of cerebral 
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damage, elimination of parasites in the environment that cause diseases such as malaria and 
cysticercosis and use of bed nets to prevent mosquito bites), educating people with epilepsy and 
their care-takers on the importance of seeking treatment, strict adherence to medication and 
identification of epilepsy-related risks of death. Monitoring of people with epilepsy, could 
mitigate some of the risks associated with epilepsy-related causes of death although this may be 
difficult to implement. An important factor that is associated with non-adherence in this 
population is long distances to AED distribution points, due to erratic supply in peripheral health 
facilities (Mbuba CK et al., 2012). Increasing access to AEDs by ensuring adequate supply at the 
primary health care level would lead to a significant reduction in mortality in people with 
epilepsy. 
Limitations of the study 
Our study suffered large attrition of people without ACE who were followed-up within the 
regular HDSS census. Due to cost and logistical implications, we did not attempt to determine 
their vital status and this loss to follow up may not have caused bias in our estimate of the 
mortality ratios since mortality rate in the non-ACE cohort was similar to what it is was the 
KHDSS generally. 
We used a prevalence cohort of cases which might under-estimate short-term mortality because 
cases with more severe aetiologies of epilepsy die early in the course of the condition and may 
not be counted in estimation of mortality over the observation period. In view of this, a 
prospectively identified population-based cohort of incident cases would be the ideal to study 
mortality, but is much more expensive and logistically challenging. 
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There is a need for studies of cause-specific mortality of people with epilepsy to increase the 
impact of potential interventions aimed at reducing mortality in this population group. 
Conclusion 
Our study shows that mortality in people with ACE is more than six time that of the general 
population and was increased in all age groups in the KHDSS. Mortality is associated with non- 
adherence to treatment which is to a large extent preventable. 
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Chapter 8: Summary and Conclusions, Implications for public health and directions for 
future research 
215 
Introduction 
The studies in this thesis examine the burden of epilepsy at the global level using systematic 
review and meta-analysis of existing literature and at the level of LMIC using population-based 
cross-sectional methods to identify people with ACE for determination of prevalence and 
incidence. They also assess the methodology used in this and other studies to identify cases, 
quantify and compare mortality between epilepsy and non-epilepsy populations as well as 
identify the factors associated with mortality in people with ACE in the Kilifi HDSS. 
This chapter summarizes and puts into context the main research findings with reference to the 
study objectives (Chapter 1), enumerates the public health implications of these findings and 
proposes some for public health actions and directions for future research. 
Background 
Epilepsy is an important cause of disability and mortality. It accounts for 0.5-1.0% of the global 
burden of disease and contributes up to 7 million disability adjusted life-years (DALYs) 
annually. DALY is a health gap measure that extends the concept of potential years of life lost 
due to premature death to include equivalent years of `healthy' life lost by virtue of being in 
states of poor health or disability (Leonardi M and Ustan TB, 2002; WHO/IBE/ILAE, 2005). In 
LMIC, the perceptions of causes and consequences of epilepsy differ from those in the HIC and 
often lead to stigmatization (Scambler G and Hopkins A, 1986). The stigma may in turn generate 
a hidden burden of epilepsy in which patients are unwilling to seek medical advice, generating 
large treatment gaps (Meinardi et al., 2001; Scott et al., 2001). 
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Epilepsy is associated with significant psychosocial co-morbidities that impact on the quality of 
life of patients and also influence prognosis. These include social maladjustments due to phobia 
of the unexpected and uncontrollable nature of epileptic seizures and the stigma (Dilorio C et al., 
2003). Cognitive problems such as neuropsychological impairment (including poor memory, 
language skills, executive functions and motor speed) (Alvarado et al., 1992) and psychiatric 
conditions (particularly anxiety and depression) (Gaitatzis et at., 2004; Pellock, 2004; Trimble 
and Krishnamoorthy, 2003) occur with much higher frequency in people with epilepsy (PWE) 
than the general population, and higher frequency of seizures is associated with greater degree of 
psychopathology (Gaitatzis et al., 2004). 
In 1993, The World Bank declared the control of epilepsy as highly cost-effective, in terms of 
the DALYs averted per the amount of monetary resources (measured in international dollars) 
used (World Bank, 1993) since relatively inexpensive AEDs were effective in controlling 
seizures in the majority of patients (Coleman et al., 2002). In the study by The World Bank, 
epilepsy was placed in the category of conditions that could be substantially controlled with a 
cost effective intervention (World Bank, 1993). A more recent study on cost-effectiveness of 
AEDs by the WHO-CHOICE (Choosing Interventions that are Cost-Effective) programme 
refined these data and estimated that extending treatment coverage to 50% of the current 
primary (idiopathic) epilepsy cases would avert 150 - 650 DALYs/million population (about 13 
- 40% of the current 
burden) at an annual cost of 0.2 - 1.3 $ per case. Older first-line AEDs 
(phenobarbital, phenytoin, carbamazepine and valproic acid) were the most cost effective on 
account of similar efficacy and lower acquisition cost (800 - 2000 $ /DALY averted) (Chisholm, 
2005). Despite the availability of cost-effective treatment, several studies in LMIC have shown 
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that the majority of PWE do not receive appropriate treatment and hence their epilepsy is 
uncontrolled (Mbuba et al., 2008; Meinardi et al., 2001; Scott et al., 2001) . 
In 1997, The Global Campaign Against Epilepsy (GCAE), was started as a result of a partnership 
between the International League Against Epilepey (ILAE), the World Health Organisation 
(WHO) and the International Bureau for Epilepsy (IBE) (WHO/IBE/ILAE, 2001). The theme of 
this campaign was to bring epilepsy `out of the shadows' by supporting LMIC to reduce the 
burden caused by epilepsy through improved acceptability, access to services, prevention and 
quality of care. In 1999, the WHO gave epilepsy a cabinet level status, in which each WHO 
regional office pledged to commit personnel and resources to the GCAE. The second phase of 
the GCAE was launched in 2001 with the initiation of demonstration projects in several countries 
(China, Argentina, Zimbabwe and Senegal). The specific objectives were to develop models of 
epilepsy control worldwide. To date more than 90 countries are involved in the campaign whose 
overall goal is to improve the identification and management of people with convulsive 
epilepsies within existing primary health care systems (WHO/IBE/ILAE, 2001). 
The studies reported in this thesis augment these efforts by estimating the burden of epilepsy 
(particularly Active Epilepsy, which should be on treatment) through well documented and 
reproducible methods, describing the distribution of ACE in resource limited settings as well as 
factors associated with mortality in PWE. 
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Overview of findings 
This research focused on the global, regional and local investigations of burden, distribution and 
outcomes of epilepsy. The chapters are organized in a sequence that corresponds to the 
objectives outlined in chapter 1. 
The systematic review and meta-analysis of chapter 2 estimates the burden of both life-time 
(LTE) and active epilepsy (AE) and examines the influence of various study-level factors in the 
reported heterogeneity of estimates. The prevalence of AE in rural areas (12.7/1000) of LMIC 
was more than two times higher than that of HIC (4.9/1000) and urban areas of LMIC 
(5.9/1000). Using average global population estimates for the period in which the reviewed 
studies were conducted, the estimated number of cases of AE in HIC was 5.7 million, 17 million 
for rural areas of LMIC and 10 million for urban areas of LMIC. These estimates reflect the 
global burden of epilepsy that should be on treatment. The data provided evidence of 
heterogeneity, with studies involving all age groups or only adults, those conducted in rural areas 
and those with small sample sizes having significantly higher prevalence estimates. In a 
subsequent multicentre study of prevalence of epilepsy (reported in chapter 5), the component of 
the heterogeneity in estimates that is related to methodological differences was reduced by 
including all age groups, studying large populations and using standardized methods of case 
identification and definitions of ACE. 
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The third chapter of the thesis is a systematic review and meta-analysis which estimated pooled 
incidence of epilepsy at the global, HIC and LMIC levels and also investigated sources of 
heterogeneity of estimates. These analyses were based on the premise that since mortality is high 
at the onset of epilepsy and spontaneous remission also occurs, prevalence data could potentially 
grossly underestimate the burden of disease. Estimation of incidence of epilepsy which is not 
affected by disease-specific mortality could thus be a useful alternative in the assessment of 
burden. As with prevalence, the incidence of epilepsy in LMIC was approximately twice that of 
HIC. Compared with hospital-based studies, our results showed that population-based studies 
reported higher incidence, studies with small sample sizes (<20,000 participants) also reported 
higher estimates while retrospective studies reported significantly lower estimates than 
prospective studies. These findings suggested that: (i) hospital-based studies could be missing 
out on non-severe cases of epilepsy thus the reported low incidence, (ii) researchers, particularly 
in LMIC, conduct small studies to estimate incidence of epilepsy in areas that are endemic for 
risk factors for development of epilepsy and thus these are not representative of the general 
populations and, (iii) retrospective cohort studies do not identify all incident cases. These results 
emphasized the need for large population-based prospective cohort studies to measure incidence 
of epilepsy much more accurately, particularly in LMIC. This was attempted in the study of 
incidence of epilepsy in the Kilifi HDSS, which is reported in chapter 6 of this thesis. 
The study reported in chapter 4 was a population-based assessment of the three-stage cross- 
sectional screening methodology that had been used in a previous study to identify cases of ACE 
in the Kilifi HDSS and which was also used in the prevalence studies reported in this thesis. The 
three-stage cross-sectional survey method had poor sensitivity (48.6%) in detecting cases of 
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ACE in the community. To a large extent, the low sensitivity was attributed to the first stage of 
the survey which accounted for 15/18 (83.8%) of the false negatives. Given the conspicuous 
nature of convulsive seizures and the fact that the first stage was conducted by field personnel 
who resided within the study community, it was likely that the reported low sensitivity was 
stigma-related. The three-stage method, though 60% cheaper than the more `traditional' two- 
stage survey methodology used in many prevalence studies, may not be suitable for identification 
of people with ACE in LMIC where the condition is stigmatized. However, where it is used e. g. 
for cost and logistical considerations, the methodology would need to be validated in the target 
populations and the prevalence estimates adjusted accordingly. 
The prevalence studies reported in chapter 5 were conducted in four locations in sub-Saharan 
Africa that differed with regard to endemicity of factors associated with development of 
epilepsy. To minimize methodological heterogeneity in these studies, standardized tools, 
methodologies, definitions of ACE and operational procedures were used. Striking findings from 
these studies were the between site and within site (by age) heterogeneity in the distribution of 
ACE. Prevalence of ACE was highest in the Ifakara HDSS in Tanzania and lowest in Agincourt 
HDSS in South Africa (after adjusting for loss to follow-up and sensitivity of the three-stage 
survey methodology). Since I focused on ACE (as opposed to life-time and non-convulsive 
epilepsies), these results reflect the component of the burden of epilepsy that is most vulnerable 
to stigma and premature mortality and that should be on treatment in these sites. The 
heterogeneity documented in this chapter (after standardizing the methods and definitions) 
suggests real heterogeneity (e. g. due to differences in the distribution and types of risk factors or 
patient vulnerability). This fording implies the need for case-control studies to gain a better 
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understanding of the factors driving the high prevalence in some of the sites and the between site 
heterogeneity. 
Chapter 6 estimated the incidence of ACE in a large population-based cohort using two cross- 
sectional surveys five years apart. The incidence rate, estimated at 77/100,000 persons per year, 
was higher than that reported in most other studies from LMIC. Although the high incidence 
could have been caused by inclusion of epilepsy cases in the non-epilepsy cohort because of low 
sensitivity in the baseline survey, it is also possible that this study nevertheless underestimated 
the incidence due to mortality of incident cases shortly after the onset of seizures. The results 
showed strong evidence of association between age and development of ACE, with the lowest 
incidence in the young and middle-aged adults (29-49 years). This was suggestive of higher risk 
of epilepsy in the young children and adolescents and in the elderly and potential interventions to 
prevent epilepsy in this community should target these groups. 
Chapter 7 documents a study on the magnitude and risk factors associated with mortality in 
people with ACE in the Kilifi HDSS. The findings of this study show that ACE was associated 
with a raised mortality rate. When the data were adjusted for age, mortality was more than 6 
times higher in people with ACE compared to the general population. Non-adherence to 
medication was an important epilepsy-related predictor of death in patients and interventions to 
prevent mortality should target this factor as a matter of priority. 
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Implications for public health 
High prevalence, incidence and mortality in people with ACE are documented in the studies 
presented in this thesis. These findings suggest that epilepsy is likely to have far reaching effects 
on the health, welfare and quality of life of patients in the sites in which the studies were 
conducted and in LMIC more generally. 
At the global level, our findings show that the burden of epilepsy is much larger than previously 
thought and have provided estimates of the burden of active epilepsy representing people who 
should be on treatment in both HIC and LMIC. These findings should be used to prioritize 
epilepsy as an important global public health problem and lobby for increased resources, 
particularly in LMIC, to improve diagnostic, treatment and preventive services and to campaign 
for the destigmatisation of epilepsy. 
For the local health systems, these findings would in the short term translate directly into 
increased health expenditure in terms of treatment services for the patients identified in these 
studies. In the medium term, the health systems would need to increase and sustain capacity to 
provide more appropriate health services to PWE at the primary care level e. g. in terms of 
training and retaining nurses or clinical officers to diagnose and manage epilepsy as well as 
provision of counseling services to patients with attendant psychosocial co-morbidities. In the 
medium to long term, preventive interventions must be given priority and this means identifying 
the preventable causes of epilepsy. This includes the deployment of measures such as health 
promotion to educate the communities on causes of epilepsy (as well as risk factors of mortality 
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in PWE), improved ante-natal and perl-natal services and provision of prompt and effective 
treatment of traumatic head injuries and infections of the central nervous system (CNS). 
Additionally, childhood vaccination for vaccine preventable causes of CNS infection (e. g. 
Haemophilus meningitis) could have an important effect on the prevention of epilepsy. However, 
causes of epilepsy in these communities would need to be identified using formal 
epidemiological methods. 
Directions for future research 
Collectively, the studies reported in this thesis suggest a large burden of epilepsy in LMIC, 
particularly in SSA, and poor prognosis of epilepsy in one of the sites (Kilifi HDSS). There is 
need to quantify the magnitude of epilepsy mortality in the other study sites in order to assess the 
effect of epilepsy in these populations as well as to compare the mortality experience in these 
cohorts given that similar methodology and case definitions were used across these sites. 
Epilepsy-related risk factors for mortality were also identified only in the Kilifi HDSS and these 
would need to be identified in the other study sites. Studies of cause-specific mortality (cause of 
death studies) in PWE would be useful in the quantification of the role of epilepsy related causes 
of death e. g. status epilepticus, sudden unexpected death in epilepsy (i. e. SUDEP) and accidental 
injuries. Cause of death as well as mortality risk factor information would form core elements of 
public health messages aimed at reducing the risk of mortality in PWE in this region. 
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These studies documented substantial between site heterogeneity in the distribution of ACE. 
Given that the studies were conducted using similar methodology and case definitions, it is 
postulated that the observed heterogeneity was due to differences in the distribution and types of 
risk factors for development of epilepsy between sites and/or in the vulnerability of different 
segments of populations (particularly age-groups) within sites to endemic risk factors. However, 
these hypotheses would need to be tested formally in case-control studies. These would identify 
risk factors that would be key to preventive public health interventions. 
The studies reported in chapters 5 and 6 utilized a cohort of prevalent cases to estimate the 
incidence and mortality of ACE. Mortality is high early in the course of epilepsy and remission 
is known to occur. Therefore, studies based on prospectively identified cohorts of incident cases 
would be ideal in estimating more accurately the incidence and mortality of epilepsy, although 
they would be much more costly and logistically challenging to conduct. 
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Appendix 1.1: A Concept to assess the burden and outcome of epilepsy across INDEPTH 
sites 
Anthony K Ngugi', Victor Doku2, Charles R Newton' (April 2007) 
1. Centre for Geographical Medicine Research (CGMR-Coast), Kenya Medical Research 
Institute, Kilifi, Kenya. 
2. Kintampo DSS, Kintampo Health Research Centre, Kintampo, Ghana. 
Epilepsy is the most common neurological condition affecting more than 50 million people in the 
world. However the causes and consequences appear to be different in majority world countries 
(MWC), and this has implications regards management of epilepsy in these communities. 
Epilepsy accounts for 0.5% of the global burden of disease, translating to 7 million disability 
adjusted life years (DALY's) annually. It is estimated that more than 80% of the global burden 
of epilepsy is found in the LMIC, with 10 million cases in Africa alone; but these estimates are 
based upon little data. Epilepsy is associated with behavioural and psychiatric co-morbidities, 
impairing function within society. Additionally, studies have shown that mortality is increased 2- 
4 fold in people with epilepsy (PWE) compared to the general population. Active convulsive 
epilepsy (ACE) is the most reliably detected and is associated with the most severe co-morbidity 
and increased mortality. 
Epilepsy is a treatable condition, with evidence suggesting that up to 75% of the cases that 
receive appropriate treatment achieve remission in I to 5 years of therapy. The World Health 
Organization has estimated that it costs as little as 15 US $ per person annually to treat. 
However, up to 90% of people with epilepsy in LMIC do not receive appropriate treatment 
owing to many different factors including perception of the causes and lack of understanding of 
the concept of prophylaxis. 
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Given the serious health and outcome implications of epilepsy, its attendant comorbidities and 
inadequate data on the burden and outcome of epilepsy, there is a need for good quality 
epidemiological studies. In LMIC with large rural populations where there are few specialists in 
neurology, scantily allocated heath-care resources and a substantial burden of disease; 
epidemiological studies provide information necessary for promoting health to optimize care in 
epilepsy. Well-planned and coordinated studies in diverse sites would minimize methodological 
heterogeneity, generate more accurate estimates of disease burden and provide data on co- 
morbidity and increased mortality. Data from such studies would be used to lobby for 
appropriate allocation of resources for education and awareness raising, medical care and 
rehabilitation of PWE and communities in general. 
We have recently conducted a survey of>150,000 people in Kilifi DSS in which the prevalence 
of ACE was estimated at 4.7/1000 after adjustment for non-response. This survey utilized a 3- 
stage system of diagnosis in which 2 questions were used to screen the entire population for 
convulsions within the DSS. 
With this concept paper, we want to determine the interest of the other InDepth DSS sites to 
partake in the planning and implementation of a multicentre study. The planning will entail an 
assessment of resources required at each site, appraisal of available skills and manpower, 
determination of logistics and co-ordination and development of a substantive funding proposal. 
We will apply for funds to organize a planning meeting to develop the proposal. 
The goal is to obtain data on: 
" Prevalence of ACE 
" Psychiatric and behavioural co-morbidities associated with ACE; 
" Epilepsy treatment gap (proportion of PWE not receiving appropriate treatment); 
" Communities' knowledge, attitudes and practices on epilepsy; 
" Socio-cultural dimensions of epilepsy, unique care-seeking barriers and how to 
develop culturally appropriate interventions. 
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ýs> 
Conducting prospective longitudinal studies to measure: 
9 Incidence of epilepsy and psychiatric and behavioural co-morbidities associated 
with ACE; 
0 Excess mortality due to epilepsy; 
9 Determine the causes of death in PWE. 
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Appendix 1.2: Epidemiology and treatment of epilepsy in Sub-Sahara Africa: quality 
assurance manual 
Introduction 
Quality assurance (QA) is the total process whereby the quality of research results can be 
guaranteed. This process consists of systematic actions necessary to demonstrate that a product 
or service meets specified requirements for quality. 
This project quality assurance manual comprises the following sections: 
1. Introduction to Epilepsy Surveys 
2. Standard operating procedures (SOPs) for pre-analytic processes 
3. Communication and consent materials 
4. Glossary 
TABLE OF CONTENTS: 
SECTION ONE: INTRODUCTION TO EPILEPSY SURVEYS 
SECTION TWO: SOPs FOR PRE-ANALYTIC PROCESSES 
1) Survey Stage I SOP 
2) Survey Stage II SOP 
3) Survey Stage III SOP 
4) Survey Stage 11 forms reception, checking and follow-up 
5) Survey Stage II - Selection of population sample 
6) Survey Stage III - Selection of matched controls 
7) Survey (All Stages) - Data entry SOPs 
SECTION THREE: COMMUNICATION AND CONSENT MATERIALS 
1) Epilepsy studies SOP for informed consent 
2) Stage I- Census Introduction 
3) Stage If - Stage I cases interviewed in stage if 
4) Stage 11- Stage II cases invited for stage III assessment 
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5) Stage II - Communication to respondents not meeting criteria for ACE 
6) Stage II - Case-control study: ICF for interviewing matched controls 
7) Stage III - Case-control study: Controls invited for stage III 
assessment 
8) Stage III - Case-control study: ICF for interviewing cases and controls 
9) Stage III - Case-control study: ICF for blood sample taking 
SECTION FOUR: GLOSSARY OF TERMS 
SECTION ONE: INTRODUCTION TO EPILEPSY SURVEYS 
Epilepsy is a disorder of the brain that is characterized by frequent seizures. Worldwide, it 
affects almost 50 million people, and it is caused by severe head injury, brain infection, and can 
be inherited through families. 
In developing countries, especially those of Africa, epilepsy remains a misunderstood condition 
and this is partly due to the existing misconceptions concerning its causes and consequences. 
Published literature documents a widely held belief among several communities that epilepsy 
results from bewitchment or possession by evil spirits or the devil, and that the condition is 
contagious and incurable. It is this conceptualization of epilepsy that is mainly responsible for 
the socio-cultural and psychological stigma and persistent negative attitudes and discrimination 
against people with epilepsy. This in turn has resulted to the sufferers being hidden (This often 
impacts on the identification of individuals with epilepsy in community settings) and 
therefore not seeking medical treatment. 
Why is this Study important? 
This study is important because it intends to document the number of people with epilepsy in our 
study communities and also determine its' causes and treatment gap (i. e. number of people with 
active epilepsy but not on appropriate treatment). This will help us advice about appropriate 
recommendations geared towards prevention and management of epilepsy. 
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How will the study be conducted? 
This study will be a panel-type survey with 3 stages and will conducted alongside the census, 
and it will involve visiting all the homesteads in the identified study area to identify individuals 
with epilepsy. These will be identified upon administration of the following one or two questions 
about epilepsy/convulsions/seizures/fits on all residents of the study area. The number of 
questions is determined by which of these are most culturally acceptable. Those answering Yes 
to any of the two questions will be visited by an epilepsy field worker and asked further question 
to detect epilepsy. Those in whom epilepsy is a possibility (by a YES response to any of the 2nd 
set of questions by the epilepsy team) will be asked to visit the epilepsy clinic for further 
assessment and examination. The two (2) questions to be administered in stage I are: 
1. Do you sometimes have fits or become rigid or experience attacks in which you fall 
to the ground and lose consciousness. 
2. Do you have fits or has someone ever told you that you have fits. 
Answers to these questions will be entered on the last two columns of the household census 
schedule and these can only be aY (Yes), N (No) or D (Don't know). 
The census field worker will, in addition to the above, notify the respondent that the epilepsy 
field team may interview some of the members of the of their household who may not have had 
convulsions, to enable the study team to determine if the first two (2) questions are detecting 
possible cases of epilepsy well. 
The Survey procedure 
This will follow the normal census procedure of going through the list of household members 
establishing their residential status. This time round, the list will have one or two columns for the 
one or two epilepsy questions. The questions will be in the last two columns and will be denoted 
by Epilepsy 1 and Epilepsy 2. 
After the normal census of each household member, the above epilepsy questions will be 
administered to the household head or any other household member with knowledge of the 
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people living in that household. The answers to these should then be entered appropriately in 
the spaces provided on schedule. This should be repeated for each member of the household and 
the last one is covered. Before asking these questions, the fieldworker should first introduce the 
study to the respondent and explain to him why it is important and the procedures involved. 
At the end of the day, all the census schedules should follow the procedures normal to the routine 
census. The epilepsy team will get this data and then prepare a list of all the people with a history 
of convulsions identified on that particular day for subsequent follow-up (These will also be 
entered in the epilepsy register, maintained by Data Manager). The follow-ups will be within 
one or two weeks of identification and the epilepsy team fieldworkers shall perform it. 
In stage II of the survey, those identified to have a possible diagnosis of epilepsy will be referred 
to stage III whereby they will be assessed by a clinician who will confirm a diagnosis of 
epilepsy. This will involve detailed medical history taking (in local language) and neurological 
examination. The diagnosis of ACE will be made on the basis of clinical history. Those who are 
positive at this stage will undergo EEG examination to enable classification of seizure types and 
epilepsy syndromes. The people identified to have ACE will be asked to be part of long-term 
studies into risk factors and causes of mortality in people with epilepsy. 
Concomitant with survey will be a case-control study in which cases of ACE will be matched to 
and compared to randomly selected population controls at a ratio of 1: 1. Matched controls will 
be recruited from the community by the administration of the stage II tool by the epilepsy field 
workers and those turning negative will be referred to stage III for assessments similar to those 
done on cases. These assessments will also include detailed socio-demographic questionnaire 
administered by a field worker unaware of the case/control status of the respondent and a blood 
sample to evaluate parasitic risk factors of epilepsy, HIV status and anti-epileptic drug levels to 
determine the prevalence of epilepsy treatment gap. 
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The Flow Chart for Epilepsy Studies 
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SECTION TWO: SOPs FOR PRE-ANALYTIC PROCESSES 
Survey Stage I SOP 
Stage I of the cross-sectional epilepsy survey: (Census screen for history of convulsions) 
Materials; 
1) Copies of census schedule with spaces for the two (2) questions screening for 
convulsions: 
a) Do you have fits or has someone ever told you that you have fits? 
b) Do you experience episodes in which your legs or arms have jerking movements 
or fall to the ground and lose consciousness? 
2) Stationary (note books, pens etc) 
3) Copies of the communication strategy 
Procedures; 
Morning activities; 
1) The study coordinator (SC)/field supervisor (FS) will assemble daily at 08: 00 hrs at the 
garage (or any other census team dispersal point) 
2) The SC/FS will ensure that the census team has adequate and appropriate materials for 
the area(s) to be enumerated that day 
Daytime activities; 
1) Upon arriving at the household (HH), the census field worker (CFW) will proceed with 
the enumeration and registration in their routine manner 
2) The CFW will explain the purpose of the questionnaire as per the communication 
strategy 
3) As the CFW enumerates for each HH member, they will ask the two (2) questions 
screening for convulsions for that HH member and fill in the spaces provided at the end 
of the census schedule as appropriate 
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4) The CFW will complete all parts of the questionnaire. If there is no information or 
response, the FW will fill in "no response" for that question. 
DO NOT LEAVE ANY BLANK SECTIONS 
Evening activities; 
1) At the end of the day, the CFWs will place all the completed census schedules in an 
envelope with their name, location and date on the cover 
2) The CFW will, upon arrival at unit hand all the completed census schedules to the FS 
3) The FS will then prepare a list of all the people with convulsions identified on that 
particular day for subsequent follow-up 
4) The FS will then enter this information into a convulsions register/study control sheet and 
hand them over to the SC for verification and consultation the following day 
5) The SC will keep an updated copy of the control sheet and transmit the data to the data 
manager (DM) for entry into the database 
6) The SC and FS will solve all logistical issues as they arise and where these require 
higher-level input, they will seek advice from the overall supervisor (name of person in- 
charge of study at the site) 
7) The SC, DM and FS will solve all data/information issues as they arise 
Information the CFW may convey to the community: 
What the study will do for the patients identified in Stage II of the survey: 
1) The study will identify people with possible epilepsy. 
2) The study will invite these people to the Epilepsy Clinic for further investigations. 
3) The study will provide fares to and from clinic for the index case and an accompanying 
responsible person. 
4) The study will provide lunch on the day of appointment for the index case and the 
accompanying responsible person. 
5) If after clinical examination the index case is found to have epilepsy, s/he will be started 
on anti-epileptic drugs provided for free by the study on this occasion. 
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6) The index case may then be given a review appointment by the study clinician. Fares to 
and from the Epilepsy Clinic and lunches will also be provided for on this occasion. 
7) The study, unless otherwise on the advice of the study clinician, will from the second 
appointment onwards consider the index to be stabilized on medication upon which s/he 
will be referred to the district hospital epilepsy clinic for future appointments. 
8) The study will from henceforth cease to provide fares and lunches for subsequent 
appointments. 
9) The study will give back individual results of examinations, tests and samples taken 
during the I" survey to the people with epilepsy at the earliest opportunity identified then 
if found during the 2°d survey. 
10) For people with epilepsy identified in the I" survey but not found during the 2"d survey, 
the study will make every attempt to trace them and give these results individually. 
11) The study will, during the 2"d survey give provisional results for examinations, tests and 
samples taken to patients, preferably on the day of examination for diagnosis and come 
for sample results at the earliest possible opportunity. 
What the study will NOT do for the patients identified in Stage 11 of the survey: 
1) The study will NOT provide free medication to index cases throughout their illness or for 
appointments beyond the study duration (six months). 
2) The study will NOT provide free lunches or transport to and from clinic throughout their 
illness or for appointments beyond the study duration (six months). 
3) For patients identified to have epilepsy during the 2"d survey and for whom examination, 
tests and samples are taken, the study will NOT follow them up in their homes to give 
individual results. 
Survey Stage II SOP 
Stage II of the cross-sectional epilepsy survey: Screening for Active Convulsive Epilepsy 
(ACE) 
Materials; 
1) Pre-printed list of the households (HH) for the area to be surveyed for the day. 
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2) Stationary (note books, pens, ink pads, petty cash vouchers etc) for the field workers. 
3) Case report forms (CRFs) pre-printed with the HH's name and PID numbers. 
4) A set of blank CRFs. 
5) Copies of the communication strategy. 
6) Copies of consent form. 
Procedures; 
1) The data manager (DM)/study coordinator (SC) will give the pre-printed list of HH, 
CRFs and consent forms to the Epilepsy field workers (EFWs). 
2) Only one EFW will each HH at a time. 
3) On arriving at the HH, the EFW will seek out the person identified on their list, and if 
they are found to have cognitive impairment the EFW will seek out a responsible close 
family member/relative to the index. 
a. If in case of mental disability none of the alternates is available at that time, the 
EFW will arrange to visit the HH the following day and leave a request that a 
senior/responsible member of the HH be around at specified a time. 
b. If on the following day this is not possible, the EFW will request for an 
appropriate appointment with the identified respondent and arrange the 2"d visit 
accordingly. 
4) The EFW will introduce themselves and the study to the appropriate respondent as in the 
COMMUNICATION STRATEGY (PARAGRAPHS I& 2). 
5) The EFW will then proceed to administer the questionnaire. If there is no information or 
response, the EFW will fill in "no response" for that question but DO NOT leave any 
blank sections. 
6) If the respondent is classified as a case, the EFW will read the communication strategy 
(PARAGRAPHS 3- 7) to the respondent and invite them to sign two (2) copies of the 
consent form (PARAGRAPHS 8- LAST). 
7) If the respondent is unwilling to sign, the EFW will elicit the reasons for the decline and 
indicate these in the pre-printed CRF for that respondent, thank the respondent and move 
to the next HH on their list. 
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8) The EFW will invite those who fulfill the criteria of active convulsive epilepsy (ACE) to 
come to the Epilepsy Clinic for further assessments at an appropriate date, preferably 
accompanied by relative/care giver. 
9) S/he will give an invitation/appointment tag with the name, other identification details 
and the date of appointment among other relevant information. (The EFW will emphasize 
that the person brings the appointment tag to the clinic. This will enable the study to track 
the appointments and to identify those not in the preceding stage of the study and those 
not recruited as controls). 
10) The EFW will provide fare for the subjects who fulfill the criteria and agreed to come for 
assessments and a relative to attend the clinic. 
11) The EFW will leave one copy of the signed communication/consent form with the 
respondent and bring the other copy back to the office. 
12) For the respondents turning negative to the stage II questions, the EFW will read the 
communication strategy for the controls (as detailed in PARAGRAPHS 8- LAST, 
EMPHASIZING THAT THEY MAY NOT HAVE EPILEPSY). 
13) S/he will notify the negatives of the possibility of coming back to recruit them as controls 
for the study. 
14) S/he will explain the concept of a control and request if the negative respondent is willing 
to participate as such, including giving a teaspoonful of blood for appropriate tests. This 
information will also be entered in the appropriate sections of the questionnaire. 
Activity flow; 
Morning activities; 
1) The driver will be available everyday at 8.00 am 
2) The EFWs will assemble at the assessment centre each day at 8.00 am 
3) The SC will see to it that all the necessary materials for the day are availed to the field 
team. 
4) The SC, with the assistance of the DM together with the EFWs will review all the 
outstanding issues from the previous day's CRFs (missing data, inconsistent data, HH not 
available, HH to be revisited etc). 
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5) The drivers will ferry the EFWs to the field at 8.30 am. 
Daytime activities; 
1) Ideally, the actual field work will be carried out between 9.00 am and 4.30 pm, with a 
one hour lunch break between 1.00 pm and 2.00pm. This will translate to 6 'h hours of 
actual work hours in the field*. 
2) The SC and DM will check the previous day's CRFs for any problems/queries and come 
up with remedial measures. 
3) The drivers will move around in the field, ferrying the EFWs between homesteads as they 
administer the interviews. 
4) Two days every week, the SC will visit the field and use the vehicle to make spot checks 
and address issues as they arise in the field 
*Assuming maximum questionnaire administration duration of 20 minutes per HH and an inter- 
HH movement duration of 15 minutes, we will have a questionnaire administration cycle of 35 
minutes per EFW. Thus, given an average of 6 1/2 hours (390 minutes) of actual field work time 
per day, each EFW will be able to interview an average of eleven (11) subjects per day (-' 10 
subjects/EFW/day). 
Evening activities; 
1) At the end of the day, the EFWs will hand all the completed CRFs to the FS. 
2) The FS will scrutinize the CRFs for errors, omissions etc and refer back to the 
responsible EFW for correction 
3) The unused CRFs will also be handed to the FS at the end of the day for re-issuing for 
follow-up the following morning/as appropriate. 
4) The driver will begin to collect the EFWs from their last positions of the day at 4.30pm. 
5) The SC will be at hand at 5.00 pm to receive the CRFs from the FS. 
6) The SC will discuss with the FS and note down a summary of issues arising for the day in 
the study log. 
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7) The SC will then check and verify the CRFs, update the daily study register/control sheet 
and forward all the day's CRFs to the DM for entry into the database (most likely the 
following day). 
Survey Stage III SOP 
Stage II of the cross-sectional epilepsy survey: Assessment, Examination, Sampling and 
Diagnosis of ACE 
Materials; 
1) Pre-printed list of all the patients referred for assessments for that day 
2) Stationary (note books, pens etc) for the assessors/clinicians 
3) Copies of assessment tools (questionnaires) pre-printed with the patient's name and PID 
number among other ID details. These include: 
4) Socio-demography, birth & medical history form (both adult and child) 
5) Epilepsy screening and medical history form 
6) Neurological examination form 
7) Epilepsy examination summary form 
8) EEG classification form 
9) Blood withdrawal form/consent 
10) Copies of the communication strategy 
11) Copies of consent form 
12) Patient examinations/assessment log files (front sheet) 
Procedures; 
Reception, consent and socio-demographic assessment; 
1) Patients referred for the day will be received at the reception of the assessment centre. 
2) Assessors on a first come first served basis will see patients at the reception area. 
3) S/he will request the patient/guardian to produce the assessment appointment tag given 
by the EFW during phase 11 of the study. 
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4) S/he will then explain the study to the individual patient (read the communication 
strategy) and administer the consent. 
5) If the patient/guardian is unwilling to sign, the assessor will elicit the reasons for the 
decline and indicate these in the space provided in the sociodemography questionnaire, 
thank the respondent and move to the next person on the queue. 
6) If the patient/guardian consents to the study, the assessor will guide them to sign two (2) 
copies of the consent form, one copy will remain with the assessor and the respondent 
will keep the other copy. 
7) The assessor will then administer the sociodemography & birth history questionnaire. 
8) The assessor will ensure to complete all sections of the questionnaire. If there is no 
information or response, s/he will fill in "no response" for that question but do not leave 
any blank sections. 
9) S/he will log the patient details in the assessment check list upon completion of the socio- 
demographic form. 
10) The assessor will then usher into the study clinician-I's office the patient for whom the 
socio-demography questionnaire is satisfactorily completed and logged. 
History and epilepsy screening 
1) The study clinician-1 will take complete history of the patient as detailed in the Epilepsy 
screening form. 
2) S/he will ensure to take all details of history provided for in this form. 
3) If there is no information or response, s/he will fill in "no response" for that question but 
do not leave any blank sections. 
4) S/he will then forward the patient to the study clinician-2's office. 
5) S/he will log the patient details in the assessment check list upon completion of the 
history and epilepsy screening form. 
6) S/he will give history and diagnosis details for that patient to study clinician-2. 
Neurological evaluation and EEG examination; 
1) The study clinician-2 will administer a full neurological examination to the patient. 
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2) S/he will to record all the examination findings in the Neurological examination form and 
ensure not to leave any blank sections on the form. 
3) The study clinician-2 will then refer for EEG examination ONLY those patients with a 
positive diagnosis of active convulsive epilepsy (ACE) as per the study clinician-1's 
findings. 
4) The study clinician-2 will then record his/her findings on the EEG classification form, 
ensuring to fill in all the details. 
5) S/he will log the ID details for the patient upon completion of the neurological 
examination form. 
6) The EEG technician will perform the EEG examination on all patients referred by the 
clinicians and summarize his/her findings as provided for in the EEG summary form. 
7) S/he will then log the patient details and refer the patient to clinician 1 or 2 for blood 
drawing. 
Blood drawing; 
1) The study clinician 1 or 2 will administer consent for blood drawing very carefully, 
explaining the intention and need for HIV testing and emphasizing on confidentiality and 
options for getting results. The clinician will then invite the patient to sign the consent. 
2) The study clinician will draw 2ml of heparinized blood from the patients who have given 
consent. 
3) The clinician will label the sample appropriately and place it in a cool box. 
4) S/he will then fill in all the details in the appropriate form and log. 
The sociodemographics assessors will provide money for lunches and fares back home to 
patients who have been fully assessed and have them sign the petty cash voucher. 
They will identify cases at this point and notify them of the treatment gap follow-up to be done 
within a week of assessment. 
Evening activities/day's audit; 
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1) At the close of business each day, each assessor/clinician will reconcile their completed 
forms with the details logged in the assessments checklist/front sheet, note and explain 
any discrepancies. 
2) The study clinicians will ensure that all the blood samples have been transmitted to the 
lab and the handover verified and signed for. 
3) Each assessor will then hand his or her completed set questionnaires to the study 
clinicians to use in the summary examination form. 
4) The clinicians, on completing summary will hand over the forms to the SC who will go 
over the forms and the log checklist and raise any queries. 
5) The SC will then summarize the important issues in a master log. 
6) S/he will then use the data to update the study control sheet, and transmit the forms to the 
DM for data every 3 days. 
Survey Stage H forms reception, checking and follow-up 
SOP for Stage II screening forms reception and checking. 
1. The field supervisor (FS) (Name: will collect and 
check that all the forms are filled in appropriately at the end of each day. 
2. At the end of a field day, the study co-ordinator (SC) will receive the verified forms from 
the field supervisor (FS); 
3. The SC will count and verify the number of forms with the FS; 
4. The SC will discuss with the FS and note down in the Stage II log the field issues arising on 
that day; 
5. The SC/FS will allocate the study numbers (EPISURVNO) to all the forms in the order in 
which they are received from the field, continuing from the last number of the previous day; 
6. The SC will check each individual form (or a sample thereof) and note in the study log 
issues such as wrong entries, missing data, inconsistent data, lack of adequate explanation 
for no consent etc. S/he will note against these details the FW code, PID, EZ HM. These 
will be raised with team the following morning and remedial action taken; 
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7. The SC will then update the study register (obtained earlier from the data manager - DM) 
by indicating those found on that day or otherwise as provided for in the register; 
8. The SC will then update the study control sheet with a summary of the days' data and check 
for any important trends. 
9. The SC will then prepare a list of follow-ups (FU) of those respondents not found on that 
day; 
10. The SC, in consultation with the DM will allocate FU dates for the FUs identified. This will 
be given to the FS for implementation; 
11. The SC will then hand over the forms to the DM for data entry. 
SOP for Stage II follow-up (FU) of individuals not screened on a particular day. 
1. The 0 FU for all individuals (cases and controls) not seen on a particular day will be 
carried out by the epilepsy field team (EFT) on the date allocated by the SC; 
2. The 2"d FU for all individuals not seen on the 1" FU will be carried out by the EFT if 
screening in that area/EZ on that particular day; otherwise it will be carried out by the 
`mop-up' field workers (MFW); 
3. The 3`d FU for all individuals not seen in the 2°d FU will be by the MFW. They will at 
this time request for an appointment at the most appropriate datehime for the respondent 
i. e. when the respondent is most likely to be available. Those for who appointments are 
not given by the P FU will be considered missing; 
4. The 4 `h FU for all individuals not seen in the 3`d FU and who have scheduled 
appointments will be by the MFW; 
5. Those CASES that had appointments but still not found by the 4`h FU will be classified 
as missing observations; 
6. The replacement of controls will be carried out by the MFW and will follow the same 
procedure as follows; 
7. Those CONTROLS that had appointments but still not seen by the 4`h FU will be 
replaced with an individual from the age-band who is topmost in the list of randomly 
selected replacements; 
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8. This will proceed to the 2"d topmost person in that list and that age-band if the I' person 
in the replacement list is not found after two visits, the 2"d of which will be by 
appointment; 
9. The FU for replacements will stop with the 3 `d person in the list of replacements for that 
age-band. 
Survey Stage 11 - Selection of population sample 
Materials 
1. Population dataset from the most current census. This will be the denominator dataset. 
Procedure 
1. The number of people in the population sample determined for each site will be selected 
randomly from the census dataset using the Random command (in which software? ). 
Survey Stage III - Selection of matched controls 
Materials 
1. A list of cases of ACE determined from stage III of the study 
2. The most current census dataset. 
Procedure 
1. Remove the determined ACE cases from the census dataset. 
2. Remove from the census dataset the stage II respondents who had refused consent to 
participate in stage III as matched controls i. e. when being interviewed as part of the 
population sample. 
3. Create an age band field in census and ACE cases datasets, and populate it with data in 
relation to the age of the person as below: - 
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Age groups (years) Age band 
a. 0-5 -1 
b. 6-12 -2 
c. 13- 18 -3 
d. 19 - 28 -4 
e. 29 - 49 -5 
F. 50 and Above -6 
4. Match the ACE cases to the census dataset resulting from steps I and 2 of this procedure 
ensuring to match by the age bands. 
5. While matching limit the selection to five controls for each ACE case and ensure that a 
control is not selected more than once. 
6. Those selected as controls are the eliminated from the denominator census dataset in 
readiness for the next round of matching. 
7. When the follow-up list of controls is exhausted, i. e. all controls in the list are either 
found, missed, refuse to participate or do not satisfy the control selection criteria e. g. 
they have had seizures in past, the un-matched cases will be re-matched again to the 
census dataset resulting from step 6 of this procedure. 
Survey (All Stages) - Data entry SOPs 
Procedures 
Data forms reception; 
I. The forms are brought to DM section after the SC has gone through. 
2. The DM notes down the date when received and the list of forms received. 
3. DM goes through the forms and avails them for data entry if everything is 
in order, but in case there are queries refers back to the appropriate person. 
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Data entry; 
1. The I' entry is done as the files are received. Any anomalies noted and 
taken for clarification by the person who filled the form. 
2. The 2nd entry is done by a different person for the forms that 0 entry has 
been done. 
3. During 2nd entry interactive verification is done where the second entry 
operator resolves discrepancies between first and second entry and is 
aware of the first entered values. 
4. A third person could resolve any discrepancies between first and second 
entry when both entries are completed. 
5. The entry screens are with same format as the data collection forms to 
enable ensuring entry are done in the appropriate variables. 
SECTION FOUR: GLOSSARY OF TERMS 
PID: Personal identification (number) -a unique number assigned to each resident of 
the DSS study area 
EZ: Enumeration zone - used to refer to a mapped cluster of homesteads delineated 
on the basis of some geographical feature? 
EZHHID: A unique homestead identifier which is a composite of EZ number and 
homestead number 
ACE: Active convulsive epilepsy - two or more unprovoked generalized tonic clonic 
seizures (GTCS) with (or without) other types of seizures and in which one 
seizure was in the previous one year 
SOP: Standard operating procedure(s) -a set of instructions detailing systematic actions 
to be taken in achieving a stated objective and having the force of a directive, 
covering those features of operations that lend themselves to a definite or 
standardized procedure without loss of effectiveness 
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SC: Study co-ordinator - person charged with the responsibility of overseeing the 
study in each site on a daily basis 
HH: Household (or homestead) 
CFW: Census field worker - any person who, in the context of this study is involved in 
the administration of the Stage I tool 
EFW: Epilepsy field worker - any person who, in the context of this study is involved in 
the administration of the Stage II tool 
DM: Data manager 
EEG: Electroencephalography 
EPISURVNO: Epilepsy survey number -a unique study number assigned to all study 
participants who respond to the stage II tool of the survey and is used in the 
subsequent stages of the study 
HM: Homestead (number) 
FU: Follow-up 
EFT: Epilepsy field team -a group of epilepsy field workers as defined previously 
MFW: "Mop-up" field worker(s) -a stage II field worker involved in FU of respondents 
missed by the core EFT after a stipulated number of visits 
SCC: Scientific steering committee 
CCC: Consent and communication committee 
ERC: Ethical review committee (board) 
ICF: Informed consent form 
IC: Informed consent (process) 
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Appendix 1.3: Communication and consent materials: epilepsy studies SOP for informed 
consent 
1.0 Introduction 
This study will be a panel-type survey carried out in three stages, and will comprise of four 
communications and consent taking processes, one of which will be for blood sample collection. 
1.1. Stage I: Census screen for convulsions 
The first stage of the study will be embedded within an on-going census survey and will be 
carried out by the census teams in their regular re-enumeration and registration exercises within 
the DSS. It will involve screening for convulsions by asking each household head (or any 
responsible adult with knowledge of people in the homestead) about the history of convulsions 
for each member of the household. This stage will involve introducing the study to the 
community and no consent will be sought for the two question interview. 
1.2. Stage II: Interview of Stage I positives and Stage III matched controls 
This stage of the study will involve administering a ten item questionnaire to people with a 
history of convulsions identified in stage I and the matched controls randomly selected for stage 
III of the study. This will be conducted by a team of epilepsy field workers and the 
communication and consent taking process will be as follows; 
a) Communication and consent for interview of individuals with a history of convulsions 
identified in stage I 
b) Further information and invitation for clinical assessments of individuals with possible 
epilepsy identified in stage II 
c) Communication and consent for interview of individuals selected as matched controls for 
stage III of the study 
d) Further information and invitation for clinical assessment of individuals eligible to be 
matched controls for stage III of the study 
e) Information for individuals with a history of convulsions but not meeting the study 
criteria for epilepsy 
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1.3. Stage III: Clinical assessment, examination and sample taking 
The third stage of the study will involve socio-demographic and clinical interviews of individual 
in groups in stage II (b) and (d), above, clinical assessment/examination and blood sample 
taking. The participants in the stage of the study will first undergo a socio-demography and 
medical history interview by a field worker unaware of their case/control status who will give 
information pertaining to this stage of the study and take consent for the same. S/he will then 
take the participant to a clinician who will take detailed clinical history and take a blood sample 
for which s/he will give information and also take consent. 
2.0 Background 
We aim for our Studies to conform to the following principles for informed consent; 
The subject/guardian must be COMPETENT in the language of communication 
The research team must DISCLOSE all relevant information to the subject 
" The subject must COMPREHEND the information and understand 
how their involvement in 
the study differs from normal clinical care. 
" The subject must AGREE to the proposed intervention/procedures 
in the research study 
" The subject's agreement must be VOLUNTARY and free from coercion 
" The subject must be informed that, even after voluntarily agreeing to take part, they may 
WITHDRAW their agreement at any time without penalty 
*In Kenya, children below the age of 18 years are not allowed to give consent, and informed 
consent for them to take part in studies is sought from their parents or 
legal guardians. If the 
parent or guardian is unable to read the informed consent 
documentation, the consent process 
must be witnessed. An exception to this occurs 
for emancipated minors2, defined in Kenya as 
those aged under 18 years who are married, pregnant, 
have children or are in the armed forces, 
and who are able to give consent on their own (and their children's) behalf. 
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3.0. The study 
This SOP describes the process to be followed for obtaining written informed consent from 
subjects/guardians taking part in the research study to ensure compliance with the above 
principles 
STUDY TITLE: EPIDEMIOLOGY AND TREATMENT OF EPILEPSY IN SUB-SAHARAN 
AFRICA 
The PI(s) for this study is/are (Name Pis in the site) and the sponsor is (WELLCOME TRUST) 
Name 
............................................................................................................ 
Name 
............................................................................................................ 
Name ............................................................................................................ 
Name ............................................................................................................ 
Name 
...................................................................................... ...................... 
4.0. SCOPE/ RESPONSIBILITY 
This SOP applies to study staff involved in obtaining informed consent from participants in this 
study. These will be: 
1) Epilepsy Field Workers 
2) Epilepsy Clinician/Nurse 
5.0. Development of ICF 
i. The English versions are written and submitted with this SOP to the SCC for approval. 
They are then submitted to (City) and any other ethics committees as required. This 
version is numbered l and dated. 
ii. Any amendments will be made following protocol review and the new version (with new 
number and date) is created. 
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iii. All translated versions are now generated in local languages by ------------------------------- 
iv. In the event of a revision of the ICF: 
" Where the ICF is amended (any change that affect the study participants or the data 
analysis) the amended ICF will be submitted to Consent & Communication 
Committee (CCC) prior to forwarding to SSC and ERC for approval before its use is 
instituted. 
" Where the ICF is modified (a non substantive change to the wording of an ICF) the 
modified ICF will be submitted to CCC for review, prior to forwarding to SSC and 
ERC for notification. Use will be instituted following CCC approval and forwarding. 
6.0 Training of staff involved in the informed consent process 
The overall study coordinator, Anthony Ngugi, is responsible for training the study 
coordinators, clinicians/nurses and field staff involved in the IC process in all the 4 sites. 
i) The training objectives: the training on the IC process will be built-in to the training on the 
survey methodology to ensure that the staff are conversant with the study background, 
methodologies and SOPs; ii) The study communication/consent forms and study SOPs will 
be used in the training; iii) the total duration of trainings in each site will be one week; iv) the 
training will be evaluated using role plays; v) over time, the trainees will be monitored 
through continuous checking of the consent forms filed in an overall built-in study control 
and monitoring mechanism. 
7.0 Administration of Informed Consent 
When and where will consent be taken? 
The communication material used in stage I will be administered at the homesteads by the census 
field workers during the census process. In stage II, these will be administered at home by the 
epilepsy field workers. 
Individuals diagnosed with Active convulsive Epilepsy (ACE) in stage III will be provided with 
anti-epilepsy drugs (AEDs) free of charge for the duration of the study and requested to be part 
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of a long-term cohort study into risk factors and causes of death in people with epilepsy. It is not 
envisaged that these individuals will form part of other studies within this project. 
Who gives and witnesses consent? 
Consent will be sought from all respondents identified in Stage I of the study as having a 
history of convulsions or their guardians if they are minors or cognitively challenged and 
from cases and controls identified for Stage III assessment. In the event that a witness is 
required, the witness shall be a responsible literate adult in the household or 
neighbourhood. 
How will it be sought? : 
0 The consent forms and all the questionnaires will be translated in to the local languages 
and the ability of the respondents to read will be determined by asking them of their 
literacy status and on whether or not they prefer to print their name and sign or append 
their thumb print on the consent forms. The need for a witness will be determined if the 
respondent is deemed to be illiterate or cognitively challenged. 
The person administering the consent will READ slowly and systematically the 
information as printed on the consent form to the respondent, pausing from time to time 
to assess the respondent's reactions/body language for cues to 
understanding/comprehending the information. 
The subject/guardian will be made aware that they are free to ask questions or seek 
clarification at any stages of the consenting process or questionnaire administration. The 
person administering the consent/questionnaire will attempt to respond to all the queries 
to the best of their abilities. If they are unable to respond to some of the information 
needs, they will refer the subject to the people named for such queries at the bottom of 
the consent forms. 
The subject/guardian will be invited to make a free choice to participate in the study once 
the interviewer has given them all information as detailed in the consent form, has 
responded to all the queries and is satisfied that the respondent has understood the 
information given. 
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Signing the consent form 
If the consent giver can read (so no need for a witness) 
" The investigator/designee to ask the subject/guardian to print their name, sign and date 
the ICF 
" The investigator/designee to sign and date the ICF 
"A copy of the ICF is given to the subject/guardian by (YES) 
" The giving of informed consent is recorded in the source document by (THE 
INTERVIEWER) 
" The signed ICF will be filed in (A FOLDER TOGETHER WITH OTHER CRFs BY 
THE SAME RESPONDENT) 
" Describe where the outcome (e. g. refusal) of all ICF processes are filed ON A 
SEPARATE FOLDER SET ASIDE FOR ALL REFUSALS) 
If the consent giver cannot read then a witness is needed; 
" To print the name of the subject/guardian on the ICF; and sign and date the ICF 
confirming that the information has been provided and that they have understood fully. 
The subject/guardian to make their mark (e. g. thumb print) on the ICF 
8.0 Ensuring the quality of the consent process 
i. The study team will ensure that the consent process is being adhered to by SPOT- 
CHECKS AND DOCUMENTATION REVIEW. 
ii. The quality assurance mechanisms of the Epilepsy study will ensure that the procedures 
described in this document are adhered to by checking adherence to this SOP during the 
monitoring process 
iii. Understanding of the participant will be checked by inviting the consent giver to seek 
further clarification and ask questions and confirming their understanding that they are in 
the study. 
iv. Detail any external monitoring that may be planned. (NONE) 
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SURVEY STAGE I- CENSUS INTRODUCTION 
My name is ............................................................................. . and I'm from 
(Organisation). I am here for the normal census exercise we conduct in every 
, 
months/year 
(i. e. Updates for births, deaths, in-migrants etc). 
Besides that we will ask you 1-2 extra questions regarding to the history of convulsions for each 
member of your household. (Organisation) is interested in knowing the extent of epilepsy in this 
community, to enable them to come up with better ways of treating and managing the condition 
now and in the future. 
If your responses to any one of the 2 questions for you/any member of your household is YES, 
you/they will be visited by another group of (Organisation) workers within 2 weeks to establish 
if you/they may have epilepsy. Further to this, the 2"d group of (Organisation) workers may also 
be interested in asking the same questions to some members of your household even if your 
responses for them is NO. This will enable us to find out those with epilepsy who may have been 
left out in this round. Those found to have epilepsy and currently not on medication will be 
started on anti-epilepsy drugs. 
STAGE II: STAGE I POSITIVE CASES INTERVIEWED IN STAGE II 
What is (Name of Research Organisation)? 
KEMRI is a Government organisation that carries out health research to learn more about 
diseases that affect children and adults in Kenya. Sometimes research only involves asking 
questions of patients, their parents, community members or health providers about what they 
know, feel or do. All research at KEMRI, including those involving only interviews, are 
approved by committees in Kilifi, and by national independent expert committees in Nairobi to 
make sure that participants' safety and rights are respected. 
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What is this research about? 
As you may have heard from your community leaders, one of (organization's) current interests is 
to learn more about the causes, distribution and effects of epilepsy among the different age 
groups in this community. This is important because although epilepsy is known to be an 
important problem for citizens, developing appropriate interventions for the country needs far 
better information about how many people suffer and why. 
In order to do this, we would like to talk to people individually in their homes. 
Why do you want to talk to me and what does it involve? 
A few weeks ago, an individual from (Organisation) on their regular registration and 
enumeration exercise asked you two questions regarding your (child's) history of convulsions. 
Given the responses you gave to these 2 questions, I/We would like, with your permission, to ask 
you a few more questions regarding your (child's) history of epilepsy. If you do not want to 
answer any of the questions you may say so and I will move on to the next question. Our 
discussion will take place in here in your home. No-one else but you and I will be present unless 
you would like someone else here. The discussion should take approximately 15 minutes. 
On the basis of your responses to these questions, we are inviting the people who we think may 
have epilepsy to (Organisation's) epilepsy clinic for further assessments including blood sample 
taking. 
CONSENT FORM - INTERVIEWS 
STAGE III - CASE-CONTROL STUDY: ICF FOR INTERVIEWING AND INVITING 
CONTROLS 
NB: Verbal consent can be obtained for interviews in which the information being sought is 
non-sensitive. In such situations the person giving consent will not sign but the person 
seeking consent can sign as below to document that informed consent was obtained. 
259 
I have had the study explained to me. I have understood all that has been read and had my 
questions answered satisfactorily. I understand that I change my mind at any stage [and it will 
not affect the benefits due to me/my child]. 
O please tick I agree to be interviewed 
Signature: Date 
Participant/guardian Time: 
Name (please print name) 
I certify that I have followed the study SOP to explain this study to the [participant/guardian], 
and that s/he understands the nature and the purpose of the study and consents to the 
participation [of the child] in the study. S/he has been given opportunity to ask questions which 
have been answered satisfactorily. 
Signature: Date 
Designee/iovestigator's Time: 
Name (please print name) 
Thumbprint of the parent as named above if they cannot write: 
THE PARENTX UARDIAN SHOULD NOW BE GIVEN A SIGNED COPY TO KEEP 
STAGE H: STAGE If POSITIVES INVITED FOR STAGE III ASSESSMENT 
On the basis of the questions that we have just asked, I/we believe that you (your child) might 
have epilepsy. We are therefore asking you to assist us in learning about the disease by 
coming/bringing your child to (Clinic) where; 
1) A clinician will first see you to ask various questions to confirm that there is a possibility 
that you have epilepsy. 
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2) If you are suspected to have epilepsy, you will also be examined and a recording will be 
done from your head using an EEG (show picture of EEG), a machine that diagnoses and 
classifies epilepsy and does not cause any discomfort. 
3) A blood sample (5mls) equivalent to one teaspoonful may be taken from you/from your 
child. There is no harm in taking this amount of blood. This blood sample will be used to 
look for the causes of epilepsy. 
Also, we may request a sub-group of those found to have and not have epilepsy to be involved in 
a more detailed and long-term study on that visit to the hospital. 
You will be provided with breakfast, lunch and travel expenses. 
Are there any disadvantages or advantages involved in taking part? 
If you (your child) are (is) found to be suffering from epilepsy, you (your child) would be given 
medication at no cost for the duration of the study; and an epilepsy clinic has been (will be) 
established at (the hospital) for the purpose of dispensing drugs at a minimal cost after the study. 
This study is intended to provide a better understanding of the problem of epilepsy in this 
community and Africa in general. 
You will be given more information when you come (bring your child) to the epilepsy clinic for 
further assessments. 
Who will have access to the information I give? 
We will not share individual information about you or other participants with anyone beyond a 
few people who are closely concerned with the research. All of our documents are stored 
securely in locked cabinets and on password protected computers. 
The knowledge gained from this research will be shared in summary form, without revealing 
individuals' identities, with other researchers in the field. Participants will get their individual 
results. 
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What will happen if I refuse to participate? 
All participation in research is voluntary. You are free to decide if you want to take part or not. 
If you do agree you can change your mind at any time. 
What if I have any questions? 
For information about this study. you can contact the researchers who are responsible: 
[Pi's name(s) and contacts] 
KEMRI- Wellcome Trust [Kilifi District Hospital, ] 
P. O. Box. 230, Kilifi. Telephone: 041 522 063 
If you want to ask someone independent anything about this research please contact 
Dorcas Kamuva, at KEMRI - Wellcome Trust 
P. O. Box 230, Kilifi. Telephone: 041 522 063 Or 
Mr. Ambrose Rachier, Chairman - KEMRI/National Ethics Review Committee 
P. O. BOX 54840-00200, Nairobi, Tel number: 020 272 2541 Mobile: 0723342780 or 
0738472281 
STAGE H: COMMUNICATION TO RESPONDENTS WITH A HISTORY OF 
CONVULSIONS BUT WHO DO NOT MEET THE MINIMUM CRITERIA FOR ACE. 
These are people who do not qualify to be either cases or controls and include: 
1. Respondents who have had only one fit/seizure/convulsion in their life-time. 
2. Respondents who have had more than one fit/seizure/convulsion in their life time 
whereby the last one was not within the 12 months preceding the survey interview. 
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3. Those who have had fits but only during febrile illnesses when aged 6 months to 6 years 
only. 
The epilepsy field workers (EFW) will elicit whether such respondents have any health concerns 
given their history of fits. If they respond in the affirmative, the EFW will state that they are not 
doctors but advice the respondent to seek medical attention from their local health facility, 
particularly if they experienced more fits. 
The interview should go as follows; 
EFW: According to your responses to the questions I just asked, and to the training I have been 
given by (Organisation), I believe you may not have epilepsy, even though you have had 
fits in the past. However, if. 
" you are worried about your health now or in the future, OR 
" you have any further fits; 
You should seek advice from a trained health worker (since I am not a doctor). 
STAGE II - CASE-CONTROL STUDY: ICF FOR INTERVIEWING MATCHED 
CONTROLS 
What is (Name of Research Organisation)? 
KEMRI is a Government organisation that carries out health research to learn more about 
diseases that affect children and adults in Kenya. Sometimes research only involves asking 
questions of patients, their parents, community members or health providers about what they 
know, feel or do. All research at KEMRI, including those involving only interviews, are 
approved by committees in Kilifi, and by national independent expert committees in Nairobi to 
make sure that participants' safety and rights are respected. 
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What is this research about? 
A few weeks ago, a team from (Organisation) visited your household to ask the normal 
enumeration and registration questions asked every months/year. At this last visit, 2 extra 
questions were asked of everybody about fits. These questions were a first step to teaching us 
how common epilepsy is in this community. 
You/your head of household answered NO to the two convulsion questions, suggesting no 
possibility of epilepsy. Although we are now mostly following up those who answered YES, we 
have also randomly selected some who answered NO to visit. This is because we can learn more 
about epilepsy when we compare the characteristics of those who do and do not have epilepsy. 
If you are willing to take part, we would like to ask you some additional questions just to check 
that we have not missed any possibility of epilepsy. Assuming that your answers conform no 
epilepsy, we would then like to invite you (your child) to our clinic. At the clinic we will be 
seeing both those suspected of suffering from epilepsy and those who are not. 
If you do not want to answer any of the questions you may say so and the interviewer will move 
on to the next question. The discussion will take place in here in your home. No-one else but 
you and I will be present unless you would like someone else there. The discussion should take 
approximately 15 minutes. 
CONSENT FORM - INTERVIEWS 
STAGE 11 - CASE-CONTROL STUDY: ICF FOR INTERVIEWING MATCHED CONTROLS 
NB: Verbal consent can be obtained for interviews in which the information being sought is non- 
sensitive. In such situations the person giving consent will not sign but the person seeking 
consent can sign as below to document that informed consent was obtained. 
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I have had the study explained to me. I have understood all that has been read and had my 
questions answered satisfactorily. I understand that I change my mind at any stage [and it 
will not affect the benefits due to me/my child]. 
Oplease tick I agree to be interviewed 
Signature: 
Participant/guardian 
Name 
Date 
Time: 
(please print name) 
I certify that I have followed the study SOP to explain this study to the [participant/guardian], 
and that s/he understands the nature and the purpose of the study and consents to the 
participation [of the child] in the study. S/he has been given opportunity to ask questions which 
have been answered satisfactorily. 
Signature: Date 
Designee/investigator's Time: 
Name (please print name) 
Thumbprint of the parent as named above if they cannot write: 
THE PARENT/GUARDIAN SHOULD NOW BE GIVEN A SIGNED COPY TO KEEP 
STAGE Q: CONTROLS INVITED FOR STAGE III ASSESSMENT 
Given your (child's) responses to the questions I just asked, I believe you/they may not have 
epilepsy. We are therefore requesting you/your child to become involved in this study by 
allowing us to compare your (child's) characteristics to those of a person with epilepsy to help us 
learn more about factors that are associated with development of epilepsy in some people and not 
in others. 
We are requesting you to come (bring your child) to the Epilepsy clinic for a full medical 
examination, including blood tests. This will enable us to find out those characteristics that are 
different between people with and without epilepsy. 
You will be provided with breakfast, lunch and travel expenses. 
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At the clinic: 
1) A clinician will first see you (your child) to ask various questions to confirm that you do 
not have epilepsy. 
2) A blood sample (Smis) equivalent to one teaspoonful may be taken from you/from your 
child. There is no harm in taking this amount of blood. This blood sample will be used to 
look for the causes of epilepsy. 
You will be given more information when you come (bring your child) to the epilepsy clinic for 
further assessments. 
Are there any disadvantages or advantages involved in taking part? 
By participating in this project, you/your child will get a full medical examination by a qualified 
clinician and any medical conditions that you/your child may have will be diagnosed and you 
will be advised accordingly. For instance, if you/your child are found to have anaemia (less 
blood in the body) or if you/they have worms in the stomach, you will be advised accordingly 
and put on medication. 
At the community level, you will be assisting in efforts to find out factors associated with 
epilepsy in this community and in Africa in general, some of which may be preventable and 
which will enable us to come up with preventive strategies. 
Who will have access to the information I give? 
We will not share individual information about you or other participants with anyone beyond a 
few people who are closely concerned with the research. All of our documents are stored 
securely in locked cabinets and on password protected computers. 
The knowledge gained from this research will be shared in summary form, without revealing 
individuals' identities, with other researchers in the field. Participants will get their individual 
results. 
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What will happen if I refuse to participate? 
All participation in research is voluntary. You are free to decide if you want to take part or not. 
If you do agree you can change your mind at any time. 
What if I have any questions? 
For information about this study, you can contact the researchers who are responsible: 
[PI's name(s) and contacts] 
KEMRI- Wellcome Trust [Kilifi District Hospital, ] 
P. O. Box. 230, Kilifi. Telephone: 041 522 063 
If you want to ask someone independent anything about this research please contact 
Dorcas Kamuya , at KEMRI - Wellcome Trust 
P. O. Box 230, Kilifi. Telephone: 041 522 063 Or 
Mr. Ambrose Rachier, Chairman - KEMRI/National Ethics Review Committee 
P. O. BOX 54840-00200, Nairobi, Tel number: 020 272 2541 Mobile: 0723342780 or 
0738472281 
STAGE III - CASE-CONTROL STUDY: ICF FOR INTERVIEWING CASES AND 
CONTROLS 
What is (Research Organisation)? 
KEMRI is a Government organisation that carries out health research to learn more about 
diseases that affect children and adults in Kenya. Sometimes research only involves asking 
questions of patients, their parents, community members or health providers about what they 
know, feel or do. All research at KEMRI, including those involving only interviews, are 
approved by committees in Kilifi, and by national independent expert committees in Nairobi to 
make sure that participants' safety and rights are respected. 
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What is this research about? 
A few weeks ago. an individual from (Organisation) visited your household to ask you some 
questions regarding your (child's) history of epilepsy and then you were invited to come to this 
clinic for further examination by a clinician. This is still part of the study to teach us how 
common epilepsy is in this community. 
I will first ask you some questions regarding your (child's) social background and medical 
history and then I will take you to the doctor who will ask you a few more questions, carry out a 
medical examinations and take a sample of your (child's) blood. The doctor will explain to you 
why we would like to take a sample of your (child's) blood and request your consent/permission 
to do so. You may decline to give a sample of your (child's) blood but still take part in this study. 
Further, we are requesting those individuals found to have epilepsy to participate in a long-term 
study to help us identify some of the causes of mortality in people with epilepsy. This will 
involve collecting information from you regarding the frequency of seizures and use of anti- 
epileptic drugs on a regular basis (every 3-6 months) during your (child's) routine clinic visit or 
in your home. This will also involve administering a questionnaire (verbal autopsy - VA) the 
relatives of the person with epilepsy when they die to probe the factors immediately associated 
with the death. 
I would now like, with your permission, to ask you the questions I just mentioned. If you do not 
want to answer any of the questions you may say so and I will move on to the next question. The 
discussion will take place in here at the clinic. No-one else but I and you (and your child) will be 
present unless you would like someone else here. The discussions should take approximately 15 
minutes. 
CONSENT FORM - INTERVIEWS 
STAGE III - CASE-CONTROL STUDY: ICF FOR INTERVIEWING CASES AND 
CONTROLS 
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NB: Verbal consent can be obtained for interviews in which the information being sought is 
non-sensitive. In such situations the person giving consent will not sign but the person 
seeking consent can sign as below to document that informed consent was obtained. 
I have had the study explained to me. I have understood all that has been read and had my 
questions answered satisfactorily. I understand that I change my mind at any stage [and it will 
not affect the benefits due to me/my child]. 
Q please lick I agree to be interviewed 
0 please tick I agree to be in a long-term study of causes of death among people with 
epilepsy 
Signature: Date 
Participant/¢uardian Time: 
Name (please print name) 
I certify that I have followed the study SOP to explain this study to the [participant/guardian], 
and that s/he understands the nature and the purpose of the study and consents to the 
participation [of the child] in the study. S/he has been given opportunity to ask questions which 
have been answered satisfactorily. 
Signature: Date 
Designee/investigator's 
Name (please print name) 
Time: 
Thumbprint of the parent as named above if they cannot write: 
THE PARENT/GUARDIAN SHOULD NOW BE GIVEN A SIGNED COPY TO KEEP 
STAGE III - CASE-CONTROL STUDY: ICF FOR BLOOD SAMPLE TAKING 
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Wbat is (Research Orgasisatios)'. 
KEMRI is a government organisation that carries out medical research. Research is different 
from normal treatment because research aims to find better ways of preventing and treating 
illness in the future for everybody's benefit. You have come to the hospital/clinic because 
you/your child werelwas invited to take part in the ongoing epilepsy research. We would like to 
ask for your help in our research by allowing us to take a blood sample. The rest of your 
treatment and care will be as normal. We are asking this of several people in this community; 
those with and those without epilepsy. 
Why an I requested to give blood I. this research? 
Besides finding out how many people have epilepsy in this community, we are interested in 
learning what some of the causes of epilepsy might be. We are therefore asking you to assist us 
further learn more about the disease by allowing us do some detailed blood tests to help us 
understand what causes epilepsy in this community. Causes that we are interested in include 
inheritance (genetic factors i. e. characteristics that you inherit from your parents e. g. shape of 
your ear). There are other factors that may explain why people develop epilepsy including 
infections like cerebral malaria, meningitis and HIV. All these factors can be assessed by doing 
some blood tests and will be compared between those with epilepsy and those without. 
Whet weir it iivotve for me/my child? 
We will take a small sample of blood (about I teaspoonful - 5ml) from your (child's) arm. 
The procedure for testing for HIV will be as follows: 
If you agree to participate in this study a trained professional will offer you the opportunity to 
have counselling for an HIV test if you are not sure you want the test. If after the counselling you 
decide you want the results of the test then we will arrange for it to take place here at the 
research centre, and for your results to be given to you soonest possible. Those who want their 
test results given to them, and who test positive will be seen regularly in the hospital/clinic to try 
and treat and prevent illnesses that might arise in future. If you decide that you do not want to 
know the HIV test result your decision will be respected. In this case we would like to use the 
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result of the test to help our research project but nobody except the doctor in charge of the study 
will know the resuh. If you do not want an HIV test to be done at all on your blood you can still 
be in the study. You can make your wishes known at the end of this form or after counselling. 
Are there any risks or advantages to me or my child of participating? 
Taking blood from the arm causes a small amount of pain where the needle enters the skin, but 
this does not last. The amount of blood taken will be too small to affect your/your child's health. 
By participating in this project, you/your child will get a full medical examination by a qualified 
clinician and any medical conditions that you/your child may have will be diagnosed and you 
will be advised accordingly. For instance, if you/your child are found to have anaemia (less 
blood in the body) or worms in the stomach, you will be advised accordingly and put on 
medication. 
If you (your child) are diagnosed to have epilepsy, you/they will be put on medication free of 
charge for the duration of this project. 
At the community level, you will be assisting in efforts to find out factors associated with 
epilepsy in this community and in Africa in general, some of which may be preventable and 
which will enable us to come up with preventive strategies. 
What bappeas if I refuse to participate? 
All participation in research is voluntary. You are free to decide if you want (your child) to give 
a blood sample. You/your child will have the same level of care whether youlthey give a sample 
or not. This will not affect you/your child's care now or in the future. 
What bappew to the samples? 
Some of the tests that are needed as part of this research cannot be done in this country at the 
moment, so part of the samples will be sent to laboratories abroad for these tests. 
After the research has been done, a small portion of the blood will be stored. In the future, new 
resear, ch may be done on these samples about [illness, or indicate if any illness]. Future research 
must fest be approved by a national independent expert committee in (Capital city) to ensure that 
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participants' safety and rights are respected. Individual names will be removed and replaced by 
codes, so that information cannot be linked to the participants. 
Who will have access to information about me/my child in this research? 
All our research records are stored securely in locked cabinets and password protected 
computers. Only a few people who are closely concerned with the research will be able to view 
information from participants. 
Who has allowed this research to take place? 
An independent committee in (Country) that is run by the Government and a committee in 
(Local town) have looked carefully at this and agreed that the research is important, that it should 
be safe to take part in and will be conducted properly. 
What if I have any questions? 
You may ask any of our staff questions at any time. You can also contact those who are 
responsible for the care of your child and this research: 
Pi's name(s) and contacts 
Dr. 
KEMRI- Wellcome Trust [Kilifi District Hospital, ] 
P. O. Box. 230, Kenya. Telephone: 041 522 063 
If you want to ask someone independent anything about this research please contact 
Dorcas Kamuva 
, at 
KEMRI - Wellcome Trust 
P. O. Box 230, Kilifi. Telephone: 0723342780 or 041 522 063 
Or 
Mr. Ambrose Rachier, Chairman - KEMRI/National Ethics Review Committee 
P. O. BOX 54840-00200, Nairobi, Tel number: 020 272 2541 Mobile: 0722205901 or 
0733400003 
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STAGE I11 - CASE-CONTROL STUDY: ICF FOR BLOOD SAMPLE TAKING 
I, [being a guardian of (name of child)], have had the 
research explained to me. I have understood all that has been read and had my questions 
answered satisfactorily. I understand that I can change my mind at any stage and it will not affect 
the benefits due to me/my child. 
Please insert the boxes below where relevant: 
0 Yes Q No please tick I agree to take part/allow my child to take part in this research 
O Yes 0 No please tick I agree to samples being stored 
O Yes Q No please tick I agree to samples being exported 
0 Yes Q No please tick I agree to a HIV test 
0 Yes 0 No please tick I agree to a HIV test only after counseling 
Subject/Parent/guardian's signature: Date 
Subject/Parent/guardian's name: Time 
(Please print name) 
I certify that I have followed all the study specific procedures in the SOP for obtaining informed 
consent. 
Designee/investigator's signature: 
Desig. ee/investigstor's same : 
(Please print name) 
Only necessary f the parenrdgaardiiaii cannot read: 
Date 
Time 
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I *attest that the information concerning this research was accurately explained to and apparently 
understood by the parent/guardian and that informed consent was freely given by the 
parent/guardian. 
Witness' signature: Date 
Witness' name: Time 
(Please print name) 
*A witness is a person who is independent from the study or a member of staff who was not 
involved in gaining the consent. 
Thumbprint of the parent as named above if they cannot write: 
THE SUBJECT/PARENT/GUARDIAN SHOULD NOW BE GIVEN A SIGNED COPY TO 
KEEP 
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Appendix 2.1: Description of search strategy for studies of prevalence of epilepsy. 
Search Element MEDLINE/EMBASE/ Other Databases 
PsycINFO 
Epilepsy (AND) Thesaurus Exploded Epilepsy (kw, ti, ab) (AND) 
Epilepsy Prevalence (kw, ti, ab) 
Epilepsy, Tonic-Clonic 
Epilepsy, Frontal Lobe 
Epilepsy, Rolandic 
Epilepsy, Generalized 
Epilepsy, Absence 
Epilepsy, Complex Partial 
Myoclonic Epilepsy, 
Juvenile 
Epilepsy, Benign Neonatal 
Epilepsy, Temporal Lobe 
Epilepsy, Partial, Motor 
Epilepsy, Partial, Sensory 
Epilepsy, Post-Traumatic 
Epilepsies, Myoclonic 
Epilepsies, Partial 
Myoclonic Epilepsies, 
Progressive 
Epidemiology (OR) Epidemiology 
+subheading 
"epidemiology" 
Morbidity (OR) Morbidity 
Prevalence Prevalence 
Data collection 
Cross-sectional studies 
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Appendix 2.2: Reasons for exclusion from meta-analysis of prevalence studies. 
Reason No of 
Lack of/inadequate definition of epilepsy (2 or more non-provoked seizures studies 
occurring at least 24 hours apart) 52 
Study on subpopulation with epilepsy e. g. prevalence in patients with a history of 6 
head trauma 15 
Published as a review article 23 
Study on single epilepsy syndromes 15 
Published as correspondence/letter/editorial/abstract only 5 
Study on single seizure syndromes 9 
Study of epilepsy as a risk factor to other conditions e. g. fractures 4 
Duplicate study 3 
Study did not provide denominator data 4 
Study not on prevalence of epilepsy 136 
Total 
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Appendix 2.3(b): List of prevalence studies included in the meta-analysis 
Al rajeh S, Awada A, Bademosi 0& Ogunniyi A. (2001 Sep) The prevalence of epilepsy and 
other seizure disorders in an Arab population: a community-based study. Seizure 10: 410- 
414. 
Al rajah S, Bademosi A, Ismail H, Awada A, Awodu A, Al-freihi H, Assuhaimi S, Borollosi M 
& Al-shammasi S. (1993) A community survey of neurological disorders in Saudi 
Arabia: the Thugbah study. Neuroepidemiology 12: 164-178. 
Almu S, Tadesse Z, Cooper P& Hackett R. (2006 Apr) The prevalence of epilepsy in the Zay 
Society, Ethiopia--an area of high prevalence. Seizure 15: 211-213. 
Argumosa A& Herranz X. (2000) The economic cost of childhood epilepsy in Spain. Rev 
Neurol. 30: 104-108. 
Asawavichienjinda T, Sitthir-Amon C& Tanyanont W. (2002) Prevalence of epilepsy in rural 
Thailand: A population based study. J Med Assoc Thai 85: 1066-1073. 
Attia-Romdhane N, Mrabet A& Ben Hamida M. (1993 Nov-Dec) Prevalence of epilepsy in 
Kelibia, Tunisia. Epilepsia 34: 1028-1032. 
Aziz H, Guvener A, Akhtar SW & Hasan KZ. (1997(b)) Comparative epidemiology of epilepsy 
in Pakistan and Turkey: population-based studies using identical protocols. Epilepsia 36: 
716-722. 
Aziz H, Guvener A, Akhtar SW & Hasan KZ. (1997(a)) Comparative epidemiology of epilepsy 
in Pakistan and Turkey: population-based studies using identical protocols. Epilepsia 38: 
716-722. 
Beilmann A, Napa A, Soot A, Talvik I& Talvik T. (1999 Jul) Prevalence of childhood epilepsy 
in Estonia. Epilepsia 40: 1011-1019. 
Birbeck GL & Kalichi EM. (2004 Jan) Epilepsy prevalence in rural Zambia: a door-to-door 
survey. Trop Med Int Health 9: 92-95. 
Christianson AL, Zwane ME, Manga P, Rosen E, Venter A& Kromberg JGR. (2000) Epilepsy 
in rural South African children: Prevalence, associated disability and management. South 
African Medical Journal 90: 262-266. 
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Cornaggia CM, Caveninni MP, Christie W, Giuccioli D, Facheris MA, Sabbadini M& Canger 
R. (1990) Epidemiologic survey of epilepsy among army draftees in Lombardy, Italy. 
Epilepsia 31: 27-32. 
Cowan LD, Bodensteiner JB, Leviton A& Doherty L. (1989) Prevalence of the epilepsies in 
children and adolescents. Epilepsia 30: 94-106. 
De la court A, Breteler MM, Meinardi H, Hauser WA & Hofuran A. (1996) Prevalence of 
epilepsy in the elderly: the Rotterdam Study. Epilepsia 37: 141-147. 
Debrock C, Preux PM, Houinato D, Druet-Cabanac M, Kassa F, Adjien C, Avode G, Denis F, 
Boutros-Toni F& Dumas M. (2000 Apr) Estimation of the prevalence of epilepsy in the 
Benin region of Zinvie using the capture-recapture method. Int J Epidemiol. 29: 330-335. 
Del Brutto OH, Santibanez R, Idrovo L, Rodriguez S, Diaz-Calderon E, Navas C, Gilman RH, 
Cuesta F, Mosquera A, Gonzalez AE, Tsang VC & Garcia HH. (2005 Apr) Epilepsy and 
neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. 
Epilepsia 46: (4) 583-587. 
Dent W, Helbok R, Matuja WB, Scheunemann S& Schmutzhard E. (2005 Dec) Prevalence of 
active epilepsy in a rural area in South Tanzania: a door-to-door survey. Epilepsia 46: 
1963-1969. 
Endziniene M, Pauza V& Micevisiene I. (1997) Prevalence of childhood epilepsy in Kaunas, 
Lithuania. Brain & Development 19: 379-387. 
Eriksson KJ & Koivikko MJ. (1997) Prevalence, Classification and Severity of Epilepsy and 
Epileptic syndromes in children. Epilepsia 38: 1275-1282. 
Fong GC, Mak W, Cheng TS, Chan KH, Fong X. & Ho SL. (2003) A prevalence study of 
epilepsy in Hong Kong. Hong Kong Med J. 9: 252-257. 
Forsgren L. (1992 May-Jun) Prevalence of epilepsy in adults in northern Sweden. Epilepsia., 33, 
450-8. 
Gallitto G, Serra S, la Spina P, Postorino P, Lagana A, Tripodi F, Gangemi S, Calabro S, Savica 
R, di Perri R, Beghi E& Musolino R. (2005 Nov) Prevalence and characteristics of 
epilepsy in the Aeolian islands. Epilepsia 46: 1828-1835. 
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Garcia-Nova J, Moreno E, de Mata F, Soto de Alfaro H, Fletes C, Craig PS & Allan JC. (2001) 
An epidemiological study of epilepsy and epileptic seizures in two rural Guatemalan 
communities. Ann Trop Med Parasitol. 95: 167-175. 
Gourie-Devi M, Satishchandra G, Subbakrishna P& Subbakrishna DK. (1996) Neuro- 
epidemiological pilot survey of an urban population in a developing country. A study in 
Bangalore, south India. Neuroepidemiology 15: 313-320. 
Garcia F, de Lao S& Castillo L. (1990) Epidemiology of epilepsy in Guaymi Indians of Bocas 
del Toro province, republic of Panama. Epilepsia 31: 718-723. 
Hackett RJ, Hackett L& Bhakta P. (1997) The prevalence and associated factors of epilepsy in 
children in Calicut District, Kerala, India. Acta Paediatr. 86: 1257-1260. 
Jacoby A, Buck D, Baker G, Mcnamee P, Graham-Jones S& Chadwick D. (1998 Jul) Uptake 
and costs of care for epilepsy: findings from a UK regional study. Epilepsia 39: 512-519. 
Keranen T, Riekkinen PJ & Sillanpaa M. (1989) Incidence and prevalence of epilepsy in adults 
in eastern Finland. Epilepsia 30: 413-421. 
Hauser WA, Annergers JF & Kurkland LT. (1991) Prevalence of epilepsy in Rochester, 
Minnesotta: 1940 - 1980. Epilepsia 32: 429-445. 
Kochen S& Melcon MO. (2005 Dec) Prognosis of epilepsy in a community-based study: 8 years 
of follow-up in an Argentine community. Acta Neurol Scand. 112: 370-374. 
Kraagac N, Yeni SN, Senocak M, Bozluolcay M, Savrun FK, Ozdemir H& Cagatay P. (1999 
May) Prevalence of epilepsy in Silivri, a rural area of Turkey. Epilepsia 40: 637-642. 
Kun LN, Ling LW, Wah YW & Lian TT. ( 1999 Oct) Epidemiologic study of epilepsy in young 
Singaporean men. Epilepsia 40: 1384-1387. 
Kurtz Z, Tookey P& Ross E. (1998 Jan 31) Epilepsy in young people: 23 year follow up of the 
British national child development study. BMJ 316: 339-342. 
Kwong KL, Chak WK, Wong SN & So KT. (2001) Epidemiology of childhood epilepsy in a 
cohort of 309 Chinese children. Pediatr Neurol. 24: 276-282. 
Lavados JG, Morales A, Campero M& Lavados P. (1992) A descriptive study of epilepsy in the 
district of El Salvador, Chile, 1984 - 1988. Acta Neurol Scand. 85: 249-256. 
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Luengo A, Parra J, Colas J, Ramos F, Carreras T, Fernandez-Pozos MJ, Munoz A& Hernando 
V. (2001 Sep) Prevalence of epilepsy in northeast Madrid. J Neurol. 248: 762-767. 
Medina MT, Martinez L, Osorio JR, Estrada AL, Zuniga C, Cartagena D, Collins JS, Holden 
KR. (2005 Jan) Prevalence, incidence, and etiology of epilepsies in rural Honduras: the 
Salama Study.. Epilepsia 46: 124-131. 
Mendizabal JE & Salguero LF. (1996 Apr; ) Prevalence of epilepsy in a rural community of 
Guatemala. Epilepsia 37: 373-376. 
Montano SM, Villaran MV, Ylquimiche L, Figueroa U, Rodriguez S, Bautista CT, Gonzalez 
AE, Tsang VC, Gilman RH & Garcia HH. (2005) Neurocysticercosis: association 
between seizures, serology, and brain CT in rural Peru. Neurology 65: 229-233. 
Morgan CL & Kerr MP. (2004 Jul) Estimated cost of inpatient admissions and outpatient 
appointments for a population with epilepsy: a record linkage study. Epilepsia 45: 849- 
854. 
Ndoye NF, Sow AD, Diop AG, Sessouma B, Sene-Diouf F, Boissy L, Wone I, Toure K, Ndiaye 
M, Ndiaye P, de Boer H, Engel J, Mandlhate C, Meinardi H, Prilipko L& Sander JW 
(2005 Mar). Prevalence of epilepsy its treatment gap and knowledge, attitude and practice 
of its population in sub-urban Senegal an ILAE/IBE/WHO study. Seizure 14: 106-111. 
Nicoletti A, Bartoloni A, Sofia V, Bartalesi F, Chavez JR, Osinaga R, Paradisi F, Dumas JL, 
Tsang VC, Reggio A& Hall AJ. (2005 Jul; ) Epilepsy and neurocysticercosis in rural 
Bolivia: a population-based survey. Epilepsia 46: 1127-1132. 
Okan N, Okan M, Eralp 0& Aytekin AH. (1995) The prevalence of neurological disorders 
among children in Gemlik (Turkey). Dev Med & Child Neurol. 37: 597-603. 
Olafsson E& Hauser WA. (1999 Nov) Prevalence of epilepsy in rural Iceland: a population- 
based study. Epilepsia 40: 1529-1534. 
Onal AE, Tumerdem Y, Ozturk MK, Gurses C, Baykan B, Gokyigit A& Ozel S. (2002 Sep) 
Epilepsy prevalence in a rural area in Istanbul. Seizure 11: 397-401. 
Oun A, Haldre S& Magi M. (2002 Jan) Prevalence of adult epilepsy in Estonia. Epilepsy Res., 
52,233-42. 
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Radhakrishnan K, Pandian JD, Santhoshkumar T, Thomas SV, Deetha TD, Sarma PS, 
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Appendix 2.4: Results of random effects meta-regression of prevalence of life-time epilepsy 
from all studies, multivariate analyses 
Covariate Categories No. of studies Odds Ratio 95% CI P value 
Development Developed 20 1.0 - - 
Developing 26 1.6 1.06-2.3 <0.02 
Age Adult 7 1.0 - - 
Children 11 0.7 0.4-1.1 0.08 
All 28 0.5 0.3-0.8 0.004 
Study size >20,000 19 1.0 - - 
1,000-20,000 22 1.8 1.2-2.5 0.001 
<=1,000 5 4.1 2.3-7.5 <0.0001 
Amount of heterogeneity explained = 52.8% 
Appendix 2.5: Results of random effects meta-regression of prevalence of active epilepsy 
from all studies, multivariate analyses 
Covariate Categories No. of studies Odds Ratio 95% CI P value 
Development Developed 18 1.0 - - 
Developing 19 1.4 1.0-2.1 0.055 
Age Adult 8 1.0 - - 
Children 7 0.9 0.6-1.4 0.7 
All 22 0.8 0.5-1.3 0.3 
Study size >20,000 20 1.0 - - 
1,000-20,000 14 1.3 0.9 -1.9 0.2 
<=1,000 3 2.9 1.4-61. 0.004 
Amount of heterogeneity explained = 40.0% 
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Appendix 3.1: Description of search strategy and search results of meta-analysis of incident 
studies. 
Database Search strategy Limits Number No of articles 
of after [Ti & 
articles Ab review 
1) Medline epilep*[Title/Abstract]) AND "(Humans, English, 1,841 41 
incidence[Title/Abstract]) NOT French, German, 
review[Title/Abstract]) NOT Spanish, Portugese)" 
letter[TitlelAbstract]) NOT AND "(Clinical 
comment[Title/Abstract]) NOT Conference OR 
editorial[Title/Abstract]; Journal Article OR 
Multicenter Study)" 
2) EMBASE epilep*[Title/Abstract]) AND "(Human, EMBASE, 374 0 
incidence [Title/Abstract]) English, French, 
German, Spanish, 
Portuguese)" AND 
"(Article OR 
Conference abstract 
OR Conference paper 
OR "Conference 
review" OR 
Journal))" 
3) SCIELO [Epilepsy & Incidence'Ti & Ab None 3 1 
4) Index [Epilepsy AND Incidence/All None 35 0 
Medicus for Indices] 
South East 
Asia 
5) Directorate [Epilepsy AND Incidence/All None 14 0 
of Open Indices] 
Access 
Journals 
6) Arquivos de [Epilepsy AND Incidence/All None 8 0 
Neuro- Indices] 
Psi uiatria 
7) Index [Epilepsy AND Incidence/KW] None 23 0 
Medicus for 
Eastern 
Mediterrenean 
Region 
8) LILACS [Epilepsy AND Incidence/Ti None 1 0 
9) Others [Epilepsy AND None 2 1 
IncidencelTi/Ab/Kw 
10) Reference 3 0 
lists 
Legend: Ti = Tit le; Ab = Abstract; Kw = Key word 
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Appendix 3.2: Description of study-level covariates in the meta-analysis of incidence 
studies. 
Covariates 
Development Case Decade Age Duration Population Study design 
ascertainment of group of follow- size 
stud up 
HIC Medical < 1990 Adults <3 years <20,000 Prospective Records MR 
LMIC 
Questionnaires 1990- Children 3-5 years 
20,000- Retrospective 
(Q) 1999 100,000 
Levels Adults 
MR+Q <2000 and 
5-10 
>100,000) 
Children years 
Appendix 3.3: Studies included in the meta-analysis of incidence 
5ýn Country 
Study sie category ease Age mcioence ronow-up Economic 
(thousands) ascertainment category rate/100,000 (years) status 
1111 Prospective Sweden 20-100 Q+MR Child 82.3 <3 HIC 
20 Retrospective Italy 20-100 Q+MR All 33.1 >10 HIC 
3171 Retrospective China 20-100 Q+MR All 25 <3 LMIC 
413 Retrospective Denmark 20-100 MR All 42 5-10 HIC 
50 Prospective Japan S20 MR Child 55.3 5-10 HIC 
613 Retrospective Finland >100 MR Adult 24 3-5 HIC 
70 Prospective UK 520 Q+MR Child 43 5-10 HIC 
818 Prospective Ecuador 20-100 Q All 122 <3 LMIC 
9m Retrospective US >100 MR All 44 >10 HIC 
30® Prospective Sweden 20-100 MR Child 53 <3 HIC 
110 Retrospective Iceland 20-100 MR All 47 <3 HIC 
123 Retrospective Canada >100 MR Child 41 5-10 HIC 
1313 Prospective Ethiopia 20-100 Q All 64 3-5 LMIC 
140 Prospective India 20-100 MR All 49.3 <3 LMIC 
ism Prospective UK 520 MR Child 36.6 >10 HIC 
1601 Prospective Uganda S20 Q All 215 3-5 LMIC 
1713 Retrospective Tanzania 520 Q All 73.3 5-10 LMIC 
ism Retrospective US 20-100 MR All 52.3 3-5 HIC 
1913 Prospective Estonia >100 MR Child 45 <3 HIC 
20® Retrospective US 20-100 MR All 35.5 5-10 HIC 
21M Prospective UK >100 MR All 46 <3 HIC 
220 Prospective Germany >100 Q+MR Child 60.7 <3 HIC 
2312 Retrospective Estonia 20-100 Q+MR Adult 35.4 <3 HIC 
243 Prospective Iceland >100 Q+MR All 33.3 <3 HIC 
25M Prospective Honduras 520 Q All 92.7 <3 LMIC 
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260 Prospective Netherlands >100 MR Child 30.3 <3 HIC 
27M Prospective Canada >100 MR Child 63 5-10 HIC 
28M Retrospective Sweden 20-100 MR Child 40 3-5 HIC 
290 Retrospective Denmark >300 MR All 83.3 5-10 HIC 
300 Prospective Spain 20-100 MR Child 62.1 <3 HIC 
3118 Prospective US >100 MR All 38.6 <3 HIC 
3Z0 Prospective Peru S20 Q All 162.4 3-5 LMIC 
33M Retrospective Tanzania S20 Q All 81.1 3-5 LMIC 
Key: Q=questionnaire, MR=medical records, HIC=High Income Country, LMIC=Low and Middle Income Country 
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Appendix 4.1: Stage I (SI) of the cross-sectional survey: (Census screen for convulsions) 
Q1 : Do you have fits or has someone ever told you that you have fits? 
Q2: Do you experience episodes in which your legs or arms have jerking movements or fall to 
the ground and lose consciousness? 
Appendix 4.2: Stage H (SII) screening questions 
Q1. Have you ever had a fit? 
Q2. Has someone ever told you that you have fits? 
Q3. Have you ever been told that you have epilepsy or epileptic fits? 
Q4. Have you ever had attacks in which you fall to the ground with loss of consciousness? 
Q5. Have you ever fallen to the ground without a reason and experienced: 
a) Twitching? 
b) Shaking of the arms or legs without control? 
c) Wetting yourself? 
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d) Biting of the tongue? 
Q6. Have you ever been told by a doctor that you have epilepsy or epileptic fits? 
Appendix 5.1: Clinical History Form 
EPISURV Number: LAJ_G] NJ_0J_8_Lj_]_]_1 11 
Sex: ( ] 
DOB: [ If 1/[ 1[ )/ [ J[ ]( ]f 1 
Date of assessment: [ ][ ]/ [ ][ ]/ [ ][ ][ ][ I 
Summary 
Does s/he have epilepsy? Yes/ No [] (HE) 
If Yes is it Active Epilepsy? Yes/ No [] (AE) 
Does this s/he need an EEG? Yes/ No [] (EEG) 
If Yes, when done? [ ][ ]/[ ][ ]/[ ][ ][ ][ ] (EEGDATE) 
Does s/he have any sickle cell disease? Yes/ No 
mellitus Yes/ No 
Hypertension Yes/ No 
Stroke Yes/ No 
Others, specify 
[] (SCD) Diabetes 
[] (DM) 
[l (HYP) 
[l (STK) 
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EPILEPSY RECORD 
Answer Yes (Y) or No (N) or Unknown (U) 
Has s/he ever had a fit [] (CF) 
Has s/he ever had episodes when s/he loses consciousness [] (CLC) 
Has s/he ever fallen to the ground without a reason [] (CFG) 
and the arms or legs twitch/shake [] (ALT) 
and bites the tongue [] (BT) 
and wets him/herself [] (WH) 
Have you ever noticed that s/he has episodes of 
shaking, trembling of one arm or one leg or the face [] (ST) 
becoming stiff [J (BS) 
loses contact with the surroundings [] (LCS) 
frequent loss memory from a short period of time [] (FLM) 
jerkings which move up your arm, leg or body [ ](JALB) 
Has s/he had episodes when s/he appears dazed [] (CD) 
complains of tummy aches [] (TA) 
smells an odd smell [H OS) 
sees something strange [N SS) 
Have you ever been told that s/he has had a fit [] (TCF) 
If response to any of the above questions is Yes, please fill the next section and table on the 
next page: 
Date of onset of seizures: [ ][ ]/[ ][ ]/[ ][ ] [ ][ ](DOS) 
Number of different seizure types [ ](NST) 
When was the last seizure [ J[ J/[ ][ ]/[ ][ ] [ ][ J(LS) 
How many seizures in the last year [ ][ ](SY) 
When does s/he have seizures? Daytime / Sleeping/ Both [] (WS) 
How many seizures has s/he ever had? 0-9 or Frequent (>9) [] (NS) 
How many times per month? 0-9 or Frequent (>9) [] (PM) 
How many times per week? 0-9 or Frequent (>9) 
How many times per day? 0-9 or Frequent (>9) 
Is the seizure provoked? 
If Yes is it by fever? 
If No what are the precipitating factors 
of seizures: 
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Current anti-epileptic drugs: 
Any Medication ? YIN [J (AM) 
If Yes which one/s; Phenobarbitone (PB); Phenytoin (PH); Carbamazepine (CB); Sodium 
valproate (NN) 
First drug taken: [ ][ ] (AE1) Second drug taken: [ ][ ] (AE2) 
Dose per day [ ][ ][ ] (AED1) [ It It ] (AED2) 
Previous anti-epileptic drug history: 
First drug taken: [ ][ j (AEP1) Second drug taken: [ ][ J (AEP2) 
Dose per day 
Drug reactions or unacceptable side effects from anti-epileptic drugs 
(Y/N) .............. [ ]DR 
Describe 
Traditional medicine? [I (PTRM) 
Description of seizure types: St 
Before the episode 
Does s/hc know it is going to occur eg. goes to 
another person 
Abnormal behaviour 
Becomes unresponsive (not answer questions, 
_disobey 
commands) 
FaII to the ground 
Talks nonsense 
Does not know where s/he is 
Automatisms: 
swallowing/grimacing/fiddI ing/gestures/vocalizat io 
ns/walking 
Other phenomena: fear/wee in abdominal/de'ä vu, 
Convulsive movements 
Which side: Both; Right; Left; one Side (unsure 
Which limb: Both; Arms; Legs 
Partial: Face; Lips; Hand 
2 nd_ 
(KOl) (K02) 
(ABI) (AB2) 
(BU1) (BU2) 
(FG1) (F(2) 
(TN 1) (TN2) 
(DWI) (DW2) 
(HPI) (HP2) 
(AMI) (AM2) 
(OPI) II (OP2) 
(CS)) (CS2) 
(CMI) (CM2) 
(CPI) (CP2) 
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c'S 
s 
: sf. 
Eyes involved: 
Blank look 
Stares ahead 
Deviate: Upwards; Right: Left: Deviate (unsure to 
which side) 
Jerking movements 
Lis involved: No, Smacking, Licking 
Bites tongue 
Wets self 
Soils self 
Duration (minutes) 
Headache 
Abnormal behaviour 
Disturbance of sleep 
_Speech and 
language difficulties (aphasia) 
Does s/he remember the episode 
Number per day 
per month 
Age when started (months) 
Sign if you have checked that the form is complete 
(BKI) 
(SA1) 
(EDI) 
(JM1) 
(LI1) 
(BG1) 
(WE1) 
(Sol) 
(DUI) 
(DY1) 
(SP1) 
(HEI) 
(ANI) 
(PA1) 
(DS1) 
(SLI) 
(RE1) 
(NU1) 
(NM1) 
(AS1) 
(BK2) 
(SA2) 
(ED2) 
(JM2) 
(L12) 
(BG2) 
(WE2) 
(S02) 
(DU2) 
(DY2) 
(SP2) 
(HE2) 
(AN2) 
(PA2) 
(DS2) 
(SL2) 
(RE2) 
(NU2) 
(NM2) 
(AS2) 
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Appendix 5.2: Neurological Examination Form 
EPISURV Number: LAj_Gj_N]_0j_8_L], 
_]], 
]_] 
Sex: [l 
DOB: [ ][ ]/ [ ][ ]i [ ][ ][ ][ ] 
Date of assessment: [ ][ ]/ [ ][ ]/ [ ]C ][ ][ ] 
Nutritional Measurements: 
Weight L_j I. II Kg (WT) 
OFC (J-j . I_I cm (HC) MUAC III. II cm (MUAC) 
Height ILI J. I_ I cm (HT) 
Handedness: Right Left Undetermined [ J(HD) 
Skull shape; Normal/Abnormal I J(SKS) 
Facial Appearance: Normal; Dysmorphic I J(FA) 
Skin: Any features of neurofibromatosis (Y/N) [ ](NCF') 
Any features of tuberous sclerosis (Y/N) [ ](NCT) 
Any scratch marks (Y/N) [ ](NCS) 
Any nodules (Y/N) [ ](NCN) 
Hands and feet: Normal; Abnormal [ J(HF) 
Blood pressure(BP): (mmHg). [_]-J_]/[_j_]J (BP) 
Respiratory system: Normal; Abnormal [ ](RPS) 
Cardiovascular system: Normal; Abornomal j ](CDS) 
Mental State exam: Is he oriented to: 
Place (YIN) 
Person (Y/N) [ ](ORP) 
[ ](ORPL) 
Time (Y/N) [ ](ORT) 
Does s/he have any burn marks? (Y/N) 
if yes, where 
[ ](ABM) 
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Examination of Cranial Nerves 
Cranial Nerve II 
Ptosis Yes/ No [J (PT) 
Pupils Normal/ Abnormal [ý (PU) 
Cranial nerves III, IV and VI; V and VII 
Eye movements . rantai nerves iii, iv and VI 
Squint? Yes/ No [I (SQ) 
Which eye? Right /Left/ Both [] (SWE) 
Nystagmus? Yes/ No [] (NY) 
The face Cranial nerve VII 
Muscles of facial expression 
Facial weakness? Yes/ No [] (FW) 
Forehead stronger than lower face Yes/ No [] (FS) 
Cranial nerves IX and X; XII 
The mouth, pharynx and larynx Cranial nerves IX, X, XII 
Pharynx and larynx 
Uvula: is central? Yes/ No [] (UMC) 
Deviates to: Right/ Left/ None [] (UD) 
Tongue 
Deviation? Yes/ No [] (TD) 
Motor system: 
Arms: 
Wasting? Yes/ No [] (AW) 
Where? 
Tone Normal Increased or Decreased? [] (AT) 
Contractures? Yes/ No [] (AC) 
Where? 
Power (MRC 0-5) Normal/ Abnormal/ Grossly Abnormal [] (AP) 
Right Left 
Lya 
Upper arm 
Lower arm 
Hand 
Legs: 
Wasting? Yes/ No [] (LW) 
Where? 
Tone Normal Increased or Decreased? [] (LT) 
Contractures? Yes/ No [] (LC) 
Where? 
Power (MRC 0-5) Normal/ Abnormal/ Grossly abnormal [] (LP) 
Right Left Upper leg 
Lower leg 
Foot 
Reflexes: 
Right Left 
hceps iI (tiK) II (JJL) 
Knee [] (KR) [] (KL) 
Ankle [] (AR) [] (AL) 
Plantar [] (PR) [] (PL) 
(Decreased Normal Increased) 
Co-ordination: 
Finger-nose Normal/ Abnormal [] (FN) Piano- 
playing Normal/Abnormal [] (PP) 
Dysdiadochokinesia? Yes/ No [] (DDK) 
Gait: 
Normal/ AlDnormai [l (GN) 
Describe gait abnormality 
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Ears 
Auroscope examination: Right Normal/AbnormalWax [] (UR) 
Left Normal/Abnormal/Wax [] (UL) 
Otitis Media Right Yes/No/Wax [] (OMR) 
Left Yes/No/Wax [] (OML) 
Otitis Extema Right Yes/No/Wax [j (OER) 
Left Yes/No/Wax [] (OEL) 
Cataracts Yes/No [] (CT) 
Which eye? Right /Left/ Both/None [ ](CWE) 
Other abnormality Yes/No [] (EAB) 
Describe 
Fundoscope examination: Fundi seen (YIN): [] (FE) 
Right Normal/Abnormal/Impossible[ ] (FR) 
Left Normal/Abnormal/Impossible[ ] (FL) 
Any toxocara nodules (Y/N): [] (TN) 
Any other Observations and medical history (YIN) ........................ 
[ ](AOM) 
300 
Has consent been given for the blood sample Y/N ...................... .] (CBS) Has the blood sample been taken Y/N ..................................... [l (BST) 
Summary 
Does s/he have evidence of learning difficulties [ ](ELD) 
Does s/he have any neurological deficits? (Y/N) [ ](EXND) 
Does s/he need a CT scan? (Y/N) [ ](EXCT) 
Sign if you have checked that the form is complete. 
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